

(19) **DANMARK**

(10) **DK/EP 2190296 T3**



(12)

Oversættelse af europæisk patentskrift

Patent- og
Varemærkestyrelsen

-
- (51) Int.Cl.: **A 23 C 19/032 (2006.01)** **A 21 D 8/04 (2006.01)** **C 07 K 14/195 (2006.01)**
C 12 N 9/10 (2006.01) **C 12 P 7/64 (2006.01)** **C 12 Q 1/48 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2014-12-01**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2014-09-24**
- (86) Europæisk ansøgning nr.: **08827725.6**
- (86) Europæisk indleveringsdag: **2008-08-14**
- (87) Den europæiske ansøgnings publiceringsdag: **2010-06-02**
- (86) International ansøgning nr.: **IB2008002573**
- (87) Internationalt publikationsnr.: **WO2009024862**
- (30) Prioritet: **2007-08-17 GB 0716126**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR**
- (73) Patenthaver: **DuPont Nutrition Biosciences ApS, Langebrogade 1 , Postboks 17, 1001 København K, Danmark**
- (72) Opfinder: **LARSEN, Niels Erik, Skæring Hedevej 166, 8250 Egå, Danmark**
SØE, Jørn Borch, Orøvænget 11, 8381 Tilst, Danmark
- (74) Fuldmægtig i Danmark: **NORDIC PATENT SERVICE A/S, Højbro Plads 10, 1200 København K, Danmark**
- (54) Benævnelse: **FREMGANGSMÅDE**
- (56) Fremdragne publikationer:
WO-A-2006/008508
US-A1- 2007 122 525
NERLAND A H: "THE NUCLEOTIDE SEQUENCE OF THE GENE ENCODING GCAT FROM AEROMONAS SALMONICIDA SSP. SALMONICIDA" JOURNAL OF FISH DISEASES, OXFORD, GB, vol. 19, no. 2, 1 January 1996 (1996-01-01), pages 145-150, XP008049669 ISSN: 0140-7775
NERLAND A H: "GLYCEROPHOSPHOLIPID-CHOLESTEROL ACYLTRANSFERASE PRECURSOR" SWISSPROT,, 1 January 1900 (1900-01-01), XP002318368

Description**REFERENCE TO RELATED APPLICATIONS**

5 [0001] Reference is made to the following related applications: US 2002-0009518, US 2004-0091574, WO2004/064537, WO2004/064987, WO2005/066347, WO2005/066351, WO2006/008508, WO 2008/090395 and US 2008063783.

FIELD OF THE PRESENT INVENTION

10 [0002] The present invention relates to a process for the manufacture of UHT milk, a process for enzymatic treatment of UHT milk, an enzymatically treated UHT milk and uses of an enzyme for the treatment of UHT milk to provide new and unexpected technical advantages.

BACKGROUND OF THE PRESENT INVENTION

15 [0003] Lipid acyltransferases are known to be advantageous in food applications. Lipid acyltransferases have been found to have significant acyltransferase activity in foodstuffs. This activity has surprising beneficial applications in methods of preparing foodstuffs.

20 [0004] For instance, WO 2004/064537 discloses a method for the in situ production of an emulsifier by use of a lipid acyltransferase and the advantages associated therewith. WO 2008/090395 teaches the expression of lipid acyltransferases in (heterologous) host cell.

25 [0005] Heat treatment in the production of long-life products is often called "sterilisation". This means that the product is exposed to such powerful heat treatment that all relevant microorganisms and most of the heat resistant enzymes are inactivated. Such products have excellent keeping qualities and can be stored for long periods of time at ambient temperatures. Many dairies can therefore distribute these products over long distances and thereby find new markets.

30 [0006] Typically two methods are used for the production of sterilised (otherwise known as long-life milk for ambient storage), namely in-container sterilisation or UHT treatment followed by aseptic packaging in packages protecting the product against light and atmospheric oxygen. The present invention is applicable to long-life milk produced by any method, e.g. UHT milk.

35 [0007] There are many advantages for the producer, retailer and consumer if the product does not require refrigeration and can be stored for long periods without spoiling.

[0008] These products are often called UHT-products, particularly UHT milk or UHT flavoured milks.

40 [0009] Milk exposed to UHT treatment must be of a very good quality. It is particularly important that the proteins in the raw milk do not cause thermal instability, which can be the case if the raw milk is of bad quality. A milk is unsuitable for UHT treatment if it is sour, has the wrong salt balance and/or contains too many serum proteins, typical of colostrum.

45 [0010] When milk is kept at a high temperature for a long time, certain chemical reaction products are formed, which results in discolouration (browning). It also acquires a cooked and caramel flavour, and there is occasionally a great deal of sedimentation. These defects are largely avoided by heat treatment at a higher

temperature for a short time. It is important that the optimum time/temperature combination is chosen to enable satisfactory spore destruction while keeping heat damage to the milk to a minimum.

[0011] It has been shown that when milk is heated (e.g. pasteurised at 70-80°C for 5-20 seconds), an effect known as the "cream plug phenomenon" is evident. Heat treatment of milk may be detrimental to the stability of the milk.

[0012] The principal constituents of milk are water, fat, proteins, lactose (milk sugar) and minerals (salts). Milk also contains smaller amounts of other substances such as pigments, enzymes, vitamins, phospholipids (substances with fat like properties), sterols and gases.

[0013] The many lipids of milk, together forming the 'milk fat', have a very complicated composition and structure, even more complicated than most other naturally occurring fats. Typically milk fat consists of triglycerides, di- and monoglycerides, fatty acids, sterols, carotenoids and vitamins (A, D, E and K). Other components include phospholipids, lipoproteins, glycerides, cerebrosides, proteins, nucleic acids, enzymes, metals and water.

[0014] Phospholipids are the most surface-active class, as they are amphipolar. As the molecular size is relatively large, they are hardly soluble, neither in water nor in fat. In both liquids they tend to form lamellar bilayers. Phospholipids of milk are generally seen in close connection with proteins, especially when located in the membrane(s) of milk fat globules. The main part of phospholipids in milk is Lecithins, which are surface active at moderate hydrophilicity. Thus lecithin can be seen as a suspending and dispersing agent or as an emulsifier for O/W emulsions as well as for W/O emulsions.

[0015] Phospholipids comprises 0.8-1.0% of the natural milk fat. The main types of phospholipids/lecithin in milk are phosphatidylcholine and phosphatidylethanolamine.

[0016] Sterols are highly insoluble in water, and show very little surface activity. They easily associate with phospholipids. The cholesterol may be considered an unwanted ingredient in milk when considering the nutritional value of milk. Cholesterol comprises 0.3-0.4% of the natural milk fat.

[0017] EP 1 532 863 teaches the use of a phospholipase to treat a cheese milk or a cheese milk fraction.

[0018] Tanji et al (Res. Bull. Obihiro Univ., 22 (2001): 89-94) teaches the use of lipases to enhance flavour in butter oil at 40°C.

[0019] JP 57-189637 and JP57-189638 teach the treatment of milk to produce fermented or acidic milk drinks using phospholipases - where the enzymatic treatment is done at 30-45°C.

SUMMARY ASPECTS OF THE PRESENT INVENTION

[0020] Aspects of the present invention are presented in the claims and in the following commentary.

[0021] It has surprisingly been found that the stability, particularly the long term stability, of UHT milk can be significantly improved by exposing milk or a portion thereof during UHT milk production to a lipid acyltransferase as defined herein.

[0022] Even more surprisingly the inventors of the present invention have found that the enzymatic treatment can be carried out without an additional heating step. Hence the adverse effects of heating the milk twice, i.e. once for enzymatic treatment and then again for the UHT treatment can be avoided. This has many advantages as described below.

DETAILED ASPECTS OF THE PRESENT INVENTION

[0023] According to a first aspect of the present invention there is provided a method of producing UHT milk, wherein said method comprises admixing a lipid acyltransferase and milk or a fraction thereof at a temperature and for an incubation time that is effective to ensure that there is at least 5% transferase activity measured by the molar amount of cholesterol ester formed by acyltransfer from phospholipids or triacylglycerides in milk to cholesterol, relative to the amount of cholesterol originally available, calculated using the following equation:

Transferase activity =

$$\frac{(\text{Mol/l cholesterol ester}(t) - \text{Mol/l cholesterol ester}(0)) \times 100}{\text{Mol/l cholesterol}(0)}$$

where:

Cholesterol ester (t) = the amount of cholesterol ester to the time t

Cholesterol ester (0) = the amount of cholesterol ester to the time 0

Cholesterol (0) = the amount of cholesterol in milk to the time 0;

and treating the enzyme treated milk by ultra-heat treatment to produce UHT milk.

[0024] "Ultra-heat treatment (UHT)" is a process where the milk is heated to approximately 130-150°C and held there for a few seconds, such as one to three seconds, preferably two seconds. The terms "ultra-heat treatment" and "ultra-high temperature treatment" and "high temperature treatment" are used synonymously herein.

[0025] In one embodiment, the term "ultra-heat treatment" as used herein is meant to encompass both in-container sterilisation and/or UHT treatment followed by aseptic packaging in packages protecting the product against light and atmospheric oxygen.

[0026] As one skilled in the art will appreciate, the UHT heat treatment time and temperature combination will be established based upon the product to be treated and may vary to some degree

[0027] The UHT milk after heat treatment may be sent to a Sterile tank to give a buffer prior to filling.

[0028] Filling is usually done in a sterile atmosphere where the UHT packing machine flushes the package with Nitrogen and also keeps the area within the filling heads flooded with Nitrogen to eliminate any air contamination.

[0029] According to a second aspect of the present invention there is provided a use of a lipid acyltransferase in the manufacture of UHT milk for improving the stability, particularly the long term stability, of the UHT milk.

[0030] The term "improving the stability" as used herein means that there is a reduction in the amount of creaming and/or sedimentation and/or flocculation and/or phase separation following storage (preferably following storage for at least 24 hours). Suitably the storage may be at a temperature of between about 5°C and 35°C.

[0031] In one embodiment, the term "improving the stability" as used herein means that there is a reduction in the amount of creaming without formation of a sediment layer following storage (preferably following storage for at least 24 hours). Suitably the storage may be at a temperature of between about 5°C and 35°C.

[0032] Creaming may be measured objectively by Turbiscan (as taught herein in the Examples section) and/or subjectively by the Stress Test (as taught herein in the Examples section).

[0033] Flocculation may be measured objectively by Turbiscan (as taught herein in the Examples section) and/or subjectively by the Stress Test (as taught herein in the Examples section).

[0034] Sedimentation may be measured by the Sedimentation Test (as taught herein in the Examples section).

[0035] Phase separation may be measured visually or by Turbiscan (as taught herein in the Examples section).

[0036] The term "improving the long term stability" as used herein means that there is a reduction in the amount of creaming (preferably without formation of a sediment layer) and/or sedimentation and/or flocculation and/or phase separation following storage over a prolonged period of time (preferably following storage for about 1-12 months, more preferably following storage for about 3-12 months, preferably following storage for up to about 6 months, preferably following storage for up to about 12 months, more preferably following storage for at least about 6 months). Suitably the storage may be at a temperature between about 5°C and 35°C.

[0037] According to a third aspect of the present invention there is provided a use of a lipid acyltransferase in the manufacture of UHT milk for improving the perceptible sensory difference of the UHT milk. Suitably the perceptible sensory difference of the UHT milk may be measured using the "triangle test" taught herein under.

[0038] In one aspect the "perceptible sensory difference" includes improved smell and/or taste, for example a reduced cooked taste and/or aroma and/or a reduced rancidity taste and/or aroma.

[0039] According to a fourth aspect of the present invention there is provided a use of a lipid acyltransferase in the manufacture of UHT milk for reducing the cholesterol content in the UHT milk.

[0040] A reduction in cholesterol can be measured by Thin Layer Chromatography (TLC) and/or Gas Liquid Chromatography (GLC).

[0041] According to a fifth aspect of the present invention there is provided a use of a lipid acyltransferase in the manufacture of UHT milk for eliminating or reducing creaming (preferably without formation of a sediment layer) in the UHT milk.

[0042] Suitably the improvement in the stability, particularly the long term stability, and/or the improvement in the perceptible sensory difference and/or the improvement in smell and/or taste and/or the reduction in cholesterol content and/or reduction in creaming (preferably without formation of a sediment layer) of the UHT milk means an improvement when the enzymatically treated UHT milk (treated with enzymes in accordance with the present invention) is compared with UHT milk which has not been enzymatically treated and/or compared with UHT milk which has been treated with a phospholipase (in particular either a phospholipase A1 enzyme classified as E.C. 3.1.1.32 or a phospholipase A2 enzyme classified as EC.3.1.1.4).

[0043] Suitably the improvement in the stability, particularly the long term stability, and/or the improvement in the perceptible sensory difference and/or the improvement in smell and/or taste and/or the reduction in cholesterol content and/or reduction in creaming (preferably without formation of a sediment layer) of the

UHT milk may mean an improvement when the enzymatically treated UHT milk (treated with enzymes in accordance with the present invention) is compared with UHT milk which has been treated with one or more of the following phospholipases: Phospholipase A1 from *Fusarium oxysporum* (Lipopan F™) and/or a phospholipase from *Fusarium heterosporum* and/or a phospholipase A1 from *Fusarium venenatum* (YieldMax™) and/or a phospholipase from *Aspergillus niger* and/or a phospholipase A2 from *Streptomyces violaceoruber* and/or a phospholipase A2 from porcine pancreas and/or a phospholipase A2 from *Tuber borchii*.

[0044] Suitably the improvement in the stability, particularly the long term stability, and/or the improvement in the perceptible sensory difference and/or the improvement in smell and/or taste and/or the reduction in cholesterol content and/or reduction in creaming (preferably without formation of a sediment layer) of the UHT milk may mean an improvement when the enzymatically treated UHT milk is compared with UHT milk which has been treated with a phospholipase A1 from *Fusarium oxysporum* (Lipopan F™).

[0045] Preferably it is advantageous to admix the lipid acyltransferase with the milk or a portion thereof before it is undergoes high temperature treatment. In other words the lipid acyltransferase may be added to raw milk or a portion thereof, and the enzyme-treated raw milk or portion thereof then undergoes ultra-heat treatment (resulting in UHT milk or a portion thereof).

[0046] In one embodiment of the present invention, the present invention may provide a method of producing UHT milk, wherein said method comprises comprising admixing a lipid acyltransferase and milk or a fraction thereof at a temperature and for an incubation time that is effective to ensure that there is at least 5% transferase activity measured by the molar amount of cholesterol ester formed by acyltransfer from phospholipids or triacylglycerides in milk to cholesterol, relative to the amount of cholesterol originally available, calculated using the following equation:

Transferase activity =

$$\frac{(\text{Mol/l cholesterol ester}(t) - \text{Mol/l cholesterol ester}(0)) \times 100}{\text{Mol/l cholesterol}(0)}$$

where:

Cholesterol ester (t) = the amount of cholesterol ester to the time t

Cholesterol ester (0) = the amount of cholesterol ester to the time 0

Cholesterol (0) = the amount of cholesterol in milk to the time 0.

[0047] Also, it is taught herein that a lipid acyltransferase may be added to the milk or a portion thereof after the ultra-heat treatment of the milk.

[0048] Preferably the lipid acyltransferase is added to the milk and incubated therewith at a temperature of less than about 20°C, preferably less than about 10°C.

[0049] Preferably the lipid acyltransferase is added to the milk and incubated therewith at a temperature of between about 1°C and about 10°C, preferably between about 3°C and about 7°C, more preferably about 5 °C.

[0050] Preferably the incubation time is effective to ensure that there is at least 5% transferase activity, preferably at least 10% transferase activity, preferably at least 15%, 20%, 25% 26%, 28%, 30%, 40% 50%, 60% or 75% transferase activity.

[0051] The transferase activity is measured by the molar amount of cholesterol ester formed by acyltransfer from phospholipids or triacylglycerides in milk to cholesterol relative to the amount of cholesterol originally available

Transferase activity =

$$\frac{(\text{Mol/l cholesterol ester}(t) - \text{Mol/l cholesterol ester}(0)) \times 100}{\text{Mol/l cholesterol}(0)}$$

[0052] Where:

Cholesterol ester(t)= the amount of cholesterol ester to the time t

Cholesterol ester(0)= the amount of cholesterol ester to the time 0

Cholesterol (0)= the amount of cholesterol in milk to the time 0

Cholesterol and cholesterol ester are determined by GLC

Gas Chromatography:

[0053] Gas Chromatography is used to measure the content of cholesterol and cholesterol ester in the milk samples.

[0054] The following CG setup is used:

Perkin Elmer Autosystem 9000 Capillary Gas Chromatograph equipped with WCOT fused silica column 12.5 m x 0.25 mm ID x 0.1 µ film thickness 5% phenyl-methylsilicone (CP Sil 8 CB from Chrompack).

Carrier gas: Helium.

Injector. PSSI cold split injection (initial temp 50°C heated to 385°C), volume 1.0 µl Detector FID: 395°C

Oven program (used since 30.10.2003):	1	2	3
Oven temperature, °C.	90	280	350
Isothermal, time, min.	1	0	10
Temperature rate, °C/min.	15	4	

Preparation of milk samples for GC analysis:

[0055] The milk lipids are extracted according to Mojonnier AOAC 989.05 using ethanol, NH₃, MTBE (methyl-tert-butyl ether) and p-ether. The lipid fraction is redissolved in heptane/pyridine (2:1) containing heptadecan as internal standard and cholesterol is measured by GC.

[0056] Preparing samples for cholesterol-ester measurements Squalane is added as an additional internal standard. The lipid fraction is redissolved in hexane and cholesterol-esters are concentrated using a NH₂ Bond

Elut column and hexane elution. Samples are redissolved in heptane/pyridine (2:1) and cholesterol-esters are measured by CG.

[0057] In the method of the present invention the combination of temperature and the incubation time is effective to ensure that there is at least 5% transferase activity, preferably at least 10% transferase activity, preferably at least 15%, 20%, 25% 26%, 28%, 30%, 40% 50%, 60% or 75% transferase activity.

[0058] Suitably the incubation time may be from 5 minutes up to 30 hours, suitably the incubation time may be from 45 minutes up to 30 hours.

[0059] In one embodiment the incubation time may be from about 10 hours to about 30h, preferably from about 15 to 25 hours, more preferably about 20 hours.

[0060] In a preferred embodiment the enzymatic treatment takes place at about 3°C to about 10°C (preferably about 5 °C) for at least 10 hours, preferably between about 10 and 25 hours, more preferably about 20 hours.

[0061] The use of lower temperatures in combination with effective incubation times leads to significant advantages in the present invention.

[0062] In the methods and/or uses of the present invention preferably the milk (UHT milk) is not heated during enzymatic treatment.

[0063] Preferably in the methods and/or uses of the present invention the milk is only heated once (when it is ultra-heat treated to provide a UHT milk). Therefore, preferably the milk (e.g. UHT milk) in the present invention does not undergo more than one heating step during it production.

[0064] In some aspects, the lipid acyltransferase for use in any one of the methods and/or uses of the present invention may comprise a GDSx motif and/ or a GANDY motif.

[0065] Preferably, the lipid acyltransferase enzyme is characterised as an enzyme which possesses acyltransferase activity and which comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S.

[0066] Suitably, the nucleotide sequence encoding a lipid acyltransferase or lipid acyltransferase for use in any one of the methods and/or uses of the present invention may be obtainable, preferably obtained, from an organism from one or more of the following genera: *Aeromonas*, *Streptomyces*, *Saccharomyces*, *Lactococcus*, *Mycobacterium*, *Streptococcus*, *Lactobacillus*, *Desulfotobacterium*, *Bacillus*, *Campylobacter*, *Vibrionaceae*, *Xylella*, *Sulfolobus*, *Aspergillus*, *Schizosaccharomyces*, *Listeria*, *Neisseria*, *Mesorhizobium*, *Ralstonia*, *Xanthomonas* and *Candida*. Preferably, the lipid acyltransferase is obtainable, preferably obtained, from an organism from the genus *Aeromonas*.

[0067] In some aspects of the present invention, the nucleotide sequence encoding a lipid acyltransferase for use in any one of the methods and/or uses of the present invention encodes a lipid acyltransferase that comprises an aspartic acid residue at a position corresponding to N-80 in the amino acid sequence of the *Aeromonas hydrophila* lipid acyltransferase shown as SEQ ID No. 35.

[0068] In some aspects of the present invention, the lipid acyltransferase for use in any one of the methods and/or uses of the present invention is a lipid acyltransferase that comprises an aspartic acid residue at a position corresponding to N-80 in the amino acid sequence of the *Aeromonas hydrophila* lipid acyltransferase shown as SEQ ID No. 35.

[0069] In addition or in the alternative, the nucleotide sequence encoding a lipid acyltransferase for use in any

one of the methods and/or uses of the present invention encodes a lipid acyltransferase that may comprise the amino acid sequence shown as SEQ ID No. 16, or an amino acid sequence which has 75% or more homology thereto. Suitably, the nucleotide sequence encoding a lipid acyltransferase encodes a lipid acyltransferase that may comprise the amino acid sequence shown as SEQ ID No. 16.

[0070] In addition or in the alternative, the nucleotide sequence encoding a lipid acyltransferase for use in any one of the methods and/or uses of the present invention encodes a lipid acyltransferase that may comprise the amino acid sequence shown as SEQ ID No. 68, or an amino acid sequence which has 75% or more homology thereto. Suitably, the nucleotide sequence encoding a lipid acyltransferase encodes a lipid acyltransferase that may comprise the amino acid sequence shown as SEQ ID No. 68.

[0071] In one embodiment the lipid acyltransferase for use in any one of the methods and/or uses of the present invention has an amino acid sequence shown in SEQ ID No. 16 or SEQ ID No. 68, or has an amino acid sequence which has at least 75% identity therewith, preferably at least 80%, preferably at least 85%, preferably at least 95%, preferably at least 98% identity therewith.

[0072] The term "UHT milk" means herein any long-life milk designed for ambient storage. In particular "UHT milk" means any milk which has been heat-treated using to make it long-life milk, this includes flavoured and unflavoured products.

[0073] Suitably, the method may comprise a step of removing the enzyme and/or denaturing the enzyme.

[0074] Suitably the enzyme for use in the present invention may be an immobilised enzyme.

[0075] The milk product of the present disclosure is a UHT milk or a UHT flavoured milk.

[0076] It is not intended to cover herein cheese milk (i.e. a milk which is not a UHT milk and which is used in the subsequent preparation of cheese) and/or cheese or cheese products produced from a milk which is not UHT milk.

ADVANTAGES

[0077] One advantage of the present invention is that the stability, particularly the long term stability, of UHT milk can be significantly improved.

[0078] A further advantage is that the unwanted physical effect of "creaming" of UHT milk is prevented and/or reduced compared with UHT milk which has not been enzymatically treated and/or compared with UHT milk which during its manufacture has been treated with a phospholipase (in particular either a phospholipase A1 enzyme classified as E.C. 3.1.1.32 or a phospholipase A2 enzyme classified as EC.3.1.1.4) (rather than the lipid acyltransferase as described herein).

[0079] The term "creaming" as used herein means the undesirable gravitational rise of fat globules to the top of the milk (e.g. in a container) over time.

[0080] A further advantage of the present invention may be the reduction of surface tension in UHT milk treated in accordance with the present invention compared with UHT milk which has not been enzymatically treated and/or compared with UHT milk which during its manufacture has been treated with a phospholipase (in particular either a phospholipase A1 enzyme classified as E.C. 3.1.1.32 or a phospholipase A2 enzyme classified as EC.3.1.1.4) (rather than the lipid acyltransferase as described herein).

[0081] A further advantage of the present invention may be the reduction of fouling of the UHT plant (e.g. of

the plant tubes and/or steel surfaces) when using the UHT milk treated in accordance with the present invention compared with UHT milk which has not been enzymatically treated and/or compared with UHT milk which during its manufacture has been treated with a phospholipase (in particular either a phospholipase A1 enzyme classified as E.C. 3.1.1.32 or a phospholipase A2 enzyme classified as EC.3.1.1.4) (rather than the lipid acyltransferase as described herein).

[0082] A further advantage of the present invention may be a reduction in free fatty acids in UHT milk treated in accordance with the present invention compared with UHT milk which during its manufacture has been treated with a phospholipase (in particular either a phospholipase A1 enzyme classified as E.C. 3.1.1.32 or a phospholipase A2 enzyme classified as EC.3.1.1.4) (rather than the lipid acyltransferase as described herein).

[0083] Even more surprisingly the inventors of the present invention have found that the enzymatic treatment can be carried out without an additional heating step. In particular the enzymatic treatment using the lipid acyltransferase in accordance with the present invention may be carried out at temperatures as low as approximately 1-25°C, preferably as low as approximately 1-10°C, preferably between about 3 and about 7°C, more preferably about 5°C. Hence the adverse effects of heating the milk twice, i.e. once for the UHT treatment and then again for enzymatic treatment, can be avoided. This has many advantages including:

1. a) that the process is more economic and is therefore advantageous for producers of the UHT milk;
2. b) heating of the milk can lead to adverse effects such as a breakdown in stability of the constituents of the milk, the present invention reduces significantly this disadvantageous property; and/or
3. c) less changes in organoleptic properties.

[0084] A further advantage of the present invention is a reduced cholesterol content in the UHT milk which may have major health benefits.

[0085] Suitably the improvement in any of the characteristics taught herein (such as creaming) may be compared with UHT milk which has been treated with one or more of the following phospholipases: Phospholipase A1 from *Fusarium oxysporum* (Lipopan F™) and/or a phospholipase A1 from *Fusarium venenatum* (YieldMax™) and/or a phospholipase from *Fusarium heterosporum* and/or a phospholipase from *Aspergillus niger* and/or a phospholipase A2 from *Streptomyces violaceoruber* and/or a phospholipase A2 from porcine pancreas and/or a phospholipase A2 from *Tuber borchii*; preferably Phospholipase A1 from *Fusarium oxysporum* (Lipopan F™).

HOST CELL

[0086] The host organism can be a prokaryotic or a eukaryotic organism.

[0087] In one embodiment of the present invention the lipid acyl transferase according to the present invention is expressed in a host cell, for example a bacterial cells, such as a *Bacillus* spp, for example a *Bacillus licheniformis* host cell.

[0088] Alternative host cells may be fungi, yeasts or plants for example.

[0089] It has been found that the use of a *Bacillus licheniformis* host cell results in increased expression of a lipid acyltransferase when compared with other organisms, such as *Bacillus subtilis*.

[0090] A lipid acyltransferase from *Aeromonas salmonicida* has been inserted into a number of conventional expression vectors, designed to be optimal for the expression in *Bacillus subtilis*, *Hansenula polymorpha*,

Schizosaccharomyces pombe and *Aspergillus tubigensis*, respectively. Only very low levels were, however, detected in *Hansenula polymorpha*, *Schizosaccharomyces pombe* and *Aspergillus tubigensis*. The expression levels were below 1 µg/ml, and it was not possible to select cells which yielded enough protein to initiate a commercial production (results not shown). In contrast, *Bacillus licheniformis* was able to produce protein levels, which are attractive for an economically feasible production.

[0091] In particular, it has been found that expression in *B. licheniformis* is approximately 100-times greater than expression in *B. subtilis* under the control of aprE promoter or is approximately 100-times greater than expression in *S. lividans* under the control of an A4 promoter and fused to cellulose (results not shown herein).

[0092] The host cell may be any *Bacillus* cell other than *B. subtilis*. Preferably, said *Bacillus* host cell being from one of the following species: *Bacillus licheniformis*; *B. alkalophilus*; *B. amyloliquefaciens*; *B. circulans*; *B. clausii*; *B. coagulans*; *B. firmus*; *B. lautus*; *B. lentus*; *B. megaterium*; *B. pumilus* or *B. stearothermophilus*.

[0093] The term "host cell" - in relation to the present invention includes any cell that comprises either a nucleotide sequence encoding a lipid acyltransferase as defined herein or an expression vector as defined herein and which is used in the recombinant production of a lipid acyltransferase having the specific properties as defined herein.

[0094] Suitably, the host cell may be a protease deficient or protease minus strain and/or an α-amylase deficient or α-amylase minus strain.

[0095] The term "heterologous" as used herein means a sequence derived from a separate genetic source or species. A heterologous sequence is a non-host sequence, a modified sequence, a sequence from a different host cell strain, or a homologous sequence from a different chromosomal location of the host cell.

[0096] A "homologous" sequence is a sequence that is found in the same genetic source or species i.e. it is naturally occurring in the relevant species of host cell.

[0097] The term "recombinant lipid acyltransferase" as used herein means that the lipid acyltransferase has been produced by means of genetic recombination. For instance, the nucleotide sequence encoding the lipid acyltransferase has been inserted into a cloning vector, resulting in a *B. licheniformis* cell characterised by the presence of the heterologous lipid acyltransferase.

REGULATORY SEQUENCES

[0098] In some applications, a lipid acyltransferase sequence for use in the methods and/or uses of the present invention may be obtained by operably linking a nucleotide sequence encoding same to a regulatory sequence which is capable of providing for the expression of the nucleotide sequence, such as by the chosen host cell (such as a *B. licheniformis* cell).

[0099] By way of example, a vector comprising the nucleotide sequence operably linked to such a regulatory sequence, i.e. the vector is an expression vector, may be used.

[0100] The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

[0101] The term "regulatory sequences" includes promoters and enhancers and other expression regulation signals.

[0102] The term "promoter" is used in the normal sense of the art, e.g. an RNA polymerase binding site.

[0103] Enhanced expression of the nucleotide sequence encoding the enzyme having the specific properties as defined herein may also be achieved by the selection of regulatory regions, e.g. promoter, secretion leader and terminator regions that are not regulatory regions for the nucleotide sequence encoding the enzyme in nature.

[0104] Suitably, the nucleotide sequence may be operably linked to at least a promoter.

[0105] Suitably, the nucleotide sequence encoding a lipid acyltransferase may be operably linked to at a nucleotide sequence encoding a terminator sequence. Examples of suitable terminator sequences for use in any one of the vectors, host cells, methods and/or uses of the present invention include: an α -amylase terminator sequence (for instance, CGGGACTTACCGAAAGAAACCATCAATGATGGTTTCTTTTTTGTTCATAAA - SEQ ID No. 64), an alkaline protease terminator sequence (for instance, CAAGACTAAAGACCGTTCGCCCGTTTTTGCAATAAGCGGGCGAATCTTACATAAAA ATA - SEQ ID No. 65), a glutamic-acid specific terminator sequence (for instance, ACGGCCGTTAGATGTGACAGCCCGTTCCAAAAGGAAGCGGGCTGTCTTCGTGTAT TATTGT - SEQ ID No. 66), a levanase terminator sequence (for instance, TCTTTTAAAGGAAAGGCTGGAATGCCCGGCATTCCAGCCACATGATCATCGTTT - SEQ ID No. 67) and a subtilisin E terminator sequence (for instance, GCTGACAAATAAAAAGAAGCAGGTATGGAGGAACCTGCTTCTTTTACTATTATTG - SEQ ID No. 119). Suitably, the nucleotide sequence encoding a lipid acyltransferase may be operably linked to an α -amylase terminator, such as a *B. licheniformis* α -amylase terminator.

PROMOTER

[0106] The promoter sequence to be used in accordance with the present invention may be heterologous or homologous to the sequence encoding a lipid acyltransferase.

[0107] The promoter sequence may be any promoter sequence capable of directing expression of a lipid acyltransferase in the host cell of choice.

[0108] Suitably, the promoter sequence may be homologous to a *Bacillus* species, for example *B. licheniformis*. Preferably, the promoter sequence is homologous to the host cell of choice.

[0109] Suitably the promoter sequence may be homologous to the host cell. "Homologous to the host cell" means originating within the host organism; i.e. a promoter sequence which is found naturally in the host organism.

[0110] Suitably, the promoter sequence may be selected from the group consisting of a nucleotide sequence encoding: an α -amylase promoter, a protease promoter, a subtilisin promoter, a glutamic acid-specific protease promoter and a levansucrase promoter.

[0111] Suitably the promoter sequence may be a nucleotide sequence encoding: the LAT (e.g. the α -amylase promoter from *B. licheniformis*, also known as AmyL), AprL (e.g. subtilisin Carlsberg promoter), EndoGluC (e.g. the glutamic-acid specific promoter from *B. licheniformis*), AmyQ (e.g. the α amylase

promoter from *B. amyloliquefaciens* alpha-amylase promoter) and SacB (e.g. the *B. subtilis* levansucrase promoter).

[0112] Other examples of promoters suitable for directing the transcription of a nucleic acid sequence in the methods of the present invention include: the promoter of the *Bacillus lentus* alkaline protease gene (aprH); the promoter of the *Bacillus subtilis* alpha-amylase gene (amyE); the promoter of the *Bacillus stearothermophilus* maltogenic amylase gene (amyM); the promoter of the *Bacillus licheniformis* penicillinase gene (penP); the promoters of the *Bacillus subtilis* xylA and xylB genes; and/or the promoter of the *Bacillus thuringiensis* subsp. *tenebrionis* CryIIIa gene.

[0113] In a preferred embodiment, the promoter sequence is an α -amylase promoter (such as a *Bacillus licheniformis* α -amylase promoter). Preferably, the promoter sequence comprises the -35 to -10 sequence of the *B. licheniformis* α -amylase promoter - see Figures 53 and 55.

[0114] The "-35 to -10 sequence" describes the position relative to the transcription start site. Both the "-35" and the "-10" are boxes, i.e. a number of nucleotides, each comprising 6 nucleotides and these boxes are separated by 17 nucleotides. These 17 nucleotides are often referred to as a "spacer". This is illustrated in Figure 55, where the -35 and the -10 boxes are underlined. For the avoidance of doubt, where "-35 to -10 sequence" is used herein it refers to a sequence from the start of the -35 box to the end of the -10 box i.e. including both the -35 box, the 17 nucleotide long spacer and the -10 box.

SIGNAL PEPTIDE

[0115] The lipid acyltransferase produced by a host cell by expression of the nucleotide sequence encoding the lipid acyltransferase may be secreted or may be contained intracellularly depending on the sequence and/or the vector used.

[0116] A signal sequence may be used to direct secretion of the coding sequences through a particular cell membrane. The signal sequences may be natural or foreign to the lipid acyltransferase coding sequence. For instance, the signal peptide coding sequence may be obtained from an amylase or protease gene from a *Bacillus* species, preferably from *Bacillus licheniformis*.

[0117] Suitable signal peptide coding sequences may be obtained from one or more of the following genes: maltogenic α -amylase gene, subtilisin gene, beta-lactamase gene, neutral protease gene, prsA gene, and/or acyltransferase gene.

[0118] Preferably, the signal peptide is a signal peptide of *B. licheniformis* α -amylase, *Aeromonas* acyltransferase (for instance, mkkwfvcllgialtvqa - SEQ ID No. 21), *B. subtilis* subtilisin (for instance, mrskklwisllfaltlftmfsnmsaqa - SEQ ID No. 22) or *B. licheniformis* subtilisin (for instance, mmrkksfwfgmltafmvlftmefdsasa - SEQ ID No. 23). Suitably, the signal peptide may be the signal peptide of *B. licheniformis* α -amylase.

[0119] However, any signal peptide coding sequence capable of directing the expressed lipid acyltransferase into the secretory pathway of a *Bacillus* host cell (preferably a *B. licheniformis* host cell) of choice may be used.

[0120] In some embodiments of the present disclosure, a nucleotide sequence encoding a signal peptide may be operably linked to a nucleotide sequence encoding a lipid acyltransferase of choice.

[0121] The lipid acyltransferase of choice may be expressed in a host cell as defined herein as a fusion protein.

EXPRESSION VECTOR

[0122] The term "expression vector" means a construct capable of *in vivo* or *in vitro* expression.

- 5 [0123] Preferably, the expression vector is incorporated in the genome of the organism, such as a *B. licheniformis* host. The term "incorporated" preferably covers stable incorporation into the genome.

- 10 [0124] The nucleotide sequence encoding a lipid acyltransferase as defined herein may be present in a vector, in which the nucleotide sequence is operably linked to regulatory sequences such that the regulatory sequences are capable of providing the expression of the nucleotide sequence by a suitable host organism (such as *B. licheniformis*), i.e. the vector is an expression vector.

- 15 [0125] The vectors may be transformed into a suitable host cell as described above to provide for expression of a polypeptide having lipid acyltransferase activity as defined herein.

[0126] The choice of vector, e.g. plasmid, cosmid, virus or phage vector, genomic insert will often depend on the host cell into which it is to be introduced. The present disclosure may cover other forms of expression vectors which serve equivalent functions and which are, or become, known in the art.

- 20 [0127] Once transformed into the host cell of choice, the vector may replicate and function independently of the host cell's genome, or may integrate into the genome itself.

- 25 [0128] The vectors may contain one or more selectable marker genes - such as a gene which confers antibiotic resistance e.g. ampicillin, kanamycin, chloramphenicol or tetracyclin resistance. Alternatively, the selection may be accomplished by co-transformation (as described in WO91/17243).

[0129] Vectors may be used *in vitro*, for example for the production of RNA or used to transfect or transform a host cell.

- 30 [0130] The vector may further comprise a nucleotide sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMB1 and pIJ702.

LIPID ACYL TRANSFERASE

- 35 [0131] The nucleotide sequence encoding a lipid acyl transferase for use in any one of the methods and/or uses of the present invention may encode a natural lipid acyl transferase or a variant lipid acyl transferase.

[0132] The lipid acyl transferase for use in any one of the methods and/or uses of the present invention may be a natural lipid acyl transferase or a variant lipid acyl transferase.

- 40 [0133] For instance, the nucleotide sequence encoding a lipid acyl transferase for use in the present invention may be one as described in WO2004/064537, WO2004/064987, WO2005/066347, or WO2006/008508.

- 45 [0134] The term "lipid acyl transferase" as used herein preferably means an enzyme that has acyltransferase activity (generally classified as E.C. 2.3.1.x, for example 2.3.1.43), whereby the enzyme is capable of transferring an acyl group from a lipid to one or more acceptor substrates, such as one or more of the following: a sterol; a stanol; a carbohydrate; a protein; a protein subunit; a sugar alcohol, such as ascorbic acid and/or glycerol - preferably glycerol and/or a sterol, such as cholesterol.

[0135] Preferably, the lipid acyl transferase for use in any one of the methods and/or uses of the present

invention is a lipid acyltransferase that is capable of transferring an acyl group from a phospholipid (as defined herein) to a sugar alcohol, such as ascorbic acid and/or glycerol and/or a sterol, preferably glycerol or a sterol, most preferably a sterol (e.g. cholesterol).

5 [0136] For some aspects the "acyl acceptor" may be any compound comprising a hydroxy group (-OH), such as for example, polyvalent alcohols, including glycerol; sterols; stanols; carbohydrates; hydroxy acids including fruit acids, citric acid, tartaric acid, lactic acid and ascorbic acid; proteins or a sub-unit thereof, such as amino acids, protein hydrolysates and peptides (partly hydrolysed protein) for example; and mixtures and derivatives thereof. Preferably, the "acyl acceptor" according to the present invention is not water. Preferably,
10 the "acyl acceptor" according to the present invention is a sugar alcohol, such as a polyol, most preferably glycerol. For the purpose of this invention ascorbic acid is also considered a sugar-alcohol.

[0137] The acyl acceptor is preferably not a monoglyceride.

15 [0138] The acyl acceptor is preferably not a diglyceride

[0139] In one aspect, the lipid acyltransferase for use in any one of the methods and/or uses of the present invention is a lipid acyltransferase that may, as well as being able to transfer an acyl group from a lipid to glycerol, additionally be able to transfer the acyl group from a lipid to one or more of the following: a
20 carbohydrate, a protein, a protein subunit, sterol and/or a stanol, preferably it is capable of transferring to both a sugar alcohol, such as ascorbic acid and/or glycerol, most preferably a sterol such as cholesterol, and/or plant sterols/stanols.

25 [0140] Preferably, the lipid substrate upon which the lipid acyl acts is one or more of the following lipids: a phospholipid, such as a lecithin, e.g. phosphatidylcholine and/or phosphatidylethanolamine.

[0141] This lipid substrate may be referred to herein as the "lipid acyl donor". The term lecithin as used herein encompasses phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine and phosphatidylglycerol.
30

[0142] For some aspects, preferably the lipid acyl transferase for use in any one of the methods and/or uses of the present invention is a lipid acyltransferase that is incapable, or substantially incapable, of acting on a triglyceride and/or a 1-monoglyceride and/or 2-monoglyceride.

35 [0143] For some aspects, preferably the lipid acyl transferase for use in any one of the methods and/or uses of the present invention is a lipid acyltransferase that does not exhibit triacylglycerol lipase activity (E.C. 3.1.1.3) or does not exhibit significant triacylglycerol lipase activity (E.C. 3.1.1.3).

40 [0144] The ability to hydrolyse triglyceride (E.C. 3.1.1.3 activity) may be determined by lipase activity is determined according to Food Chemical Codex (3rd Ed., 1981, pp 492-493) modified to sunflower oil and pH 5.5 instead of olive oil and pH 6.5. The lipase activity is measured as LUS (lipase units sunflower) where 1 LUS is defined as the quantity of enzyme which can release 1 [mu]mol of fatty acids per minute from sunflower oil under the above assay conditions. Alternatively the LUT assay as defined in WO9845453 may be used.
45

[0145] The lipid acyl transferase for use in any one of the methods and/or uses of the present invention may be a lipid acyltransferase which is substantially incapable of acting on a triglyceride may have a LUS/mg of less than 1000, for example less than 500, such as less than 300, preferably less than 200, more preferably less than 100, more preferably less than 50, more preferably less than 20, more preferably less than 10, such as less than 5, less than 2, more preferably less than 1 LUS/mg. Alternatively LUT/mg activity is less than 500, such as less than 300, preferably less than 200, more preferably less than 100, more preferably less than 50, more
50

preferably less than 20, more preferably less than 10, such as less than 5, less than 2, more preferably less than 1 LUT/mg.

[0146] The lipid acyl transferase for use in any one of the methods and/or uses of the present invention may be a lipid acyltransferase which is substantially incapable of acting on a monoglyceride. This may be determined by using mono-oleate (M7765 1-Oleoyl-rac-glycerol 99%) in place of the sunflower oil in the LUS assay. 1 MGHU is defined as the quantity of enzyme which can release 1 [mu]mol of fatty acids per minute from monoglyceride under the assay conditions.

[0147] The lipid acyl transferase for use in any one of the methods and/or uses of the present invention is a lipid acyltransferase which is preferably substantially incapable of acting on a triglyceride may have a MGHU/mg of less than 5000, for example less than 1000, for example less than 500, such as less than 300, preferably less than 200, more preferably less than 100, more preferably less than 50, more preferably less than 20, more preferably less than 10, such as less than 5, less than 2, more preferably less than 1 MGHU/mg.

[0148] Suitably, the lipid acyltransferase for use in any one of the methods and/or uses of the present invention is a lipid acyltransferase that may exhibit one or more of the following phospholipase activities: phospholipase A2 activity (E.C. 3.1.1.4) and/or phospholipase A1 activity (E.C. 3.1.1.32). The lipid acyl transferase may also have phospholipase B activity (E.C 3.1.1.5).

[0149] Suitably, for some aspects the lipid acyltransferase may be capable of transferring an acyl group from a phospholipid to a sugar alcohol, preferably glycerol and/or ascorbic acid.

[0150] Suitably, for some aspects the lipid acyltransferase may be capable of transferring an acyl group from a phospholipid to a stanol and/or sterol, preferably cholesterol.

[0151] For some aspects, preferably the lipid acyltransferase for use any one of the methods and/or uses of the present invention encodes a lipid acyltransferase that is capable of transferring an acyl group from a phospholipid to a sterol and/or a stanol to form at least a sterol ester and/or a stanol ester.

[0152] The lipid acyltransferase may be capable of transferring an acyl group from a lipid to a polyol such as glycerol, and/or a sterol such as cholesterol or plant sterol/stanols. Thus, in one embodiment the "acyl acceptor" according to the present invention may be glycerol and/or cholesterol or plant sterol/stanols.

[0153] Preferably, the lipid acyltransferase enzyme may be characterised using the following criteria:

the enzyme possesses acyl transferase activity which may be defined as ester transfer activity whereby the acyl part of an original ester bond of a lipid acyl donor is transferred to an acyl acceptor, preferably glycerol or cholesterol, to form a new ester; and

the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S.

[0154] Preferably, X of the GDSX motif is L or Y. More preferably, X of the GDSX motif is L. Thus, preferably the enzyme according to the present invention comprises the amino acid sequence motif GDSL.

[0155] The GDSX motif is comprised of four conserved amino acids. Preferably, the serine within the motif is a catalytic serine of the lipid acyl transferase enzyme. Suitably, the serine of the GDSX motif may be in a position corresponding to Ser-16 in *Aeromonas hydrophila* lipid acyltransferase enzyme taught in Brumlik & Buckley (Journal of Bacteriology Apr. 1996, Vol. 178, No. 7, p 2060-2064).

[0156] To determine if a protein has the GDSX motif according to the present invention, the sequence is preferably compared with the hidden markov model profiles (HMM profiles) of the pfam database in accordance with the procedures taught in WO2004/064537 or WO2004/064987.

[0157] Preferably the lipid acyl transferase enzyme can be aligned using the Pfam00657 consensus sequence (for a full explanation see WO2004/064537 or WO2004/064987).

[0158] Preferably, a positive match with the hidden markov model profile (HMM profile) of the pfam00657 domain family indicates the presence of the GDSL or GDSX domain according to the present invention.

[0159] Preferably when aligned with the Pfam00657 consensus sequence the lipid acyltransferase for use in the methods or uses of the invention may have at least one, preferably more than one, preferably more than two, of the following, a GDSx block, a GANDY block, a HPT block. Suitably, the lipid acyltransferase may have a GDSx block and a GANDY block. Alternatively, the enzyme may have a GDSx block and a HPT block. Preferably the enzyme comprises at least a GDSx block. See WO2004/064537 or WO2004/064987 for further details.

[0160] Preferably, residues of the GANDY motif are selected from GANDY, GGND, GGNDL, most preferably GANDY.

[0161] Preferably, when aligned with the Pfam00657 consensus sequence the enzyme for use in the methods or uses of the invention have at least one, preferably more than one, preferably more than two, preferably more than three, preferably more than four, preferably more than five, preferably more than six, preferably more than seven, preferably more than eight, preferably more than nine, preferably more than ten, preferably more than eleven, preferably more than twelve, preferably more than thirteen, preferably more than fourteen, of the following amino acid residues when compared to the reference *A. hydrophila* polypeptide sequence, namely SEQ ID No. 1: 28hid, 29hid, 30hid, 31 hid, 32gly, 33Asp, 34Ser, 35hid, 130hid, 131Gly, 132Hid, 133Asn, 134Asp, 135hid, 309His.

[0162] The pfam00657 GDSX domain is a unique identifier which distinguishes proteins possessing this domain from other enzymes.

[0163] The pfam00657 consensus sequence is presented in Figure 3 as SEQ ID No. 2. This is derived from the identification of the pfam family 00657, database version 6, which may also be referred to as pfam00657.6 herein.

[0164] The consensus sequence may be updated by using further releases of the pfam database (for example see WO2004/064537 or WO2004/064987).

[0165] In one embodiment, the lipid acyl transferase enzyme for use in any one of the methods and/or uses of the present invention is a lipid acyltransferase that may be characterised using the following criteria:

1. (i) the enzyme possesses acyl transferase activity which may be defined as ester transfer activity whereby the acyl part of an original ester bond of a lipid acyl donor is transferred to acyl acceptor, preferably glycerol or cholesterol, to form a new ester, preferably monoglyceride or cholesterol ester respectfully;
2. (ii) the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S.;
3. (iii) the enzyme comprises His-309 or comprises a histidine residue at a position corresponding to His-309 in the *Aeromonas hydrophila* lipid acyltransferase enzyme shown in Figures 2 and 4 (SEQ ID No. 1 or SEQ ID No. 3).

[0166] Preferably, the amino acid residue of the GDSX motif is L.

[0167] In SEQ ID No. 3 or SEQ ID No. 1 the first 18 amino acid residues form a signal sequence. His-309 of the full length sequence, that is the protein including the signal sequence, equates to His-291 of the mature part of the protein, i.e. the sequence without the signal sequence.

[0168] In one embodiment, the lipid acyl transferase enzyme for use any one of the methods and uses of the present invention is a lipid acyltransferase that comprises the following catalytic triad: Ser-34, Asp-306 and His-309 or comprises a serine residue, an aspartic acid residue and a histidine residue, respectively, at positions corresponding to Ser-34, Asp-306 and His-309 in the *Aeromonas hydrophila* lipid acyl transferase enzyme shown in Figure 4 (SEQ ID No. 3) or Figure 2 (SEQ ID No. 1). As stated above, in the sequence shown in SEQ ID No. 3 or SEQ ID No. 1 the first 18 amino acid residues form a signal sequence. Ser-34, Asp-306 and His-309 of the full length sequence, that is the protein including the signal sequence, equate to Ser-16, Asp-288 and His-291 of the mature part of the protein, i.e. the sequence without the signal sequence. In the pfam00657 consensus sequence, as given in Figure 3 (SEQ ID No. 2) the active site residues correspond to Ser-7, Asp-345 and His-348.

[0169] In one embodiment, the lipid acyl transferase enzyme for use any one of the methods and/or uses of the present invention is a lipid acyltransferase that may be characterised using the following criteria:

the enzyme possesses acyl transferase activity which may be defined as ester transfer activity whereby the acyl part of an original ester bond of a first lipid acyl donor is transferred to an acyl acceptor to form a new ester; and

the enzyme comprises at least Gly-32, Asp-33, Ser-34, Asp-134 and His-309 or comprises glycine, aspartic acid, serine, aspartic acid and histidine residues at positions corresponding to Gly-32, Asp-33, Ser-34, Asp-306 and His-309, respectively, in the *Aeromonas hydrophila* lipid acyltransferase enzyme shown in SEQ ID No. 3 or SEQ ID No. 1.

[0170] Suitably, the lipid acyltransferase enzyme for use in any one of the methods and/or uses of the present invention may be encoded by one of the following nucleotide sequences:

1. (a) the nucleotide sequence shown as SEQ ID No. 36 (see Figure 29);
2. (b) the nucleotide sequence shown as SEQ ID No. 38 (see Figure 31);
3. (c) the nucleotide sequence shown as SEQ ID No. 39 (see Figure 32);
4. (d) the nucleotide sequence shown as SEQ ID No. 42 (see Figure 35);
5. (e) the nucleotide sequence shown as SEQ ID No. 44 (see Figure 37);
6. (f) the nucleotide sequence shown as SEQ ID No. 46 (see Figure 39);
7. (g) the nucleotide sequence shown as SEQ ID No. 48 (see Figure 41);
8. (h) the nucleotide sequence shown as SEQ ID No. 49 (see Figure 57);
9. (i) the nucleotide sequence shown as SEQ ID No. 50 (see Figure 58);
10. (j) the nucleotide sequence shown as SEQ ID No. 51 (see Figure 59);
11. (k) the nucleotide sequence shown as SEQ ID No. 52 (see Figure 60);
12. (l) the nucleotide sequence shown as SEQ ID No. 53 (see Figure 61);
13. (m) the nucleotide sequence shown as SEQ ID No. 54 (see Figure 62);
14. (n) the nucleotide sequence shown as SEQ ID No. 55 (see Figure 63);
15. (o) the nucleotide sequence shown as SEQ ID No. 56 (see Figure 64);
16. (p) the nucleotide sequence shown as SEQ ID No. 57 (see Figure 65);
17. (q) the nucleotide sequence shown as SEQ ID No. 58 (see Figure 66);
18. (r) the nucleotide sequence shown as SEQ ID No. 59 (see Figure 67);

19. (s) the nucleotide sequence shown as SEQ ID No. 60 (see Figure 68);
20. (t) the nucleotide sequence shown as SEQ ID No. 61 (see Figure 69);
21. (u) the nucleotide sequence shown as SEQ ID No. 62 (see Figure 70);
22. (v) the nucleotide sequence shown as SEQ ID No. 63 (see Figure 71);
23. (w) or

a nucleotide sequence which has 70% or more, preferably 75% or more, identity with any one of the sequences shown as SEQ ID No. 36, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 42, SEQ ID No. 44, SEQ ID No. 46, SEQ ID No. 48, SEQ ID No. 49, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54, SEQ ID No. 55, SEQ ID No. 56, SEQ ID No. 57, SEQ ID No. 58, SEQ ID No. 59, SEQ ID No. 60, SEQ ID No. 61, SEQ ID No. 62 or SEQ ID No. 63.

[0171] Suitably the nucleotide sequence may have 80% or more, preferably 85% or more, more preferably 90% or more and even more preferably 95% or more identity with any one of the sequences shown as SEQ ID No. 36, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 42, SEQ ID No. 44, SEQ ID No. 46, SEQ ID No. 48, SEQ ID No. 49, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 52, SEQ ID No. 53, SEQ ID No. 54, SEQ ID No. 55, SEQ ID No. 56, SEQ ID No. 57, SEQ ID No. 58, SEQ ID No. 59, SEQ ID No. 60, SEQ ID No. 61, SEQ ID No. 62 or SEQ ID No. 63.

[0172] In one embodiment, the nucleotide sequence encoding a lipid acyltransferase enzyme for use any one of the methods and uses of the present invention is a nucleotide sequence which has 70% or more, preferably 75% or more, identity with any one of the sequences shown as: SEQ ID No. 49, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 62, and SEQ ID No. 63. Suitably the nucleotide sequence may have 80% or more, preferably 85% or more, more preferably 90% or more and even more preferably 95% or more identity with any one of the sequences shown as: SEQ ID No. 49, SEQ ID No. 50, SEQ ID No. 51, SEQ ID No. 62, and SEQ ID No. 63.

[0173] In one embodiment, the nucleotide sequence encoding a lipid acyltransferase enzyme for use in any one of the methods and uses of the present invention is a nucleotide sequence which has 70% or more, 75% or more, 80% or more, preferably 85% or more, more preferably 90% or more and even more preferably 95% or more identity the sequence shown as SEQ ID No. 49.

[0174] Suitably, the lipid acyl transferase enzyme for use any one of the methods and/or uses of the present invention may be a lipid acyltransferase that comprises one or more of the following amino acid sequences:

1. (i) the amino acid sequence shown as SEQ ID No. 3
2. (ii) the amino acid sequence shown as SEQ ID No. 4
3. (iii) the amino acid sequence shown as SEQ ID No. 5
4. (iv) the amino acid sequence shown as SEQ ID No. 6
5. (v) the amino acid sequence shown as SEQ ID No. 7
6. (vi) the amino acid sequence shown as SEQ ID No. 8
7. (vii) the amino acid sequence shown as SEQ ID No. 9
8. (viii) the amino acid sequence shown as SEQ ID No. 10
9. (ix) the amino acid sequence shown as SEQ ID No. 11
10. (x) the amino acid sequence shown as SEQ ID No. 12
11. (xi) the amino acid sequence shown as SEQ ID No. 13
12. (xii) the amino acid sequence shown as SEQ ID No. 14
13. (xiii) the amino acid sequence shown as SEQ ID No. 1
14. (xiv) the amino acid sequence shown as SEQ ID No. 15
15. (xv) the amino acid sequence shown as SEQ ID No. 16
16. (xvi) the amino acid sequence shown as SEQ ID No. 17
17. (xvii) the amino acid sequence shown as SEQ ID No. 18

18. (xviii) the amino acid sequence shown as SEQ ID No. 34

19. (xix) the amino acid sequence shown as SEQ ID No. 35 or

an amino acid sequence which has 75%, 80%, 85%, 90%, 95%, 98% or more identity with any one of the sequences shown as SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14 or SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 34 or SEQ ID No. 35.

[0175] Suitably, the lipid acyl transferase enzyme for use any one of the methods and uses of the present invention may be a lipid acyltransferase that comprises either the amino acid sequence shown as SEQ ID No. 3 or as SEQ ID No. 4 or SEQ ID No. 1 or SEQ ID No. 15 or SEQ ID No. 16, or SEQ ID No. 34 or SEQ ID No. 35 or comprises an amino acid sequence which has 75% or more, preferably 80% or more, preferably 85% or more, preferably 90% or more, preferably 95% or more, identity with the amino acid sequence shown as SEQ ID No. 3 or the amino acid sequence shown as SEQ ID No. 4 or the amino acid sequence shown as SEQ ID No. 1 or the amino acid sequence shown as SEQ ID No. 15 or the amino acid sequence shown as SEQ ID No. 16 or the amino acid sequence shown as SEQ ID No. 34 or the amino acid sequence shown as SEQ ID No. 35.

[0176] Suitably the lipid acyl transferase enzyme for use any one of the methods and/or uses of the present invention may be a lipid acyltransferase that comprises an amino acid sequence which has 80% or more, preferably 85% or more, more preferably 90% or more and even more preferably 95% or more identity with any one of the sequences shown as SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 34 or SEQ ID No. 35.

[0177] Suitably, the lipid acyl transferase enzyme for use any one of the methods and/or uses of the present invention may be a lipid acyltransferase that comprises one or more of the following amino acid sequences:

1. (a) an amino acid sequence shown as amino acid residues 1-100 of SEQ ID No. 3 or SEQ ID No. 1;
2. (b) an amino acid sequence shown as amino acids residues 101-200 of SEQ ID No. 3 or SEQ ID No. 1;
3. (c) an amino acid sequence shown as amino acid residues 201-300 of SEQ ID No. 3 or SEQ ID No. 1; or
4. (d) an amino acid sequence which has 75% or more, preferably 85% or more, more preferably 90% or more, even more preferably 95% or more identity to any one of the amino acid sequences defined in (a)-(c) above.

[0178] Suitably, the lipid acyl transferase enzyme for use in methods and uses of the present invention may comprise one or more of the following amino acid sequences:

1. (a) an amino acid sequence shown as amino acid residues 28-39 of SEQ ID No. 3 or SEQ ID No. 1;
2. (b) an amino acid sequence shown as amino acids residues 77-88 of SEQ ID No. 3 or SEQ ID No. 1;
3. (c) an amino acid sequence shown as amino acid residues 126-136 of SEQ ID No. 3 or SEQ ID No. 1;
4. (d) an amino acid sequence shown as amino acid residues 163-175 of SEQ ID No. 3 or SEQ ID No. 1;
5. (e) an amino acid sequence shown as amino acid residues 304-311 of SEQ ID No. 3 or SEQ ID No. 1; or

6. (f) an amino acid sequence which has 75% or more, preferably 85% or more, more preferably 90% or more, even more preferably 95% or more identity to any one of the amino acid sequences defined in (a)-(e) above.

[0179] In one aspect, the lipid acyl transferase enzyme for use any one of the methods and/or uses of the present invention is a lipid acyltransferase that may be the lipid acyl transferase from *Candida parapsilosis* as taught in EP 1 275 711. Thus in one aspect the lipid acyl transferase for use in the method and uses of the present invention may be a lipid acyl transferase comprising one of the amino acid sequences taught in SEQ ID No. 17 or SEQ ID No. 18.

[0180] Much by preference, the lipid acyl transferase enzyme for use in any one of the methods and uses of the present invention is a lipid acyltransferase that may be a lipid acyl transferase comprising the amino acid sequence shown as SEQ ID No. 16, or an amino acid sequence which has 75% or more, preferably 85% or more, more preferably 90% or more, even more preferably 95% or more, even more preferably 98% or more, or even more preferably 99% or more identity to SEQ ID No. 16. This enzyme could be considered a variant enzyme.

[0181] In one aspect, the lipid acyltransferase enzyme for use any one of the methods and/or uses of the present invention is a lipid acyltransferase that may be a lecithin:cholesterol acyltransferase (LCAT) or variant thereof (for example a variant made by molecular evolution)

[0182] Suitable LCATs are known in the art and may be obtainable from one or more of the following organisms for example: mammals, rat, mice, chickens, *Drosophila melanogaster*, plants, including *Arabidopsis* and *Oryza sativa*, nematodes, fungi and yeast.

[0183] In one embodiment the lipid acyltransferase enzyme for use any one of the methods and/or uses of the present invention is a lipid acyltransferase that may be the lipid acyltransferase obtainable, preferably obtained, from the E. coli strains TOP 10 harbouring pPet12aAhydro and pPet12aASalmo deposited by Danisco A/S of Langebrogade 1, DK-1001 Copenhagen K, Denmark under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure at the National Collection of Industrial, Marine and Food Bacteria (NCIMB) 23 St. Machar Street, Aberdeen Scotland, GB on 22 December 2003 under accession numbers NCIMB 41204 and NCIMB 41205, respectively.

[0184] A lipid acyltransferase enzyme for use in any one of the methods and/or uses of the present invention may be a phospholipid glycerol acyl transferase. Phospholipid glycerol acyl transferases include those isolated from *Aeromonas* spp., preferably *Aeromonas hydrophila* or *A. salmonicida*, most preferably *A. salmonicida* or variants thereof.

[0185] Most preferred lipid acyl transferases for use in the present invention are encoded by SEQ ID No.s 1, 3, 4, 15, 16, 34 and 35. It will be recognised by the skilled person that it is preferable that the signal peptides of the acyl transferase has been cleaved during expression of the transferase. The signal peptide of SEQ ID No.s 1, 3, 4, 15 and 16 are amino acids 1-18. Therefore the most preferred regions are amino acids 19-335 for SEQ ID No. 1 and SEQ ID No. 3 (*A. hydrophila*) and amino acids 19-336 for SEQ ID No. 4, SEQ ID No. 15 and SEQ ID No. 16 (*A. salmonicida*). When used to determine the homology of identity of the amino acid sequences, it is preferred that the alignments as herein described use the mature sequence.

[0186] In one embodiment, suitably the lipid acyl transferase for use in the present invention comprises (or consists of) the amino acid sequence shown in SEQ ID No. 16 or comprises (or consists of) an amino acid sequence which has at least 70%, at least 75%, at least 85%, at least 90%, at least 95%, at least 98% identity to SEQ ID No. 16.

[0187] In one embodiment, suitably the lipid acyl transferase for use in the present invention is encoded by a nucleotide sequence comprising (or consisting of) a nucleotide sequence shown in SEQ ID No. 68 or comprises (or consists of) a nucleotide sequence which has at least 70%, at least 75%, at least 85%, at least 90%, at least 95%, at least 98% identity to SEQ ID No. 68.

[0188] Therefore the most preferred regions for determining homology (identity) are amino acids 19-335 for SEQ ID No. 1 and 3 (*A. hydrophilia*) and amino acids 19-336 for SEQ ID No.s 4, 15 and 16. (*A. salmonicida*). SEQ ID No.s 34 and 35 are mature protein sequences of a lipid acyl transferase from *A. hydrophilia* and *A. salmonicida* respectively which may or may not undergo further post-translational modification.

[0189] A lipid acyltransferase enzyme for use any one of the methods and uses of the present invention may be a lipid acyltransferase that may also be isolated from *Thermobifida*, preferably *T. fusca*, most preferably that encoded by SEQ ID No. 28.

[0190] Suitable lipid acyltransferases for use in accordance with the present invention and/or in the methods of the present invention may comprise any one of the following amino acid sequences and/or be encoded by the following nucleotide sequences:

1. a) a nucleic acid which encodes a polypeptide exhibiting lipid acyltransferase activity and is at least 70% identical (preferably at least 80%, more preferably at least 90% identical) with the polypeptide sequence shown in SEQ ID No. 16 or with the polypeptide shown in SEQ ID no. 68;
2. b) a (isolated) polypeptide comprising (or consisting of) an amino acid sequence as shown in SEQ ID No. 16 or SEQ ID No. 68 or an amino acid sequence which is at least 70% identical (preferably at least 80% identical, more preferably at least 90% identical) with SEQ ID No. 16 or SEQ ID No. 68;
3. c) a nucleic acid encoding a lipid acyltransferase, which nucleic acid comprises (or consists of) a nucleotide sequence shown as SEQ ID No. 49 or a nucleotide sequence which is at least 70% identical (preferably at least 80%, more preferably at least 90% identical) with the nucleotide sequence shown as SEQ ID No. 49;
4. d) a nucleic acid which hybridises under medium or high stringency conditions to a nucleic acid probe comprising the nucleotide sequence shown as SEQ ID No. 49 and encodes for a polypeptide exhibiting lipid acyltransferase activity;
5. e) a nucleic acid which is a fragment of the nucleic acid sequences specified in a), c) or d); or
6. f) a polypeptide which is a fragment of the polypeptide specified in b).

[0191] A lipid acyltransferase enzyme for use any one of the methods and uses of the present invention may be a lipid acyltransferase that may also be isolated from *Streptomyces*, preferable *S. avermitis*, most preferably that encoded by SEQ ID No. 32. Other possible enzymes for use in the present invention from *Streptomyces* include those encoded by SEQ ID No.s 5, 6, 9, 10, 11, 12, 13, 14, 31, and 33.

[0192] An enzyme for use in the invention may also be isolated from *Corynebacterium*, preferably *C. efficiens*, most preferably that encoded by SEQ ID No. 29.

[0193] Suitably, the lipid acyltransferase enzyme for use any one of the methods and/or uses of the present invention may be a lipid acyltransferase that comprises any one of the amino acid sequences shown as SEQ ID No.s 37, 38, 40, 41, 43, 45, or 47 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, or may be encoded by any one of the nucleotide sequences shown as SEQ ID No.s 36, 39, 42, 44, 46, or 48 or a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.

[0194] In one embodiment, the nucleotide sequence encoding a lipid acyltransferase enzyme for use any one of the methods and/or uses of the present invention is selected from the group consisting of:

1. a) a nucleic acid comprising a nucleotide sequence shown in SEQ ID No. 36;
2. b) a nucleic acid which is related to the nucleotide sequence of SEQ ID No. by the degeneration of the genetic code; and
3. c) a nucleic acid comprising a nucleotide sequence which has at least 70% identity with the nucleotide sequence shown in SEQ ID No. 36.

[0195] In one embodiment, the lipid acyltransferase enzyme for use any one of the methods and/or uses of the present invention is a lipid acyltransferase that comprises an amino acid sequence as shown in SEQ ID No. 37 or an amino acid sequence which has at least 60% identity thereto.

[0196] In a further embodiment the lipid acyltransferase enzyme for use any one of the methods and/or uses of the present invention may be a lipid acyltransferase comprising any one of the amino acid sequences shown as SEQ ID No. 37, 38, 40, 41, 43, 45 or 47 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, or may be encoded by any one of the nucleotide sequences shown as SEQ ID No. 39, 42, 44, 46 or 48 or a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.

[0197] In a further embodiment the lipid acyltransferase enzyme for use any one of the methods and/or uses of the present invention may be a lipid acyltransferase comprising any one of amino sequences shown as SEQ ID No. 38, 40, 41, 45 or 47 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith for the uses described herein.

[0198] In a further embodiment the lipid acyltransferase for use in any one of the methods and/or uses of the present invention may be a lipid acyltransferase comprising any one of amino sequences shown as SEQ ID No. 38, 40, or 47 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith for the uses described herein.

[0199] More preferably in one embodiment the lipid acyltransferase for use in any one of the methods and/or uses of the present invention may be a lipid acyltransferase comprising the amino acid sequence shown as SEQ ID No. 47 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.

[0200] In another embodiment the lipid acyltransferase for use in any one of the methods and uses of the present invention may be a lipid acyltransferase comprising the amino acid sequence shown as SEQ ID No. 43 or 44 or an amino acid sequence which has at least 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.

[0201] In another embodiment the lipid acyltransferase for use in any one of the methods and uses of the present invention may be a lipid acyltransferase comprising the amino acid sequence shown as SEQ ID No. 41 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.

[0202] In one embodiment the lipid acyltransferase for use in any one of the methods and uses of the present invention may be encoded by a nucleic acid selected from the group consisting of:

1. a) a nucleic acid comprising a nucleotide sequence shown in SEQ ID No. 36;

2. b) a nucleic acid which is related to the nucleotide sequence of SEQ ID No. 36 by the degeneration of the genetic code; and
3. c) a nucleic acid comprising a nucleotide sequence which has at least 70% identity with the nucleotide sequence shown in SEQ ID No. 36.

5

[0203] In one embodiment the lipid acyltransferase according to the present invention may be a lipid acyltransferase obtainable, preferably obtained, from the *Streptomyces* strains L130 or L131 deposited by Danisco A/S of Langebrogade 1, DK-1001 Copenhagen K, Denmark under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure at the National Collection of Industrial, Marine and Food Bacteria (NCIMB) 23 St. Machar Street, Aberdeen Scotland, GB on 25 June 2004 under accession numbers NCIMB 41226 and NCIMB 41227, respectively.

10

15

[0204] Suitable nucleotide sequences encoding a lipid acyltransferase for use in any one of the methods and/or uses of the present invention may encode a polynucleotide encoding a lipid acyltransferase (SEQ ID No. 16); or may encode an amino acid sequence of a lipid acyltransferase (SEQ ID No. 16).

20

[0205] A suitable lipid acyltransferases for use in any one of the methods and/or uses of the present invention may be an amino acid sequence which may be identified by alignment to the L131 (SEQ ID No. 37) sequence using Align X, the Clustal W pairwise alignment algorithm of VectorNTI using default settings.

25

[0206] An alignment of the L131 and homologues from *S. avermitilis* and *T. fusca* illustrates that the conservation of the GDSx motif (GDSY in L131 and *S. avermitilis* and *T. fusca*), the GANDY box, which is either GGNDx or GGNDL, and the HPT block (considered to be the conserved catalytic histidine). These three conserved blocks are highlighted in Figure 42.

30

[0207] When aligned to either the pfam Pfam00657 consensus sequence (as described in WO04/064987) and/or the L131 sequence herein disclosed (SEQ ID No 37) it is possible to identify three conserved regions, the GDSx block, the GANDY block and the HTP block (see WO04/064987 for further details).

[0208] When aligned to either the pfam Pfam00657 consensus sequence (as described in WO04/064987) and/or the L131 sequence herein disclosed (SEQ ID No 37)

35

1. i) The lipid acyltransferase for use in any one of the methods and uses of the present invention may be a lipid acyltransferase that has a GDSx motif, more preferably a GDSx motif selected from GDSL or GDSY motif.

and/or

2. ii) The lipid acyltransferase for use in any one of the methods and uses of the present invention may be a lipid acyltransferase that, has a GANDY block, more preferably a GANDY block comprising amino GGNDx, more preferably GGNDx or GGNDL.

and/or

3. iii) The lipid acyltransferase for use in any one of the methods and uses of the present invention may be a lipid acyltransferase that has preferably an HTP block.

and preferably

4. iv) the lipid acyltransferase for use in any one of the methods and uses of the present invention may be a lipid acyltransferase that has preferably a GDSx or GDSY motif, and a GANDY block comprising amino GGNDx, preferably GGNDx or GGNDL, and a HTP block (conserved histidine).

45



[0209] Without wishing to be bound by theory the reaction of the lipid acyltransferase and lecithin naturally present in the UHT milk can be used to change the surface activity of the native components of the milk and/or it can be used to reduce the amount of cholesterol in the milk.

[0210] The lipid acyltransferase as used herein may be referred to as a glycerophospholipid cholesterol acyltransferase. In other words the lipid acyltransferase for use in the present invention preferably has the ability to "hydrolyse" phospholipids and at the same time esterify cholesterol with the free fatty acid from the hydrolyzation this is effective a tranferase reaction (i.e. an interesterification and/or a transesterification reaction.



[0211] The degree of "hydrolysis" can be described as the ratio of phosphatidylcholine (PC) and/or phosphatidylethanolamine (PE) converted into lyso-PC or lyso-PE respectively. By the enzymatic hydrolyzation of PC into lyso-PC, the ratio between the hydrophilic part of the phospholipid molecule (polar head group) and the hydrophobic part (fatty acid chains) is altered. By removing one fatty acid (saturated and/or unsaturated fatty acids) the hydrophobic part is reduced, thus making the entire molecule more hydrophilic. Furthermore the sterical molecule conformation may be changed, which may influence phase structures (e.g. micellation) formed by the molecules in dispersion, as well as interactions with other molecules like e.g. milk proteins.

[0212] Lyso-lecithin products are known to possess improved emulsifying properties. With a high degree of interesterification and/or transesterification it is possible to obtain smaller mean oil droplet sizes in a comparative emulsification test.

[0213] By changing cholesterol into cholesterol-ester along with a change of PC and PE to lyso-PC and lyso-PE (which both have superior surface activity compared to normal PC/PE) it is possible to produce UHT milk products without cholesterol and with improved emulsion stability. This is important in the production of UHT milk and in particular in the production of flavored UHT milk, where one of the main defects is related to low emulsion stability and a high rate of creaming.

Phosphatidylcholin**Cholesterol**

+ lipid acyltransferase ↓ enzyme

Lysophosphatidylcholine**Cholesterolster**

[0214] The use of the lipid acyltransferase as defined herein results in smaller particles in the milk which is an advantage in UHT milk, where creaming is very often seen as a defect.

[0215] The function of lipid acyltransferase is that cholesterol and phospholipids will be changed into cholesterol-esters and lyso-phospholipids, giving two resulting components with surface-active properties in relation to O/W emulsions. It has been shown that lipid acyltransferases promote increased stability against creaming as well as reduced cholesterol level in UHT milk. Thus the final products will contain no or significantly reduced cholesterol and have an improved emulsion stability.

[0216] The enzyme according to the present invention is preferably not a phospholipase enzyme, such as a phospholipase A1 classified as E.C. 3.1.1.32 or a phospholipase A2 classified as E.C. 3.1.1.4.

Variant lipid acyl transferase

[0217] In a preferred embodiment the nucleotide sequence encoding a lipid acyltransferase for use in any one of the methods and/or uses of the present invention may encode a lipid acyltransferase that is a variant lipid acyl transferase.

[0218] Variants which have an increased activity on phospholipids, such as increased hydrolytic activity and/or increased transferase activity, preferably increased transferase activity on phospholipids may be used.

[0219] Preferably the variant lipid acyltransferase is prepared by one or more amino acid modifications of the lipid acyl transferases as defined hereinabove.

[0220] Suitably, the lipid acyltransferase for use in any one of the methods and uses of the present invention may be a lipid acyltransferase that may be a variant lipid acyltransferase, in which case the enzyme may be characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S, and wherein the variant enzyme comprises one or more amino acid modifications compared with a parent sequence at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7 (as defined WO2005/066347 and hereinbelow).

[0221] For instance the variant lipid acyltransferase may be characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S, and wherein the variant enzyme comprises one or more amino acid modifications compared with a parent sequence at any one or more of the amino acid residues detailed in set 2 or set 4 or set 6 or set 7 (as defined in WO2005/066347 and hereinbelow) identified by said parent sequence being structurally aligned with the structural model of P10480 defined herein, which is preferably obtained by structural alignment of P10480 crystal structure coordinates with 1IVN.PDB and/or 1DEO.PDB as defined WO2005/066347 and hereinbelow.

[0222] In a further embodiment a lipid acyltransferase for use in any one of the methods and/or uses of the present invention may be a variant lipid acyltransferase that may be characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S, and wherein the variant enzyme comprises one or more amino acid modifications compared with a parent sequence at any one or more of the amino acid residues taught in set 2 identified when said parent sequence is aligned to the pfam consensus sequence (SEQ ID No. 2 -Figure 3) and modified according to a structural model of P10480 to ensure best fit overlap as defined WO2005/066347 and hereinbelow.

[0223] Suitably a lipid acyltransferase for use in any one of the methods and uses of the present invention may be a variant lipid acyltransferase enzyme that may comprise an amino acid sequence, which amino acid

sequence is shown as SEQ ID No. 34, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30,, SEQ ID No. 32, SEQ ID No. 33 or SEQ ID No. 35 except for one or more amino acid modifications at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7 (as defined WO2005/066347 and hereinbelow) identified by sequence alignment with SEQ ID No. 34.

[0224] Alternatively the lipid acyltransferase may be a variant lipid acyltransferase enzyme comprising an amino acid sequence, which amino acid sequence is shown as SEQ ID No. 34, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30, , SEQ ID No. 32, SEQ ID No. 33 or SEQ ID No. 35 except for one or more amino acid modifications at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7 as defined WO2005/066347 and hereinbelow, identified by said parent sequence being structurally aligned with the structural model of P10480 defined herein, which is preferably obtained by structural alignment of P10480 crystal structure coordinates with 1IVN.PDB and/or 1DEO.PDB as taught within WO2005/066347 and hereinbelow.

[0225] Alternatively, the lipid acyltransferase may be a variant lipid acyltransferase enzyme comprising an amino acid sequence, which amino acid sequence is shown as SEQ ID No. 34, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 32, SEQ ID No. 33 or SEQ ID No. 35 except for one or more amino acid modifications at any one or more of the amino acid residues taught in set 2 identified when said parent sequence is aligned to the pfam consensus sequence (SEQ ID No. 2) and modified according to a structural model of P10480 to ensure best fit overlap as taught within WO2005/066347 and hereinbelow.

[0226] Preferably, the parent enzyme is an enzyme which comprises, or is homologous to, the amino acid sequence shown as SEQ ID No. 34 and/or SEQ ID No. 15 and/or SEQ ID No. 35.

[0227] Preferably, the lipid acyltransferase may be a variant enzyme which comprises an amino acid sequence, which amino acid sequence is shown as SEQ ID No. 34 or SEQ ID No. 35 except for one or more amino acid modifications at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7 as defined in WO2005/066347 and hereinbelow.

DEFINITION OF SETS

Amino acid set 1:

[0228] Amino acid set 1 (note that these are amino acids in 1IVN - Figure 53 and Figure 54) Gly8, Asp9, Ser10, Leu11, Ser12, Tyr15, Gly44, Asp45, Thr46, Glu69, Leu70, Gly71, Gly72, Asn73, Asp74, Gly75, Leu76, Gln106, Ile107, Arg108, Leu109, Pro110, Tyr113, Phe121, Phe139, Phe140, Met141, Tyr145, Met151, Asp154, His157, Gly155, Ile156, Pro158

[0229] The highly conserved motifs, such as GDSx and catalytic residues, were deselected from set 1 (residues underlined). For the avoidance of doubt, set 1 defines the amino acid residues within 10Å of the central carbon atom of a glycerol in the active site of the 1IVN model.

Amino acid set 2:

[0230] Amino acid set 2 (note that the numbering of the amino acids refers to the amino acids in the P10480 mature sequence)

- 5 Leu17, Lys22, Met23, Gly40, Asn80, Pro81, Lys82, Asn87, Asn88, Trp111, Val112, Ala114, Tyr117, Leu118, Pro156, Gly159, Gln160, Asn161, Pro162, Ser163, Ala164, Arg165, Ser166, Gln167, Lys168, Val169, Val170, Glu171, Ala172, Tyr179, His180, Asn181, Met209, Leu210, Arg211, Asn215, Lys284, Met285, Gln289 and Val290.

- 10 Table of selected residues in Set 1 compared with Set 2:

IVN model			P10480 Mature sequence Residue Number
IVN	A.hyd homologue		
	PFAM	Structure	
Gly8	Gly32		
Asp9	Asp33		
Ser10	Ser34		
Leu11	Leu35		Leu17
Ser12	Ser36		Ser18
			Lys22
			Met23
Tyr15	Gly58		Gly40
Gly44	Asn98		Asn80
Asp45	Pro99		Pro81
Thr46	Lys100		Lys82
			Asn87
			Asn88
Glu69	Trp129		Trp111
Leu70	Val130		Val112
Gly71	Gly131		
Gly72	Ala132		Ala114
Asn73	Asn133		
Asp74	Asp134		
Gly75	Tyr135		Tyr117
Leu76	Leu136		Leu118
Gln106		Pro174	Pro156
Ile107		Gly177	Gly159
Arg108		Gln178	Gln160
Leu109		Asn179	Asn161

IVN model			P10480 Mature sequence Residue Number
IVN	A.hyd homologue		
	PFAM	Structure	
Pro110		180 to 190	Pro162
Tyr113			Ser163
			Ala164
			Arg165
			Ser166
			Gln167
			Lys168
			Val169
			Val170
			Glu171
			Ala172
Phe121	His198	Tyr197	Tyr179
		His198	His180
		Asn199	Asn181
Phe139	Met227		Met209
Phe140	Leu228		Leu210
Met141	Arg229		Arg211
Tyr145	Asn233		Asn215
			Lys284
Met151	Met303		Met285
Asp154	Asp306		
Gly155	Gln307		Gln289
Ile156	Val308		Val290
His157	His309		
Pro158	Pro310		

Amino acid set 3:

5 [0231] Amino acid set 3 is identical to set 2 but refers to the *Aeromonas salmonicida* (SEQ ID No. 4) coding sequence, i.e. the amino acid residue numbers are 18 higher in set 3 as this reflects the difference between the amino acid numbering in the mature protein (SEQ ID No. 34) compared with the protein including a signal sequence (SEQ ID No. 3).

[0232] The mature proteins of *Aeromonas salmonicida* GDSX (SEQ ID No. 4) and *Aeromonas hydrophila*

GDSX (SEQ ID No. 34) differ in five amino acids. These are Thr3Ser, Gln182Lys, Glu309Ala, Ser310Asn, and Gly318-, where the *salmonicida* residue is listed first and the *hydrophila* residue is listed last. The *hydrophila* protein is only 317 amino acids long and lacks a residue in position 318. The *Aeromonas salmonicida* GDSX has considerably high activity on polar lipids such as galactolipid substrates than the *Aeromonas hydrophila* protein. Site scanning was performed on all five amino acid positions.

Amino acid set 4:

[0233] Amino acid set 4 is S3, Q182, E309, S310, and -318.

[0234] Amino acid set 5:

[0235] F13S, D15N, S18G, S18V, Y30F, D116N, D116E, D157 N, Y226F, D228N Y230F.

Amino acid set 6:

[0236] Amino acid set 6 is Ser3, Leu17, Lys22, Met23, Gly40, Asn80, Pro81, Lys82, Asn 87, Asn88, Trp111, Val112, Ala114, Tyr117, Leu118, Pro156, Gly159, Gln160, Asn161, Pro162, Ser163, Ala164, Arg165, Ser166, Gln167, Lys168, Val169, Val170, Glu171, Ala172, Tyr179, His180, Asn181, Gln182, Met209, Leu210, Arg211, Asn215, Lys284, Met285, Gln289, Val290, Glu309, Ser310, -318.

[0237] The numbering of the amino acids in set 6 refers to the amino acids residues in P10480 (SEQ ID No. 3) - corresponding amino acids in other sequence backbones can be determined by homology alignment and/or structural alignment to P10480 and/or 1IVN.

Amino acid set 7:

[0238] Amino acid set 7 is Ser3, Leu17, Lys22, Met23, Gly40, Asn80, Pro81, Lys82, Asn 87, Asn88, Trp111, Val112, Ala114, Tyr117, Leu118, Pro156, Gly159, Gln160, Asn161, Pro162, Ser163, Ala164, Arg165, Ser166, Gln167, Lys168, Val169, Val170, Glu171, Ala172, Tyr179, His180, Asn181, Gln182, Met209, Leu210, Arg211, Asn215, Lys284, Met285, Gln289, Val290, Glu309, Ser310, -318, Y30X (where X is selected from A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W), Y226X (where X is selected from A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W), Y230X (where X is selected from A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W), S18X (where X is selected from A, C, D, E, F, H, I, K, L, M, N, P, Q, R, T, W or Y), D157X (where X is selected from A, C, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y).

[0239] The numbering of the amino acids in set 7 refers to the amino acids residues in P10480 (SEQ ID No. 3) - corresponding amino acids in other sequence backbones can be determined by homology alignment and/or structural alignment to P10480 and/or 1IVN).

[0240] Suitably, the variant enzyme comprises one or more of the following amino acid modifications compared with the parent enzyme:

S3E, A, G, K, M, Y, R, P, N, T or G

E309Q, R or A, preferably Q or R

-318Y, H, S or Y, preferably Y.

[0241] Preferably, X of the GDSX motif is L. Thus, preferably the parent enzyme comprises the amino acid motif GDSL.

[0242] Suitably, said first parent lipid acyltransferase may comprise any one of the following amino acid sequences: SEQ ID No. 34, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 32, SEQ ID No. 33 or SEQ ID No. 35.

[0243] Suitably, said second related lipid acyltransferase may comprise any one of the following amino acid sequences: SEQ ID No. 3, SEQ ID No. 34, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 32, SEQ ID No. 33 or SEQ ID No. 35.

[0244] The variant enzyme must comprise at least one amino acid modification compared with the parent enzyme. In some embodiments, the variant enzyme may comprise at least 2, preferably at least 3, preferably at least 4, preferably at least 5, preferably at least 6, preferably at least 7, preferably at least 8, preferably at least 9, preferably at least 10 amino acid modifications compared with the parent enzyme.

[0245] When referring to specific amino acid residues herein the numbering is that obtained from alignment of the variant sequence with the reference sequence shown as SEQ ID No. 34 or SEQ ID No. 35.

[0246] In one aspect preferably the variant enzyme comprises one or more of the following amino acid substitutions:

S3A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; and/or

L17A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; and/or

S18A, C, D, E, F, H, I, K, L, M, N, P, Q, R, T, W, or Y; and/or

K22A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; and/or

M23A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, or Y; and/or

Y30A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; and/or

G40A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or

N80A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or

P81A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; and/or

K82A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; and/or

N87A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or

N88A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or

W111A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; and/or

V112A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; and/or
 A114C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
 Y117A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; and/or
 L118A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; and/or
 5 P156A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; and/or
 D157A, C, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or
 G159A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
 Q160A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; and/or
 N161A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or
 10 P162A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; and/or
 S163A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; and/or
 A164C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
 R165A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; and/or
 S166A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; and/or
 15 Q167A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; and/or
 K168A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
 V169A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; and/or
 V170A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; and/or
 E171A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
 20 A172C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
 Y179A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; and/or
 H180A, C, D, E, F, G, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or
 N181A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or
 Q182A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y, preferably K; and/or
 25 M209A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, or Y; and/or

L210 A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; and/or

R211 A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or

N215 A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or

Y226A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; and/or

5 Y230A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V or W; and/or

K284A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; and/or

M285A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, or Y; and/or

Q289A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; and/or

V290A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; and/or

10 E309A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or

S310A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y.

15 **[0247]** In addition or alternatively thereto there may be one or more C-terminal extensions. Preferably the additional C-terminal extension is comprised of one or more aliphatic amino acids, preferably a non-polar amino acid, more preferably of I, L, V or G. Thus, the present invention further provides for a variant enzyme comprising one or more of the following C-terminal extensions: 318I, 318L, 318V, 318G.

20 **[0248]** Preferred variant enzymes may have a decreased hydrolytic activity against a phospholipid, such as phosphatidylcholine (PC), may also have an increased transferase activity from a phospholipid.

[0249] Preferred variant enzymes may have an increased transferase activity from a phospholipid, such as phosphatidylcholine (PC), these may also have an increased hydrolytic activity against a phospholipid.

25 **[0250]** Modification of one or more of the following residues may result in a variant enzyme having an increased absolute transferase activity against phospholipid:

S3, D157, S310, E309, Y179, N215, K22, Q289, M23, H180, M209, L210, R211, P81, V112, N80, L82, N88; N87

30 **[0251]** Specific preferred modifications which may provide a variant enzyme having an improved transferase activity from a phospholipid may be selected from one or more of the following:

S3A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; preferably N, E, K, R, A, P or M, most preferably S3A

D157A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; preferably D157S, R, E, N, G, T, V, Q, K or C

35 S310A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; preferably S310T -318 E

- E309A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; preferably E309 R, E, L, R or A
- Y179A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V or W; preferably Y179 D, T, E, R, N, V, K, Q or S, more preferably E, R, N, V, K or Q
- N215A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y; preferably N215 S, L, R or Y
- 5 K22A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W or Y; preferably K22 E, R, C or A
- Q289A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W or Y; preferably Q289 R, E, G, PorN
- M23A, C, D, E, F, G, H, I, K, L N, P, Q, R, S, T, V, W or Y; preferably M23 K, Q, L, G, TorS
- H180A, C, D, E, F, G, I, K, L, M, P, Q, R, S, T, V, W or Y; preferably H180 Q, R or K
- 10 M209 A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W or Y; preferably M209 Q, S, R, A, N, Y, E, V or L
- L210A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; preferably L210 R, A, V, S, T, I, W or M
- R211A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; preferably R211T
- P81A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; preferably P81G
- 15 V112A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W or Y; preferably V112C
- N80A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y; preferably N80 R, G, N, D, P, T, E, V, A or G
- L82A, C, D, E, F, G, H, I, M, N, P, Q, R, S, T, V, W or Y; preferably L82N, S or E
- N88A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y; preferably N88C
- 20 N87A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y; preferably N87M or G

[0252] Preferred modification of one or more of the following residues results in a variant enzyme having an increased absolute transferase activity against phospholipid:

- S3 N, R, A, G
- 25 M23 K, Q, L, G, T, S
- H180 R
- L82G
- Y179 E, R, N, V, K or Q

E309 R, S, L or A

[0253] One preferred modification is N80D. This is particularly the case when using the reference sequence SEQ ID No. 35 as the backbone. Thus, the reference sequence may be SEQ ID No. 16. This modification may be in combination with one or more further modifications. Therefore in a preferred embodiment of the present invention the nucleotide sequence encoding a lipid acyltransferase for use in any one of the methods and uses of the present invention may encode a lipid acyltransferase that comprises SEQ ID No. 35 or an amino acid sequence which has 75% or more, preferably 85% or more, more preferably 90% or more, even more preferably 95% or more, even more preferably 98% or more, or even more preferably 99% or more identity to SEQ ID No. 35.

[0254] As noted above, when referring to specific amino acid residues herein the numbering is that obtained from alignment of the variant sequence with the reference sequence shown as SEQ ID No. 34 or SEQ ID No. 35

[0255] Much by preference, the nucleotide sequence encoding a lipid acyltransferase for use in any one of the methods and uses of the present invention may encode a lipid comprising the amino acid sequence shown as SEQ ID No. 16 or the amino acid sequence shown as SEQ ID No. 68, or an amino acid sequence which has 70% or more, preferably 75% or more, preferably 85% or more, more preferably 90% or more, even more preferably 95% or more, even more preferably 98% or more, or even more preferably 99% or more identity to SEQ ID No. 16 or SEQ ID No. 68. This enzyme may be considered a variant enzyme.

[0256] For the purposes of the present invention, the degree of identity is based on the number of sequence elements which are the same. The degree of identity in accordance with the present invention for amino acid sequences may be suitably determined by means of computer programs known in the art, such as Vector NTI 10 (Invitrogen Corp.). For pairwise alignment the score used is preferably BLOSUM62 with Gap opening penalty of 10.0 and Gap extension penalty of 0.1.

[0257] Suitably, the degree of identity with regard to an amino acid sequence is determined over at least 20 contiguous amino acids, preferably over at least 30 contiguous amino acids, preferably over at least 40 contiguous amino acids, preferably over at least 50 contiguous amino acids, preferably over at least 60 contiguous amino acids.

[0258] Suitably, the degree of identity with regard to an amino acid sequence may be determined over the whole sequence.

[0259] Suitably, the nucleotide sequence encoding a lipid acyltransferase or the lipid acyl transferase enzyme for use in the present invention may be obtainable, preferably obtained, from organisms from one or more of the following genera: *Aeromonas*, *Streptomyces*, *Saccharomyces*, *Lactococcus*, *Mycobacterium*, *Streptococcus*, *Lactobacillus*, *Desulfitobacterium*, *Bacillus*, *Campylobacter*, *Vibrionaceae*, *Xylella*, *Sulfolobus*, *Aspergillus*, *Schizosaccharomyces*, *Listeria*, *Neisseria*, *Mesorhizobium*, *Ralstonia*, *Xanthomonas*, *Candida*, *Thermobifida* and *Corynebacterium*.

[0260] Suitably, the nucleotide sequence encoding a lipid acyltransferase or the lipid acyl transferase enzyme for use in the present invention may be obtainable, preferably obtained, from one or more of the following organisms: *Aeromonas hydrophila*, *Aeromonas salmonicida*, *Streptomyces coelicolor*, *Streptomyces rimosus*, *Mycobacterium*, *Streptococcus pyogenes*, *Lactococcus lactis*, *Streptococcus pyogenes*, *Streptococcus thermophilus*, *Streptomyces thermosacchari*, *Streptomyces avermitilis*, *Lactobacillus helveticus*, *Desulfitobacterium dehalogenans*, *Bacillus sp*, *Campylobacter jejuni*, *Vibrionaceae*, *Xylella fastidiosa*, *Sulfolobus solfataricus*, *Saccharomyces cerevisiae*, *Aspergillus terreus*, *Schizosaccharomyces pombe*, *Listeria innocua*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Mesorhizobium loti*, *Ralstonia solanacearum*,

Xanthomonas campestris, *Xanthomonas axonopodis*, *Candida parapsilosis*, *Thermobifida fusca* and *Corynebacterium efficiens*.

[0261] In one aspect, preferably the nucleotide sequence encoding a lipid acyltransferase for use in any one of the methods and/or uses of the present invention encodes a lipid acyl transferase enzyme according to the present invention is obtainable, preferably obtained or derived, from one or more of *Aeromonas spp.*, *Aeromonas hydrophila* or *Aeromonas salmonicida*.

[0262] In one aspect, preferably the lipid acyltransferase for use in any one of the methods and/or uses of the present invention is a lipid acyl transferase enzyme obtainable, preferably obtained or derived, from one or more of *Aeromonas spp.*, *Aeromonas hydrophila* or *Aeromonas salmonicida*.

[0263] Enzymes which function as lipid acyltransferases in accordance with the present invention can be routinely identified using the assay taught herein below:

ASSAY FOR TRANSFERASE ACTIVITY

[0264] The transferase activity is preferably measured by the molar amount of cholesterol ester formed by acyltransfer from phospholipids and/or lipids in milk to cholesterol relative to the amount of cholesterol originally available.

[0265] Milk is incubated with enzyme or water (as control) for 30 minutes at 40 °C

[0266] Milk lipids are isolated by solvent extraction and the isolated lipids are analysed by GLC.

[0267] Based on GLC analysis the amount of cholesterol (CHL), cholesterol ester(CHLE) and free fatty acids(FFA) are calculated.

$$\% \text{ Transferase} = \frac{(\text{CHLE}(t) - \text{CHLE}(0)) \times 100}{\text{CHLE}(t) - \text{CHLE}(0) + (\text{FFA}(t) - \text{FFA}(0))}$$

[0268] Where

CHLE(O) = Mol/l Cholesterol ester Control

CHLE(t) = Mol/l Cholesterol ester Enzyme treatment

FFA(O) = Mol/l Free fatty acids Control

FFA(t) = Mol/l Free fatty acids Enzyme treatment

[0269] GLC analysis may be carried out as follows:

GLC analysis

[0270] Perkin Elmer Autosystem 9000 Capillary Gas Chromatograph equipped with WCOT fused silica column 12.5 m x 0.25 mm ID x 0.1 μ film thickness 5% phenyl-methylsilicone (CP Sil 8 CB from Chrompack).

Carrier gas: Helium.

5 Injector. PSSI cold split injection (initial temp 50°C heated to 385°C), volume 1.0 μ l Detector FID: 395°C

Oven program:		1	2	3
Oven temperature, °C.		90	280	350
Isothermal, time, min.	1	0	10	
Temperature rate, °C/min.		15	4	

Sample preparation: 30 mg of sample was dissolved in 9 ml Heptane:Pyridin, 2:1 containing internal standard heptadecane, 0.5 mg/ml. 300 μ l sample solution was transferred to a crimp vial, 300 μ l MSTFA (N-Methyl-N-trimethylsilyl-trifluoroacetamide) was added and reacted for 20 minutes at 60°C.

10 Calculation: Response factors for mono-di-triglycerides and free fatty acid were determined from Standard 2 (mono-di-triglyceride), for Cholesterol, Cholesteryl palmitate and Cholesteryl stearate the response factors were determined from pure reference material (weighing for pure material 10mg).

15 [0271] Using this assay, lipid acyltransferases/lipid acyl transferase in accordance with the present invention are those which have at least 5% transferase activity, preferably at least 10% transferase activity, preferably at least 15%, 20%, 25% 26%, 28%, 30%, 40% 50%, 60% or 75% transferase activity.

[0272] The term "transferase" as used herein is interchangeable with the term "lipid acyltransferase".

20 [0273] Suitably, the lipid acyltransferase as defined herein catalyses one or more of the following reactions: interesterification, transesterification, alcoholysis, hydrolysis.

[0274] The term "interesterification" refers to the enzymatic catalysed transfer of acyl groups between a lipid donor and lipid acceptor, wherein the lipid donor is not a free acyl group.

25 [0275] The term "transesterification" as used herein means the enzymatic catalysed transfer of an acyl group from a lipid donor (other than a free fatty acid) to an acyl acceptor (other than water).

30 [0276] As used herein, the term "alcoholysis" refers to the enzymatic cleavage of a covalent bond of an acid derivative by reaction with an alcohol ROH so that one of the products combines with the H of the alcohol and the other product combines with the OR group of the alcohol.

[0277] As used herein, the term "alcohol" refers to an alkyl compound containing a hydroxyl group.

35 [0278] As used herein, the term "hydrolysis" refers to the enzymatic catalysed transfer of an acyl group from a lipid to the OH group of a water molecule.

[0279] The term "without increasing or without substantially increasing the free fatty acids" as used herein means that preferably the lipid acyl transferase according to the present invention has 100% transferase activity (i.e. transfers 100% of the acyl groups from an acyl donor onto the acyl acceptor, with no hydrolytic activity); however, the enzyme may transfer less than 100% of the acyl groups present in the lipid acyl donor to the acyl acceptor. In which case, preferably the acyltransferase activity accounts for at least 5%, more preferably at least 10%, more preferably at least 20%, more preferably at least 30%, more preferably at least 40%, more preferably 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90% and more preferably at least 98% of the total enzyme activity. The %

45

transferase activity (i.e. the transferase activity as a percentage of the total enzymatic activity) may be determined by the following the "Assay for Transferase Activity" given above.

[0280] In some aspects of the present invention, the term "without substantially increasing free fatty acids" as used herein means that the amount of free fatty acid in a edible oil treated with an lipid acyltransferase according to the present invention is less than the amount of free fatty acid produced in the edible oil when an enzyme other than a lipid acyltransferase according to the present invention had been used, such as for example as compared with the amount of free fatty acid produced when a conventional phospholipase enzyme, e.g. Lecitase Ultra™ (Novozymes A/S, Denmark), had been used.

[0281] The term 'milk' as used herein may comprise milk from either animal or vegetable origin. It is possible to use milk from animal sources such as buffalo, (traditional) cow, sheep, goat etc. either individually or combined. Vegetable milks such as soya milk may also be used, normally in combination with the animal milk, typically at a low percentage (of vegetable milk) say below 15%, or below 20%, or below 25% v/v. The term milk preferably does not comprise cheese milk and cream.

[0282] The term 'essentially consists' as used herein, when referring to a product or composition, preferably means that the product or composition, may consist of other products or compositions but only to a maximum concentration of, preferably 10%, such as 5%, such as 3%, such as 2% or 1%, or 0.5% or 0.1 %.

[0283] For the enzyme modification of milk and/or cream for example it may be preferable to use a temperature of less than about 30°C for example, suitably less than 20°C for example, suitably less than 10°C for example. Suitable temperatures of between 1-30°C may be used, such as between 3-20°C for example, such as between 1-10°C.

[0284] The enzyme according to the present invention may be used with one or more other suitable food grade enzymes. Thus, it is within the scope of the present invention that, in addition to the enzyme, at least one further enzyme is added to the foodstuff. Such further enzymes include starch degrading enzymes such as endo- or exoamylases, pullulanases, debranching enzymes, hemicellulases including xylanases, cellulases, oxidoreductases, e.g. peroxidases, phenol oxidases, glucose oxidase, pyranose oxidase, sulfhydryl oxidase, or a carbohydrate oxidase such as one which oxidises maltose, for example hexose oxidase (HOX), lipases, phospholipases, glycolipases, galactolipases and proteases.

[0285] In one embodiment the enzyme may be Dairy HOX™, which acts as an oxygen scavenger to prolong shelf life of cheese while providing browning control in pizza ovens. Therefore in a one aspect the present disclosure relates to the use of an enzyme capable of reducing the maillard reaction in a foodstuff (see WO02/39828 incorporated herein by reference), such as a dairy product, for example cheese, wherein the enzyme is preferably a maltose oxidising enzyme such as carbohydrate oxidase, glucose oxidase and/or hexose oxidase, in the process or preparing a food material and/or foodstuff.

[0286] In one preferred embodiment the lipid acyltransferase is used in combination with a lipase having one or more of the following lipase activities: glycolipase activity (E.C. 3.1.1.26, triacylglycerol lipase activity (E.C. 3.1.1.3), phospholipase A2 activity (E.C. 3.1.1.4) or phospholipase A1 activity (E.C. 3.1.1.32). Suitably, lipolytic enzymes are well known within the art and include by way of example the following lipolytic enzymes: LIOPAN® F and/or LECITASE® ULTRA (Novozymes A/S, Denmark), phospholipase A2 (e.g. phospholipase A2 from LIPOMOD™ 22L from Biocatalysts, LIPOMAX™ from Genecor), LIPOLASE® (Novozymes A/S, Denmark), the lipases taught in WO03/97835, EP 0 977 869 or EP 1 193 314. This combination of a lipid acyl transferase as defined herein and a lipase may be particularly preferred in dough or baked products or in fine food products such as cakes and confectionary.

[0287] In some embodiments, it may also be beneficial to combine the use of lipid acyltransferase with a lipolytic enzymes such as rennet paste prepared from calf, lamb, kid stomachs, or Palatase A750L (Novo),

Palatase M200L (Novo), Palatase M1000 (Novo), or Piccantase A (DSM), also Piccantase from animal sources from DSM (K, KL, L & C) or Lipomod 187, Lipomod 338 (Biocatalysts). These lipases are used conventionally in the production of cheese to produce cheese flavours. These lipases may also be used to produce an enzymatically-modified foodstuff, for example a dairy product (e.g. cheese), particularly where said dairy product consists of, is produced from or comprises butterfat. A combination of the lipid acyltransferase with one or more of these lipases may have a beneficial effect on flavour in the dairy product (e.g. cheese for instance).

[0288] The use of lipases in combination with the enzyme of the invention may be particularly advantageous in instances where some accumulation of free fatty acids maybe desirable, for example in cheese where the free fatty acids can impart a desirable flavour, or in the preparation of fine foods. The person skilled in the art will be able to combine proportions of lipolytic enzymes, for example LIPOPAN[®] F and/or LECITASE[®] ULTRA (Novozymes A/S, Denmark), phospholipase A2 (e.g. phospholipase A2 from LIPOMOD[™] 22L from Biocatalysts, LIPOMAX[™] from Genecor), LIPOLASE[®] (Novozymes A/S, Denmark), the lipases taught in WO03/97835, EP 0 977 869 or EP 1 193, 314 and the lipid acyltransferase to provide the desired ratio of hydrolytic to transferase activity which results in a preferred technical effect or combination of technical effects in the foodstuff (such as those listed herein under "Technical Effects").

[0289] It may also be beneficial to combine the use of lipid acyltransferase with a phospholipase, such as phospholipase A1, phospholipase A2, phospholipase B, Phospholipase C and/or phospholipase D.

[0290] The combined use may be performed sequentially or concurrently, e.g. the lipid acyl transferase treatment may occur prior to or during the further enzyme treatment. Alternatively, the further enzyme treatment may occur prior to or during the lipid acyl transferase treatment.

[0291] In the case of sequential enzyme treatments, in some embodiments it may be advantageous to remove the first enzyme used, e.g. by heat deactivation or by use of an immobilised enzyme, prior to treatment with the second (and/or third etc.) enzyme.

POST-TRANSCRIPTION AND POST-TRANSLATIONAL MODIFICATIONS

[0292] Suitably the lipid acyltransferase in accordance with the present invention may be encoded by any one of the nucleotide sequences taught herein.

[0293] Depending upon the host cell used post-transcriptional and/or post-translational modifications may be made. It is envisaged that the lipid acyltransferase for use in the present methods and/or uses encompasses lipid acyltransferases which have undergone post-transcriptional and/or post-translational modification.

[0294] By way of example only, the expression of the nucleotide sequence shown herein as SEQ ID No. 49 (see Figure 57) in a host cell (such as *Bacillus licheniformis* for example) results in post-transcriptional and/or post-translational modifications which lead to the amino acid sequence shown herein as SEQ ID No. 68 (see Figure 73).

[0295] SEQ ID No. 68 is the same as SEQ ID No. 16 (shown herein in Figure 1) except that SEQ ID No. 68 has undergone post-translational and/or post-transcriptional modification to remove 38 amino acids.

ISOLATED

[0296] In one aspect, the lipid acyltransferase is a recovered/isolated lipid acyltransferase. Thus, the lipid acyltransferase produced may be in an isolated form.

[0297] In another aspect, the nucleotide sequence encoding a lipid acyltransferase for use in the present invention may be in an isolated form.

- 5 [0298] The term "isolated" means that the sequence or protein is at least substantially free from at least one other component with which the sequence or protein is naturally associated in nature and as found in nature.

PURIFIED

[0299] In one aspect, the lipid acyltransferase may be in a purified form.

10

[0300] In another aspect, the nucleotide sequence encoding a lipid acyltransferase for use in the present invention may be in a purified form.

- 15 [0301] The term "purified" means that the sequence is in a relatively pure state - e.g. at least about 51% pure, or at least about 75%, or at least about 80%, or at least about 90% pure, or at least about 95% pure or at least about 98% pure.

CLONING A NUCLEOTIDE SEQUENCE ENCODING A POLYPEPTIDE ACCORDING TO THE PRESENT INVENTION

- 20 [0302] A nucleotide sequence encoding either a polypeptide which has the specific properties as defined herein or a polypeptide which is suitable for modification may be isolated from any cell or organism producing said polypeptide. Various methods are well known within the art for the isolation of nucleotide sequences.

- 25 [0303] For example, a genomic DNA and/or cDNA library may be constructed using chromosomal DNA or messenger RNA from the organism producing the polypeptide. If the amino acid sequence of the polypeptide is known, labeled oligonucleotide probes may be synthesised and used to identify polypeptide-encoding clones from the genomic library prepared from the organism. Alternatively, a labelled oligonucleotide probe containing sequences homologous to another known polypeptide gene could be used to identify polypeptide-encoding clones. In the latter case, hybridisation and washing conditions of lower stringency are used.

- 30 [0304] Alternatively, polypeptide-encoding clones could be identified by inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming enzyme-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing an enzyme inhibited by the polypeptide, thereby allowing clones expressing the polypeptide to be identified.

- 35 [0305] In a yet further alternative, the nucleotide sequence encoding the polypeptide may be prepared synthetically by established standard methods, e.g. the phosphoroamidite method described by Beaucage S.L. et al (1981) Tetrahedron Letters 22, p 1859-1869, or the method described by Matthes et al (1984) EMBO J. 3, p 801-805. In the phosphoroamidite method, oligonucleotides are synthesised, e.g. in an automatic DNA synthesiser, purified, annealed, ligated and cloned in appropriate vectors.

- 40 [0306] The nucleotide sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin, or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate) in accordance with standard techniques. Each ligated fragment corresponds to various parts of the entire nucleotide sequence. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or in Saiki R K et al (Science (1988) 239, pp 487-491).

45

NUCLEOTIDE SEQUENCES

[0307] The present disclosure also encompasses nucleotide sequences encoding polypeptides having the specific properties as defined herein. The term "nucleotide sequence" as used herein refers to an oligonucleotide sequence or polynucleotide sequence, and variant, homologues, fragments and derivatives thereof (such as portions thereof). The nucleotide sequence may be of genomic or synthetic or recombinant origin, which may be double-stranded or single-stranded whether representing the sense or antisense strand.

[0308] The term "nucleotide sequence" in relation to the present invention includes genomic DNA, cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA for the coding sequence.

[0309] In a preferred embodiment, the nucleotide sequence *per se* encoding a polypeptide having the specific properties as defined herein does not cover the native nucleotide sequence in its natural environment when it is linked to its naturally associated sequence(s) that is/are also in its/their natural environment. For ease of reference, we shall call this preferred embodiment the "non-native nucleotide sequence". In this regard, the term "native nucleotide sequence" means an entire nucleotide sequence that is in its native environment and when operatively linked to an entire promoter with which it is naturally associated, which promoter is also in its native environment. Thus, the polypeptide can be expressed by a nucleotide sequence in its native organism but wherein the nucleotide sequence is not under the control of the promoter with which it is naturally associated within that organism.

[0310] Preferably the polypeptide is not a native polypeptide. In this regard, the term "native polypeptide" means an entire polypeptide that is in its native environment and when it has been expressed by its native nucleotide sequence.

[0311] Typically, the nucleotide sequence encoding polypeptides having the specific properties as defined herein is prepared using recombinant DNA techniques (i.e. recombinant DNA). However, in an alternative embodiment, the nucleotide sequence could be synthesised, in whole or in part, using chemical methods well known in the art (see Caruthers MH et al (1980) Nuc Acids Res Symp Ser 215-23 and Horn T et al (1980) Nuc Acids Res Symp Ser 225-232).

MOLECULAR EVOLUTION

[0312] Once an enzyme-encoding nucleotide sequence has been isolated, or a putative enzyme-encoding nucleotide sequence has been identified, it may be desirable to modify the selected nucleotide sequence, for example it may be desirable to mutate the sequence in order to prepare an enzyme in accordance with the present invention.

[0313] Mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites.

[0314] A suitable method is disclosed in Morinaga et al (Biotechnology (1984) 2, p646-649). Another method of introducing mutations into enzyme-encoding nucleotide sequences is described in Nelson and Long (Analytical Biochemistry (1989), 180, p 147-151).

[0315] Instead of site directed mutagenesis, such as described above, one can introduce mutations randomly for instance using a commercial kit such as the GeneMorph PCR mutagenesis kit from Stratagene, or the Diversify PCR random mutagenesis kit from Clontech. EP 0 583 265 refers to methods of optimising PCR based mutagenesis, which can also be combined with the use of mutagenic DNA analogues such as those

described in EP 0 866 796. Error prone PCR technologies are suitable for the production of variants of lipid acyl transferases with preferred characteristics. WO0206457 refers to molecular evolution of lipases.

[0316] A third method to obtain novel sequences is to fragment non-identical nucleotide sequences, either by using any number of restriction enzymes or an enzyme such as Dnase I, and reassembling full nucleotide sequences coding for functional proteins. Alternatively one can use one or multiple non-identical nucleotide sequences and introduce mutations during the reassembly of the full nucleotide sequence. DNA shuffling and family shuffling technologies are suitable for the production of variants of lipid acyl transferases with preferred characteristics. Suitable methods for performing 'shuffling' can be found in EPO 752 008, EP1 138 763, EP1 103 606. Shuffling can also be combined with other forms of DNA mutagenesis as described in US 6,180,406 and WO 01/34835.

[0317] Thus, it is possible to produce numerous site directed or random mutations into a nucleotide sequence, either *in vivo* or *in vitro*, and to subsequently screen for improved functionality of the encoded polypeptide by various means. Using *in silico* and *exo* mediated recombination methods (see WO 00/58517, US 6,344,328, US 6,361,974), for example, molecular evolution can be performed where the variant produced retains very low homology to known enzymes or proteins. Such variants thereby obtained may have significant structural analogy to known transferase enzymes, but have very low amino acid sequence homology.

[0318] As a non-limiting example, In addition, mutations or natural variants of a polynucleotide sequence can be recombined with either the wild type or other mutations or natural variants to produce new variants. Such new variants can also be screened for improved functionality of the encoded polypeptide.

[0319] The application of the above-mentioned and similar molecular evolution methods allows the identification and selection of variants of the enzymes of the present invention which have preferred characteristics without any prior knowledge of protein structure or function, and allows the production of non-predictable but beneficial mutations or variants. There are numerous examples of the application of molecular evolution in the art for the optimisation or alteration of enzyme activity, such examples include, but are not limited to one or more of the following: optimised expression and/or activity in a host cell or *in vitro*, increased enzymatic activity, altered substrate and/or product specificity, increased or decreased enzymatic or structural stability, altered enzymatic activity/specificity in preferred environmental conditions, e.g. temperature, pH, substrate

[0320] As will be apparent to a person skilled in the art, using molecular evolution tools an enzyme may be altered to improve the functionality of the enzyme.

[0321] Suitably, the nucleotide sequence encoding a lipid acyltransferase used in the invention may encode a variant lipid acyltransferase, i.e. the lipid acyltransferase may contain at least one amino acid substitution, deletion or addition, when compared to a parental enzyme. Variant enzymes retain at least 1%, 2%, 3%, 5%, 10%, 15%, 20%, 30%, 40%, 50 %, 60%, 70%, 80%, 90%, 95%, 97%, 99% homology with the parent enzyme. Suitable parent enzymes may include any enzyme with esterase or lipase activity. Preferably, the parent enzyme aligns to the pfam00657 consensus sequence.

[0322] In a preferable embodiment a variant lipid acyltransferase enzyme retains or incorporates at least one or more of the pfam00657 consensus sequence amino acid residues found in the GDSx, GANDY and HPT blocks.

[0323] Enzymes, such as lipases with no or low lipid acyltransferase activity in an aqueous environment may be mutated using molecular evolution tools to introduce or enhance the transferase activity, thereby producing a lipid acyltransferase enzyme with significant transferase activity suitable for use in the compositions and methods of the present disclosure.

[0324] Suitably, the nucleotide sequence encoding a lipid acyltransferase for use in any one of the methods and/or uses of the present invention may encode a lipid acyltransferase that may be a variant with enhanced enzyme activity on polar lipids, preferably phospholipids and/or glycolipids when compared to the parent enzyme. Preferably, such variants also have low or no activity on lyso polar lipids. The enhanced activity on polar lipids, phospholipids and/or glycolipids may be the result of hydrolysis and/or transferase activity or a combination of both.

[0325] Variant lipid acyltransferases may have decreased activity on triglycerides, and/or monoglycerides and/or diglycerides compared with the parent enzyme.

[0326] Suitably the variant enzyme may have no activity on triglycerides and/or monoglycerides and/or diglycerides.

[0327] Alternatively, the variant enzyme may have increased activity on triglycerides, and/or may also have increased activity on one or more of the following, polar lipids, phospholipids, lecithin, phosphatidylcholine, glycolipids, digalactosyl monoglyceride, monogalactosyl monoglyceride.

[0328] Variants of lipid acyltransferases are known, and one or more of such variants may be suitable for use in the methods and uses according to the present invention and/or in the enzyme compositions according to the present invention. By way of example only, variants of lipid acyltransferases are described in the following references may be used in accordance with the present invention: Hilton & Buckley J Biol. Chem. 1991 Jan 15; 266 (2): 997-1000; Robertson et al J. Biol. Chem. 1994 Jan 21; 269(3):2146-50; Brumlik et al J. Bacteriol 1996 Apr; 178 (7): 2060-4; Peelman et al Protein Sci. 1998 Mar; 7(3):587-99.

AMINO ACID SEQUENCES

[0329] The present invention also encompasses the use of amino acid sequences encoded by a nucleotide sequence which encodes a lipid acyltransferase for use in any one of the methods and/or uses of the present invention.

[0330] As used herein, the term "amino acid sequence" is synonymous with the term "polypeptide" and/or the term "protein". In some instances, the term "amino acid sequence" is synonymous with the term "peptide".

[0331] The amino acid sequence may be prepared/isolated from a suitable source, or it may be made synthetically or it may be prepared by use of recombinant DNA techniques.

[0332] Suitably, the amino acid sequences may be obtained from the isolated polypeptides taught herein by standard techniques.

[0333] One suitable method for determining amino acid sequences from isolated polypeptides is as follows:

[0334] Purified polypeptide may be freeze-dried and 100 µg of the freeze-dried material may be dissolved in 50 µl of a mixture of 8 M urea and 0.4 M ammonium hydrogen carbonate, pH 8.4. The dissolved protein may be denatured and reduced for 15 minutes at 50°C following overlay with nitrogen and addition of 5 µl of 45 mM dithiothreitol. After cooling to room temperature, 5 µl of 100 mM iodoacetamide may be added for the cysteine residues to be derivatized for 15 minutes at room temperature in the dark under nitrogen.

[0335] 135 µl of water and 5 µg of endoproteinase Lys-C in 5 µl of water may be added to the above reaction mixture and the digestion may be carried out at 37°C under nitrogen for 24 hours.

[0336] The resulting peptides may be separated by reverse phase HPLC on a VYDAC C18 column

(0.46x15cm;10µm; The Separation Group, California, USA) using solvent A: 0.1 % TFA in water and solvent B: 0.1 % TFA in acetonitrile. Selected peptides may be re-chromatographed on a Develosil C18 column using the same solvent system, prior to N-terminal sequencing. Sequencing may be done using an Applied Biosystems 476A sequencer using pulsed liquid fast cycles according to the manufacturer's instructions (Applied Biosystems, California, USA).

SEQUENCE IDENTITY OR SEQUENCE HOMOLOGY

[0337] Here, the term "homologue" means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences. Here, the term "homology" can be equated with "identity".

[0338] The homologous amino acid sequence and/or nucleotide sequence should provide and/or encode a polypeptide which retains the functional activity and/or enhances the activity of the enzyme.

[0339] In the present context, a homologous sequence is taken to include an amino acid sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to the subject sequence. Typically, the homologues will comprise the same active sites etc. as the subject amino acid sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

[0340] In the present context, a homologous sequence is taken to include a nucleotide sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to a nucleotide sequence encoding a polypeptide (the subject sequence). Typically, the homologues will comprise the same sequences that code for the active sites etc. as the subject sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

[0341] Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences.

[0342] % homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.

[0343] Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximise local homology.

[0344] However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. "Affine gap costs" are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment

programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons.

[0345] Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the Vector NTI (Invitrogen Corp.). Examples of other software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al 1999 Short Protocols in Molecular Biology, 4th Ed - Chapter 18), and FASTA (Altschul et al 1990 J. Mol. Biol. 403-410). Both BLAST and FASTA are available for offline and online searching (see Ausubel *et al* 1999, pages 7-58 to 7-60). However, for some applications, it is preferred to use the Vector NTI program. A new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequence (see FEMS Microbiol Lett 1999 174(2): 247-50; FEMS Microbiol Lett 1999 177(1): 187-8 and tatiana@ncbi.nlm.nih.gov).

[0346] Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs. Vector NTI programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the default values for the Vector NTI package.

[0347] Alternatively, percentage homologies may be calculated using the multiple alignment feature in Vector NTI (Invitrogen Corp.), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), Gene 73(1), 237-244).

[0348] Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

[0349] Should Gap Penalties be used when determining sequence identity, then preferably the following parameters are used for pairwise alignment:

FOR BLAST			
GAP OPEN	0		
GAP EXTENSION	0		
FOR CLUSTAL	DNA	PROTEIN	
WORD SIZE	2	1	K triple
GAP PENALTY	15	10	
GAP EXTENSION	6.66	0.1	

[0350] In one embodiment, preferably the sequence identity for the nucleotide sequences is determined using CLUSTAL with the gap penalty and gap extension set as defined above.

[0351] Suitably, the degree of identity with regard to a nucleotide sequence is determined over at least 20 contiguous nucleotides, preferably over at least 30 contiguous nucleotides, preferably over at least 40 contiguous nucleotides, preferably over at least 50 contiguous nucleotides, preferably over at least 60 contiguous nucleotides, preferably over at least 100 contiguous nucleotides.

[0352] Suitably, the degree of identity with regard to a nucleotide sequence may be determined over the whole sequence.

[0353] In one embodiment the degree of amino acid sequence identity in accordance with the present invention may be suitably determined by means of computer programs known in the art, such as Vector NTI 10 (Invitrogen Corp.). For pairwise alignment the matrix used is preferably BLOSUM62 with Gap opening penalty of 10.0 and Gap extension penalty of 0.1.

[0354] Suitably, the degree of identity with regard to an amino acid sequence is determined over at least 20 contiguous amino acids, preferably over at least 30 contiguous amino acids, preferably over at least 40 contiguous amino acids, preferably over at least 50 contiguous amino acids, preferably over at least 60 contiguous amino acids.

[0355] Suitably, the degree of identity with regard to an amino acid sequence may be determined over the whole sequence.

[0356] The sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent substance. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the secondary binding activity of the substance is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

[0357] Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
AROMATIC		H F W Y

[0358] The present disclosure also encompasses homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue, with an alternative residue) that may occur i.e. like-for-like substitution such as basic for basic, acidic for acidic, polar for polar etc. Non-homologous substitution may also occur i.e. from one class of residue to another or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as O), pyriylalanine, thienylalanine, naphthylalanine and phenylglycine.

[0359] Replacements may also be made by unnatural amino acids.

[0360] Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in

addition to amino acid spacers such as glycine or β -alanine residues. A further form of variation, involves the presence of one or more amino acid residues in peptoid form, will be well understood by those skilled in the art. For the avoidance of doubt, "the peptoid form" is used to refer to variant amino acid residues wherein the α -carbon substituent group is on the residue's nitrogen atom rather than the α -carbon. Processes for preparing peptides in the peptoid form are known in the art, for example Simon RJ et al., PNAS (1992) 89(20), 9367-9371 and Horwell DC, Trends Biotechnol. (1995) 13(4), 132-134.

[0361] Nucleotide sequences for use in the present invention or encoding a polypeptide having the specific properties defined herein may include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones and/or the addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the nucleotide sequences described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the *in vivo* activity or life span of nucleotide sequences.

[0362] The present invention also encompasses the use of nucleotide sequences that are complementary to the sequences discussed herein, or any derivative, fragment or derivative thereof. If the sequence is complementary to a fragment thereof then that sequence can be used as a probe to identify similar coding sequences in other organisms etc.

[0363] Polynucleotides which are not 100% homologous to the sequences can be obtained in a number of ways. Other variants of the sequences described herein may be obtained for example by probing DNA libraries made from a range of individuals, for example individuals from different populations. In addition, other viral/bacterial, or cellular homologues particularly cellular homologues found in mammalian cells (e.g. rat, mouse, bovine and primate cells), may be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to the sequences shown in the sequence listing herein. Such sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal species, and probing such libraries with probes comprising all or part of any one of the sequences in the attached sequence listings under conditions of medium to high stringency. Similar considerations apply to obtaining species homologues and allelic variants of the polypeptide or nucleotide sequences.

[0364] Variants and strain/species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the sequences. Conserved sequences can be predicted, for example, by aligning the amino acid sequences from several variants/homologues. Sequence alignments can be performed using computer software known in the art. For example the GCG Wisconsin PileUp program is widely used.

[0365] The primers used in degenerate PCR will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.

[0366] Alternatively, such polynucleotides may be obtained by site directed mutagenesis of characterised sequences. This may be useful where for example silent codon sequence changes are required to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction polypeptide recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides.

[0367] Polynucleotides (nucleotide sequences) may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or nonradioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides as used herein.

[0368] Polynucleotides such as DNA polynucleotides and probes according to the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques.

5 [0369] In general, primers will be produced by synthetic means, involving a stepwise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.

10 [0370] Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques. This will involve making a pair of primers (e.g. of about 15 to 30 nucleotides) flanking a region of the lipid targeting sequence which it is desired to clone, bringing the primers into contact with mRNA or cDNA obtained from an animal or human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The
15 primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector.

HYBRIDISATION

20 [0371] The present invention also encompasses the use of sequences that are complementary to the sequences of the present invention or sequences that are capable of hybridising either to the sequences or to sequences that are complementary thereto.

25 [0372] The term "hybridisation" as used herein shall include "the process by which a strand of nucleic acid joins with a complimentary strand through base pairing" as well as the process of amplification as carried out in polymerase chain reaction (PCR) technologies.

30 [0373] The present invention also encompasses the use of nucleotide sequences that are capable of hybridising to the sequences that are complementary to the subject sequences discussed herein, or any derivative, fragment or derivative thereof.

[0374] The present disclosure also encompasses sequences that are complementary to sequences that are capable of hybridising to the nucleotide sequences discussed herein.

35 [0375] Hybridisation conditions are based on the melting temperature (T_m) of the nucleotide binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol. 152, Academic Press, San Diego CA), and confer a defined "stringency" as explained below.

40 [0376] Maximum stringency typically occurs at about $T_m - 5^\circ\text{C}$ (5°C below the T_m of the probe); high stringency at about 5°C to 10°C below T_m ; intermediate stringency at about 10°C to 20°C below T_m ; and low stringency at about 20°C to 25°C below T_m . As will be understood by those of skill in the art, a maximum stringency hybridisation can be used to identify or detect identical nucleotide sequences while an intermediate (or low) stringency hybridisation can be used to identify or detect similar or related polynucleotide sequences.

45 [0377] Preferably, the present invention encompasses the use of sequences that are complementary to sequences that are capable of hybridising under high stringency conditions or intermediate stringency conditions to nucleotide sequences encoding polypeptides having the specific properties as defined herein.

[0378] More preferably, the present invention encompasses the use of sequences that are complementary to

sequences that are capable of hybridising under high stringency conditions (e.g. 65°C and 0.1xSSC {1xSSC = 0.15 M NaCl, 0.015 M Na-citrate pH 7.0}) to nucleotide sequences encoding polypeptides having the specific properties as defined herein.

5 **[0379]** The present invention also relates to the use of nucleotide sequences that can hybridise to the nucleotide sequences discussed herein (including complementary sequences of those discussed herein).

10 **[0380]** The present invention also relates to the use of nucleotide sequences that are complementary to sequences that can hybridise to the nucleotide sequences discussed herein (including complementary sequences of those discussed herein).

15 **[0381]** Also included within the scope of the present invention are the use of polynucleotide sequences that are capable of hybridising to the nucleotide sequences discussed herein under conditions of intermediate to maximal stringency.

15 **[0382]** In a preferred aspect, the present invention covers the use of nucleotide sequences that can hybridise to the nucleotide sequences discussed herein, or the complement thereof, under stringent conditions (e.g. 50°C and 0.2xSSC).

20 **[0383]** In a more preferred aspect, the present invention covers the use of nucleotide sequences that can hybridise to the nucleotide sequences discussed herein, or the complement thereof, under high stringency conditions (e.g. 65°C and 0.1xSSC).

EXPRESSION OF POLYPEPTIDES

25 **[0384]** A nucleotide sequence for use in the present invention or for encoding a polypeptide having the specific properties as defined herein can be incorporated into a recombinant replicable vector. The vector may be used to replicate and express the nucleotide sequence, in polypeptide form, in and/or from a compatible host cell. Expression may be controlled using control sequences which include promoters/enhancers and other expression regulation signals. Prokaryotic promoters and promoters functional in eukaryotic cells may be used. Tissue specific or stimuli specific promoters may be used. Chimeric promoters may also be used comprising sequence elements from two or more different promoters described above.

30 **[0385]** The polypeptide produced by a host recombinant cell by expression of the nucleotide sequence may be secreted or may be contained intracellularly depending on the sequence and/or the vector used. The coding sequences can be designed with signal sequences which direct secretion of the substance coding sequences through a particular prokaryotic or eukaryotic cell membrane.

CONSTRUCTS

40 **[0386]** The term "construct" - which is synonymous with terms such as "conjugate", "cassette" and "hybrid" - includes a nucleotide sequence encoding a polypeptide having the specific properties as defined herein for use according to the present invention directly or indirectly attached to a promoter. An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the Sh1-intron or the ADH intron, intermediate the promoter and the nucleotide sequence. The same is true for the term "fused" in relation to the present invention which includes direct or indirect attachment. In some cases, the terms do not cover the natural combination of the nucleotide sequence coding for the protein ordinarily associated with the wild type gene promoter and when they are both in their natural environment.

[0387] The construct may even contain or express a marker which allows for the selection of the genetic construct.

- 5 [0388] For some applications, preferably the construct comprises at least a nucleotide sequence or a nucleotide sequence encoding a polypeptide having the specific properties as defined herein operably linked to a promoter.

ORGANISM

- 10 [0389] The term "organism" in relation to the present invention includes any organism that could comprise a nucleotide sequence according to the present invention or a nucleotide sequence encoding for a polypeptide having the specific properties as defined herein and/or products obtained therefrom.

- 15 [0390] The term "transgenic organism" in relation to the present invention includes any organism that comprises a nucleotide sequence coding for a polypeptide having the specific properties as defined herein and/or the products obtained therefrom, and/or wherein a promoter can allow expression of the nucleotide sequence coding for a polypeptide having the specific properties as defined herein within the organism. Preferably the nucleotide sequence is incorporated in the genome of the organism.

- 20 [0391] The term "transgenic organism" does not cover native nucleotide coding sequences in their natural environment when they are under the control of their native promoter which is also in its natural environment.

- 25 [0392] Therefore, the transgenic organism includes an organism comprising any one of, or combinations of, a nucleotide sequence coding for a polypeptide having the specific properties as defined herein, constructs as defined herein, vectors as defined herein, plasmids as defined herein, cells as defined herein, or the products thereof. For example the transgenic organism can also comprise a nucleotide sequence coding for a polypeptide having the specific properties as defined herein under the control of a promoter not associated with a sequence encoding a lipid acyltransferase in nature.

TRANSFORMATION OF HOST CELLS/ORGANISM

- 30 [0393] The host organism can be a prokaryotic or a eukaryotic organism.

- [0394] Examples of suitable prokaryotic hosts include bacteria such as *E. coli* and *Bacillus licheniformis*, preferably *B. licheniformis*.

- 35 [0395] Teachings on the transformation of prokaryotic hosts is well documented in the art, for example see Sambrook et al (Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press). If a prokaryotic host is used then the nucleotide sequence may need to be suitably modified before transformation - such as by removal of introns.

- 40 [0396] In another embodiment the transgenic organism can be a yeast.

- [0397] Filamentous fungi cells may be transformed using various methods known in the art - such as a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known. The use of *Aspergillus* as a host microorganism is described in EP 0 238 023.

- 45 [0398] Another host organism can be a plant. A review of the general techniques used for transforming plants may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and

Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27). Further teachings on plant transformation may be found in EP-A-0449375.

[0399] General teachings on the transformation of fungi, yeasts and plants are presented in following sections.

TRANSFORMED FUNGUS

[0400] A host organism may be a fungus - such as a filamentous fungus. Examples of suitable such hosts include any member belonging to the genera *Thermomyces*, *Acremonium*, *Aspergillus*, *Penicillium*, *Mucor*, *Neurospora*, *Trichoderma* and the like.

[0401] Teachings on transforming filamentous fungi are reviewed in US-A-5741665 which states that standard techniques for transformation of filamentous fungi and culturing the fungi are well known in the art. An extensive review of techniques as applied to *N. crassa* is found, for example in Davis and de Serres, *Methods Enzymol* (1971) 17A: 79-143.

[0402] Further teachings on transforming filamentous fungi are reviewed in US-A-5674707.

[0403] In one aspect, the host organism can be of the genus *Aspergillus*, such as *Aspergillus niger*.

[0404] A transgenic *Aspergillus* according to the present invention can also be prepared by following, for example, the teachings of Turner G. 1994 (Vectors for genetic manipulation. In: Martinelli S.D., Kinghorn J.R. (Editors) *Aspergillus: 50 years on. Progress in industrial microbiology* vol 29. Elsevier Amsterdam 1994. pp. 641-666).

[0405] Gene expression in filamentous fungi has been reviewed in Punt et al. (2002) *Trends Biotechnol* 2002 May;20(5):200-6, Archer & Peberdy *Crit Rev Biotechnol* (1997) 17(4):273-306.

TRANSFORMED YEAST

[0406] In another embodiment, the transgenic organism can be a yeast.

[0407] A review of the principles of heterologous gene expression in yeast are provided in, for example, *Methods Mol Biol* (1995), 49:341-54, and *Curr Opin Biotechnol* (1997) Oct;8(5):554-60

[0408] In this regard, yeast - such as the species *Saccharomyces cerevisiae* or *Pichia pastoris* (see FEMS *Microbiol Rev* (2000) 24(1):45-66), may be used as a vehicle for heterologous gene expression.

[0409] A review of the principles of heterologous gene expression in *Saccharomyces cerevisiae* and secretion of gene products is given by E Hinchcliffe E Kenny (1993, "Yeast as a vehicle for the expression of heterologous genes", *Yeasts*, Vol 5, Anthony H Rose and J Stuart Harrison, eds, 2nd edition, Academic Press Ltd.).

[0410] For the transformation of yeast, several transformation protocols have been developed. For example, a transgenic *Saccharomyces* according to the present invention can be prepared by following the teachings of Hinnen et al., (1978, *Proceedings of the National Academy of Sciences of the USA* 75, 1929); Beggs, J D (1978, *Nature*, London, 275, 104); and Ito, H et al (1983, *J Bacteriology* 153, 163-168).

[0411] The transformed yeast cells may be selected using various selective markers - such as auxotrophic markers dominant antibiotic resistance markers.

[0412] A suitable yeast host organism can be selected from the biotechnologically relevant yeasts species such as, but not limited to, yeast species selected from *Pichia* spp., *Hansenula* spp., *Kluyveromyces*, *Yarrowinia* spp., *Saccharomyces* spp., including *S. cerevisiae*, or *Schizosaccharomyce* spp. including *Schizosaccharomyce pombe*.

[0413] A strain of the methylotrophic yeast species *Pichia pastoris* may be used as the host organism.

[0414] In one embodiment, the host organism may be a *Hansenula* species, such as *H. polymorpha* (as described in WO01/39544).

TRANSFORMED PLANTS/PLANT CELLS

[0415] A host organism suitable for the present invention may be a plant. A review of the general techniques may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27), or in WO01/16308. The transgenic plant may produce enhanced levels of phytosterol esters and phytostanol esters, for example.

[0416] Therefore the present disclosure also relates to a method for the production of a transgenic plant with enhanced levels of phytosterol esters and phytostanol esters, comprising the steps of transforming a plant cell with a lipid acyltransferase as defined herein (in particular with an expression vector or construct comprising a lipid acyltransferase as defined herein), and growing a plant from the transformed plant cell.

SECRETION

[0417] Often, it is desirable for the polypeptide to be secreted from the expression host into the culture medium from where the enzyme may be more easily recovered. According to the present invention, the secretion leader sequence may be selected on the basis of the desired expression host. Hybrid signal sequences may also be used with the context of the present invention.

[0418] Typical examples of secretion leader sequences not associated with a nucleotide sequence encoding a lipid acyltransferase in nature are those originating from the fungal amyloglucosidase (AG) gene (*glaA* - both 18 and 24 amino acid versions e.g. from *Aspergillus*), the α -factor gene (yeasts e.g. *Saccharomyces*, *Kluyveromyces* and *Hansenula*) or the α -amylase gene (*Bacillus*).

DETECTION

[0419] A variety of protocols for detecting and measuring the expression of the amino acid sequence are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS).

[0420] A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic and amino acid assays.

[0421] A number of companies such as Pharmacia Biotech (Piscataway, NJ), Promega (Madison, WI), and US Biochemical Corp (Cleveland, OH) supply commercial kits and protocols for these procedures.

[0422] Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include US-A-3,817,837; US-A-3,850,752; US-A-3,939,350; US-A-3,996,345; US-A-4,277,437; US-A-4,275,149 and US-A-4,366,241.

[0423] Also, recombinant immunoglobulins may be produced as shown in US-A-4,816,567.

FUSION PROTEINS

[0424] The lipid acyltransferase for use in the present invention may be produced as a fusion protein, for example to aid in extraction and purification thereof. Examples of fusion protein partners include glutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and β -galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences. Preferably the fusion protein will not hinder the activity of the protein sequence.

[0425] Gene fusion expression systems in *E. coli* have been reviewed in Curr. Opin. Biotechnol. (1995) 6(5):501-6.

[0426] The amino acid sequence of a polypeptide having the specific properties as defined herein may be ligated to a non-native sequence to encode a fusion protein. For example, for screening of peptide libraries for agents capable of affecting the substance activity, it may be useful to encode a chimeric substance expressing a non-native epitope that is recognised by a commercially available antibody.

[0427] The invention will now be described, by way of example only, with reference to the following Figures and Examples.

Figure 1 shows the amino acid sequence of a mutant *Aeromonas salmonicida* mature lipid acyltransferase (GCAT) with a mutation of Asn80Asp (notably, amino acid 80 is in the mature sequence) (SEQ ID 16);

Figure 2 shows an amino acid sequence (SEQ ID No. 1) a lipid acyl transferase from *Aeromonas hydrophila* (ATCC #7965);

Figure 3 shows a pfam00657 consensus sequence from database version 6 (SEQ ID No. 2);

Figure 4 shows an amino acid sequence (SEQ ID No. 3) obtained from the organism *Aeromonas hydrophila* (P10480; GI:121051);

Figure 5 shows an amino acid sequence (SEQ ID No. 4) obtained from the organism *Aeromonas salmonicida* (AAG098404; GI:9964017);

Figure 6 shows an amino acid sequence (SEQ ID No. 5) obtained from the organism *Streptomyces coelicolor*A3(2) (Genbank accession number NP_631558);

Figure 7 shows an amino acid sequence (SEQ ID No. 6) obtained from the organism *Streptomyces coelicolor* A3(2) (Genbank accession number: CAC42140);

Figure 8 shows an amino acid sequence (SEQ ID No. 7) obtained from the organism *Saccharomyces cerevisiae* (Genbank accession number P41734);

Figure 9 shows an amino acid sequence (SEQ ID No. 8) obtained from the organism *Ralstonia* (Genbank accession number: AL646052);

Figure 10 shows SEQ ID No. 9. Scoe1 NCBI protein accession code CAB39707.1 GI:4539178 conserved hypothetical protein [*Streptomyces coelicolor* A3(2)];

5 Figure 11 shows an amino acid shown as SEQ ID No. 10. Scoe2 NCBI protein accession code CAC01477.1 GI:9716139 conserved hypothetical protein [*Streptomyces coelicolor* A3(2)];

Figure 12 shows an amino acid sequence (SEQ ID No. 11) Scoe3 NCBI protein accession code CAB88833.1 GI:7635996 putative secreted protein. [*Streptomyces coelicolor* A3(2)];

10 Figure 13 shows an amino acid sequence (SEQ ID No. 12) Scoe4 NCBI protein accession code CAB89450.1 GI:7672261 putative secreted protein. [*Streptomyces coelicolor* A3(2)];

Figure 14 shows an amino acid sequence (SEQ ID No. 13) Scoe5 NCBI protein accession code CAB62724.1 GI:6562793 putative lipoprotein [*Streptomyces coelicolor* A3(2)];

Figure 15 shows an amino acid sequence (SEQ ID No. 14) Srim1 NCBI protein accession code AAK84028.1 GI:15082088 GDSL-lipase [*Streptomyces rimosus*];

15 Figure 16 shows an amino acid sequence (SEQ ID No. 15) of a lipid acyltransferase from *Aeromonas salmonicida* subsp. *Salmonicida* (ATCC#14174);

Figure 17 shows SEQ ID No. 19. Scoe1 NCBI protein accession code CAB39707.1 GI:4539178 conserved hypothetical protein [*Streptomyces coelicolor* A3(2)];

20 Figure 18 shows an amino acid sequence (SEQ ID No. 25) of the fusion construct used for mutagenesis of the *Aeromonas hydrophila* lipid acyltransferase gene. The underlined amino acids is a xylanase signal peptide;

Figure 19 shows a polypeptide sequence of a lipid acyltransferase enzyme from *Streptomyces* (SEQ ID No. 26);

25 Figure 20 shows a polypeptide sequence of a lipid acyltransferase enzyme from *Thermobifida*_SEQ ID No. 27);

Figure 21 shows a polypeptide sequence of a lipid acyltransferase enzyme from *Thermobifida*_ (SEQ ID No. 28);

Figure 22 shows a polypeptide of a lipid acyltransferase enzyme from *Corynebacterium efficiens* GDSx 300 amino acid_ (SEQ ID No. 29);

30 Figure 23 shows a polypeptide of a lipid acyltransferase enzyme from *Novosphingobium aromaticivorans* GDSx 284 amino acid_ (SEQ ID No. 30);

Figure 24 shows a polypeptide of a lipid acyltransferase enzyme from *Streptomyces coelicolor* GDSx 269 aa (SEQ ID No. 31);

35 Figure 25 shows a polypeptide of a lipid acyltransferase enzyme from *Streptomyces avermitilis* \ GDSx 269 amino acid (SEQ ID No. 32);

Figure 26 shows a polypeptide of a lipid acyltransferase enzyme from *Streptomyces* (SEQ ID No. 33);

Figure 27 shows an amino acid sequence (SEQ ID No. 34) obtained from the organism *Aeromonas hydrophila* (P10480; GI:121051) (notably, this is the mature sequence);

5 Figure 28 shows the amino acid sequence (SEQ ID No. 35) of a mutant *Aeromonas salmonicida* mature lipid acyltransferase (GCAT) (notably, this is the mature sequence);

Figure 29 shows a nucleotide sequence (SEQ ID No. 36) from *Streptomyces thermosacchari*;

Figure 30 shows an amino acid sequence (SEQ ID No. 37) from *Streptomyces thermosacchari*;

Figure 31 shows an amino acid sequence (SEQ ID No. 38) from *Thermobifida fusca*/GDSx 548 amino acid;

10 Figure 32 shows a nucleotide sequence (SEQ ID No. 39) from *Thermobifida fusca*;

Figure 33 shows an amino acid sequence (SEQ ID No. 40) from *Thermobifida fusca*/GDSx;

Figure 34 shows an amino acid sequence (SEQ ID No. 41) from *Corynebacterium efficiens*/GDSx 300 amino acid;

Figure 35 shows a nucleotide sequence (SEQ ID No. 42) from *Corynebacterium efficiens*;

15 Figure 36 shows an amino acid sequence (SEQ ID No. 43) from *S. coelicolor*l GDSx 268 amino acid;

Figure 37 shows a nucleotide sequence (SEQ ID No. 44) from *S. coelicolor*,

Figure 38 shows an amino acid sequence (SEQ ID No. 45) from *S. avermitilis*;

Figure 39 shows a nucleotide sequence (SEQ ID No. 46) from *S. avermitilis*;

Figure 40 shows an amino acid sequence (SEQ ID No. 47) from *Thermobifida fusca*/GDSx;

20 Figure 41 shows a nucleotide sequence (SEQ ID No. 48) from *Thermobifida fusca*/GDSx;

Figure 42 shows an alignment of the L131 and homologues from *S. avermitilis* and *T. fusca* illustrates that the conservation of the GDSx motif (GDSY in L131 and *S. avermitilis* and *T. fusca*), the GANDY box, which is either GGND A or GGNDL, and the HPT block (considered to be the conserved catalytic histidine). These three conserved blocks are highlighted;

25 Figure 43 shows SEQ ID No 17 which is the amino acid sequence of a lipid acyltransferase from *Candida parapsilosis*;

Figure 44 shows SEQ ID No 18 which is the amino acid sequence of a lipid acyltransferase from *Candida parapsilosis*;

30 Figure 45 shows a ribbon representation of the 1IVN. PDB crystal structure which has glycerol in the active site. The Figure was made using the Deep View Swiss-PDB viewer;

Figure 46 shows 1IVN.PDB Crystal Structure - Side View using Deep View Swiss-PDB viewer, with glycerol in active site - residues within 10Å of active site glycerol are coloured black;

Figure 47 shows 1IVN.PDB Crystal Structure - Top View using Deep View Swiss-PDB viewer, with glycerol in active site - residues within 10Å of active site glycerol are coloured black;

5 Figure 48 shows alignment 1;

Figure 49 shows alignment 2;

Figures 50 and 51 show an alignment of 1IVN to P10480 (P10480 is the database sequence for *A. hydrophila* enzyme), this alignment was obtained from the PFAM database and used in the model building process; and

10 Figure 52 shows an alignment where P10480 is the database sequence for *Aeromonas hydrophila*. This sequence is used for the model construction and the site selection. Note that the full protein (SEQ ID No. 3) is depicted, the mature protein (equivalent to SEQ ID No. 34) starts at residue 19. *A. sal* is *Aeromonas salmonicida* (SEQ ID No. 35) GDSX lipase, *A. hyd* is *Aeromonas hydrophila* (SEQ ID No. 120) GDSX lipase. The consensus sequence contains a * at the position of a difference between
15 the listed sequences.

Figure 53 shows a gene construct used in Example 1;

Figure 54 shows a codon optimised gene construct (no. 052907) used in Example 1; and

Figure 55 shows the sequence of the XhoI insert containing the LAT-KLM3' precursor gene, the -35 and -10 boxes are underlined;

20 Figure 56 shows BML780-KLM3'CAP50 (comprising SEQ ID No. 16 - upper colony) and BML780 (the empty host strain - lower colony) after 48h growth at 37°C on 1 % tributyrin agar;

Figure 57 shows a nucleotide sequence from *Aeromonas salmonicida* (SEQ ID No. 49) including the signal sequence (preLAT - positions 1 to 87);

25 Figure 58 shows a nucleotide sequence (SEQ ID No. 50) encoding a lipid acyl transferase according to the present invention obtained from the organism *Aeromonas hydrophila*;

Figure 59 shows a nucleotide sequence (SEQ ID No. 51) encoding a lipid acyl transferase according to the present invention obtained from the organism *Aeromonas salmonicida*;

30 Figure 60 shows a nucleotide sequence (SEQ ID No. 52) encoding a lipid acyl transferase according to the present invention obtained from the organism *Streptomyces coelicolor* A3(2) (Genbank accession number NC_003888.1:8327480..8328367);

Figure 61 shows a nucleotide sequence (SEQ ID No. 53) encoding a lipid acyl transferase according to the present invention obtained from the organism *Streptomyces coelicolor* A3(2) (Genbank accession number AL939131.1:265480..266367);

35 Figure 62 shows a nucleotide sequence (SEQ ID No. 54) encoding a lipid acyl transferase according to the present invention obtained from the organism *Saccharomyces cerevisiae* (Genbank accession number Z75034);

Figure 63 shows a nucleotide sequence (SEQ ID No. 55) encoding a lipid acyl transferase according to the present invention obtained from the organism *Ralstonia*;

Figure 64 shows a nucleotide sequence shown as SEQ ID No. 56 encoding NCBI protein accession code CAB39707.1 GI:4539178 conserved hypothetical protein [*Streptomyces coelicolor* A3(2)];

5 Figure 65 shows a nucleotide sequence shown as SEQ ID No. 57 encoding Scoe2 NCBI protein accession code CAC01477.1 GI:9716139 conserved hypothetical protein [*Streptomyces coelicolor* A3(2)];

Figure 66 shows a nucleotide sequence shown as SEQ ID No. 58 encoding Scoe3 NCBI protein accession code CAB88833.1 GI:7635996 putative secreted protein. [*Streptomyces coelicolor* A3(2)];

10 Figure 67 shows a nucleotide sequence shown as SEQ ID No. 59 encoding Scoe4 NCBI protein accession code CAB89450.1 GI:7672261 putative secreted protein. [*Streptomyces coelicolor* A3(2)];

Figure 68 shows a nucleotide sequence shown as SEQ ID No. 60, encoding Scoe5 NCBI protein accession code CAB62724.1 GI:6562793 putative lipoprotein [*Streptomyces coelicolor* A3(2)];

15 Figure 69 shows a nucleotide sequence shown as SEQ ID No. 61 encoding Srim1 NCBI protein accession code AAK84028.1 GI:15082088 GDSL-lipase [*Streptomyces rimosus*];

Figure 70 shows a nucleotide sequence (SEQ ID No. 62) encoding a lipid acyltransferase from *Aeromonas hydrophila* (ATCC #7965);

Figure 71 shows a nucleotide sequence (SEQ ID No 63) encoding a lipid acyltransferase from *Aeromonas salmonicida* subsp. *Salmonicida* (ATCC#14174);

20 Figure 72 shows a nucleotide sequence (SEQ ID No. 24) encoding an enzyme from *Aeromonas hydrophila* including a xylanase signal peptide;

25 Figure 73 shows the amino acid sequence of a mutant *Aeromonas salmonicida* mature lipid acyltransferase (GCAT) with a mutation of Asn80Asp (notably, amino acid 80 is in the mature sequence) - shown herein as SEQ ID No. 16 - and after undergoing post-translational modification as SEQ ID No. 68 - amino acid residues 235 and 236 of SEQ ID No. 68 are not covalently linked following post-translational modification. The two peptides formed are held together by one or more S-S bridges. Amino acid 236 in SEQ ID No. 68 corresponds with the amino acid residue number 274 in SEQ ID No. 16 shown herein;

Figure 74 shows a turbiscan measurement from the top 5mm;

30 Figure 75 shows a turbiscan measurement from the bottom 5mm;

Figure 76 shows the surface tension of Pasterurized milk 12983-1-11 (control), 12983-1-12 (enzyme treated) and UHT milk 12983-1-13 (control), 12983-1-14 (enzyme treated);

35 Figure 77 shows measurements of Milk free cholesterol and cholesterol-ester by Gas Chromatography. 11 and 12 were pasteurised milk and 13 and 14 were UHT milk. Sample -12 and -14 were enzymatically treated with KLM3 at 5 °C for 20 hours. A commercially available UHT milk from Arla was included in the analysis in comparison;

Figure 78 shows HPTLC of extracted pasteurised (90°C) and UHT (142°C) milk lipids dissolved in CHCl₃:MeOH (2:1). Standard (Std) 16 contains SpectraLipid Soy Lecithin Mix Standard (No. SLM43) dissolved in CHCl₃:MeOH (2:1);

Figure 79 shows the results of Lumifugation of Chocolate milk with KLM3 ((DK 14636-2-3);

5 Figure 80 shows the results of Lumifugation of Chocolate milk without KLM 3 (DK14636-2-4):

Figure 81 shows Clarification (% Integral Transmission);

Figure 82 shows the results of Front tracking, i.e. monitoring the movement of the front of clearance at 15% transmission; and

10 Figure 83 shows the results of Front tracking, i.e. monitoring the movement of the front of clearance at 50% transmission.

EXAMPLE 1

Expression of KLM3' in *Bacillus licheniformis*

15 [0428] A nucleotide sequence (SEQ ID No. 49) encoding a lipid acyltransferase (SEQ. ID No. 16, hereinafter KLM3') was expressed in *Bacillus licheniformis* as a fusion protein with the signal peptide of *B. licheniformis* [alpha]-amylase (LAT) (see FIGS. 53 and 54). For optimal expression in *Bacillus*, a codon optimized gene construct (no. 052907) was ordered at Geneart (Geneart AG, Regensburg, Germany).

20 [0429] Construct no. 052907 contains an incomplete LAT promoter (only the -10 sequence) in front of the LAT-KLM3' precursor gene and the LAT transcription (Tlat) downstream of the LAT-KLM3' precursor gene (see FIGS 53 and 55). To create a *Xho*I fragment that contains the LAT-KLM3' precursor gene flanked by the complete LAT promoter at the 5' end and the LAT terminator at the 3' end, a PCR (polymerase chain reaction)
25 amplification was performed with the primers Plat5XhoI_FW and EBS2XhoI_RV and gene construct 052907 as template.

Plat5XhoI_FW:

ccccgcgcgaggctttctttggaagaaaatatagggaatggtactgttaaaaattc
ggaatattatacaatatcatatgttcacattgaaagggg

EBS2XhoI_RV: tggaatctcgagggtttatcctttacctgtctcc

30 [0430] PCR was performed on a thermocycler with Phusion High Fidelity DNA polymerase (Finnzymes OY, Espoo, Finland) according to the instructions of the manufacturer (annealing temperature of 55[deg.] C.).

35 [0431] The resulting PCR fragment was digested with restriction enzyme *Xho*I and ligated with T4 DNA ligase into *Xho*I digested pICatH according to the instructions of the supplier (Invitrogen, Carlsbad, Calif. USA).

[0432] The ligation mixture was transformed into *B. subtilis* strain SC6.1 as described in U.S. Patent Application US20020182734 (International Publication WO 02/14490). The sequence of the *Xho*I insert containing the LAT-KLM3' precursor gene was confirmed by DNA sequencing (BaseClear, Leiden, The Netherlands) and one of the correct plasmid clones was designated pICatH-KLM3'(ori1) (Figure 53). pICatH-KLM3'(ori1) was transformed into *B. licheniformis* strain BML780 (a derivative of BRA7 and BML612, see WO2005111203) at the permissive temperature (37[deg.] C.).

[0433] One neomycin resistant (neoR) and chloramphenicol resistant (CmR) transformant was selected and designated BML780(pICatH-KLM3'(ori1)). The plasmid in BML780(pICatH-KLM3'(ori1)) was integrated into the catH region on the *B. licheniformis* genome by growing the strain at a non-permissive temperature (50[deg.] C) in medium with 5 [mu]g/ml chloramphenicol. One CmR resistant clone was selected and designated BML780-pICatH-KLM3'(ori1). BML780-pICatH-KLM3'(ori1) was grown again at the permissive temperature for several generations without antibiotics to loop-out vector sequences and then one neomycin sensitive (neoS), CmR clone was selected. In this clone, vector sequences of pICatH on the chromosome are excised (including the neomycin resistance gene) and only the catH - LATKLM3' cassette is left. Next, the catH - LATKLM3' cassette on the chromosome was amplified by growing the strain in/on media with increasing concentrations of chloramphenicol. After various rounds of amplification, one clone (resistant against 50 [mu]g/ml chloramphenicol) was selected and designated BML780-KLM3'CAP50. To verify KLM3'expression, BML780-KLM3'CAP50 and BML780 (the empty host strain) were grown for 48h at 37 [deg.] C on a Heart Infusion (Bacto) agar plate with 1% tributyrin. A clearing zone, indicative for lipid acyltransferase activity, was clearly visible around the colony of BML780-KLM3'CAP50 but not around the host strain BML780 (see Figure 56). This result shows that a substantial amount of KLM3' is expressed in *B. licheniformis* strain BML780-KLM3'CAP50 and that these KLM3' molecules are functional.

COMPARATIVE EXAMPLE 1

Vector construct

[0434] The plasmid construct is pCS32new N80D, which is a pCCmini derivative carrying the sequence encoding the mature form of the native *Aeromonas salmonicida* Glycerophospholipid-cholesterol acyltransferase with a Asn to Asp substitution at position 80 (KLM3'), under control of the p32 promoter and with a CGTase signal sequence.

[0435] The host strain used for the expression, is in the *bacillus subtilis* OS21ΔAprE strain

[0436] The expression level is measured as transferase activity, expressed as % cholesterol esterified, calculated from the difference in free cholesterol in the reference sample and free cholesterol in the enzyme sample in reactions with PC (T_{PC}) as donor and cholesterol as acceptor molecule.

Culture conditions

[0437] 5 ml of LB broth (Casein enzymatic digest, 10 g/l; low-sodium Yeast extract, 5 g/l; Sodium Chloride, 5 g/l; Inert tableting aids, 2 g/l) supplemented with 50 mg/l kanamycin, was inoculated with a single colony and incubated at 30 °C for 6 hours at 205 rpm. 0.7 ml of this culture was used to inoculate 50 ml of SAS media (K_2HPO_4 , 10 g/l; MOPS (3-morpholinopropane sulfonic acid), 40 g/l; Sodium Chloride, 5 g/l; Antifoam (Sin 260), 5 drops/l; Soy flour degreased, 20 g/l; Biospringer 106 (100 % dw YE), 20 g/l) supplemented with 50 mg/l kanamycin and a solution of high maltose starch hydrolysates (60 g/l). Incubation was continued for 40 hours at 30 °C and 180 rpm before the culture supernatant was separated by

centrifugation at 19000 rpm for 30 min. The supernatant was transferred into a clean tube and directly used for transferase activity measurement.

Preparation of substrates and enzymatic reaction

- 5 [0438] PC (Avanti Polar Lipids #441601) and cholesterol (Sigma C8503) was scaled in the ratio 9:1, dissolved in chloroform, and evaporated to dryness.
The substrate was prepared by dispersion of 3% PC:Cholesterol 9:1 in 50 mM Hepes buffer pH 7. 0.250 ml substrate solution was transferred into a 3 ml glass tube with screw lid. 0.025 ml culture supernatant was added and the mixture was incubated at 40 °C for 2 hours. A reference sample with water instead of
10 enzyme was also prepared. Heating the reaction mixture in a boiling water bath for 10 minutes stopped the enzyme reaction. 2 ml of 99% ethanol was added to the reaction mixture before submitted to cholesterol assay analysis.

Cholesterol assay

- 15 [0439] 100 µl substrate containing 1.4 U/ml Cholesterol oxidase(SERVA Electrophoresis GmbH cat. No 17109), 0.4 mg/ml ABTS (Sigma A-1888), 6 U/ml Peroxidase (Sigma 6782) in 0.1 M Tris-HCl, pH 6.6 and 0.5 % Triton X-100 (Sigma X-100) was incubated at 37°C for 5 minutes before 5 µl enzyme reaction sample was added and mixed. The reaction mixture was incubated for further 5 minutes and OD₄₀₅ was measured.
The content of cholesterol was calculated from the analyses of standard solutions of cholesterol containing 0.4
20 mg/ml, 0.3 mg/ml, 0.20 mg/ml, 0.1 mg/ml, 0.05 mg/ml, and 0 mg/ml cholesterol in 99 % EtOH.

Results

[0440] The table shows the average of 8 separate expression cultures

Strain	T _{PC} ^a
OS21ΔAprE[pCS3 2new]	74.2 ± 10.1 ^b
^a T _{PC} is the transferase activity, expressed as % cholesterol esterified, calculated from the difference in free cholesterol in the reference sample and free cholesterol in the enzyme sample in reactions with PC as donor molecule and cholesterol as acceptor molecule.	
^b Average of 8 separate expression cultures	

25 Example 2: Emulsion stability, removal of cholesterol in UHT milk

- [0441] The use of the lipid acyltransferase shown here as SEQ ID No. 68 (hereinafter referred to as "KLM3") for interesterification and/or transesterification between phospholipids and cholesterol in UHT milk has an effect on improving the emulsion stability, comparing results in ordinary UHT milk and Flavoured UHT milk,
30 produced on basis of fresh milk as well as recombined milk.

[0442] For the avoidance of doubt recombined milk is a general term for milk, which is produced from original milk based solid components mixed with water and processed in such a way to produce milk with similar characteristics as the original milk.

Test of KLM3 in UHT milk and Cream**[0443]**

COMPOSITION IN PERCENTAGES	1	2	3	4	5	6	7	8
Milk 3,5 % fat	99,90	99,90	99,90	94,16				
Skim milk powder					9,00	9,00	9,00	9,00
Butter oil (AMF)					3,50	3,50	3,50	3,50
Sucrose				5,50				5,50
Strawberry Flavouring T10063				0,12				0,12
Carmin Extract (red)				0,02				0,02
RECODAN™ RS 100	0,10	0,10	0,10	0,20	0,15	0,15	0,15	0,20
K460 (KLM3) Units/liter		75 U/L	40 U/L	75 U/L		75 U/L	40 U/L	75 U/L
Water (Tap)					87,35	87,35	87,35	81,66
Total percentage	100,00	100,00	100,00	100,00	100,00	100,00	100,00	100,00

5

[0444] The samples (recombined milk) were processed in Dairy Pilot Plant as follows:**Pilot (Batch preparation)**10 **[0445]**

1. 1. - Heat water / milk to 40°C in mixer tank and add enzymes
2. 2. - Add skimmed milk powder, sugar, other dry ingredients to the water and keep for 30 minutes
3. 3. - Melt butteroil at 70°C
4. 4. - Add stabiliser / emulsifier to the melted butteroil
5. 5. - Add butteroil, stabiliser/emulsifier to the milk
6. 6. - Add flavorings.
7. 7. - Premix on silverson - medium speed for 1 minute
8. 8. - Dearate for approximately 30 minutes in the bucket

15

20

[0446] The fresh milk followed step 1, 2, 6, 7 and 8.**UHT - (PHE)**25 **[0447]**

9. - Preheat to 90°C (holding cell at 30 seconds)

10. - Indirect heating 142°C for 3 seconds

11. - Downstream homogenisation 200 bar, 75°C

12. - Cool to 15°C

13. - Aseptic Filling

5

[0448] The ingredients used for the trials were commercially purchased whole milk and/or standard raw materials used for majority of trials in the Dairy Pilot Plant.

10

[0449] The enzyme solution used was a sample of KLM3 (K460 - shown as SEQ ID No. 68 herein). The K460 contains 1400 TIPU units/ml.

TIPU ASSAY

Substrate

15

[0450] 0.6% L- α Phosphatidylcholine 95% Plant (Avanti #441601), 0.4% Triton-X 100 (Sigma X-100) and 5 mM CaCl₂ was dissolved in 0.05M HEPES buffer pH 7.

Assay procedure:

20

[0451] 400 μ l substrate was added to an 1.5 ml Eppendorf tube and placed in an Eppendorf Thermomixer at 37°C for 5 minutes. At time T= 0 min, 50 μ l enzyme solution was added. Also a blank with water instead of enzyme was analyzed. The sample was mixed at 10*100 rpm in an Eppendorf Thermomixer at 37°C for 10 minutes. At time T=10 min the Eppendorf tube was placed in another thermomixer at 99°C for 10 minutes to stop the reaction.

25

[0452] Free fatty acid in the samples was analyzed by using the NEFA C kit from WAKO GmbH. Enzyme activity TIPU pH 7 was calculated as micromole fatty acid produced per minute under assay conditions.

30

[0453] The dosage level of enzymes was 75 and 40 units per litre. Reaction time and temperature was in this experiment constant at 40°C for 30 min.

[0454] In order to evaluate results from the trial, all samples were analysed as follows:

35

- Remaining content of cholesterol and phospholipids
- Particle size distribution in water and with 1 % SDS added
- Viscosity and sediment (DLA standard methods in Dairy Pilot Plant) Viscosity is measured in centipoises on a Brookfield Viscosimeter with spindle 2 at 60rpm and 4°C. Sedimentation is measured by the Sedimentation test in % when subjecting a product sample to centrifugal force of 2800 g for 20minutes and 20 °C (Ultracentrifuge) and then calculate pellet at % of total sample.

[0455] Particle size was measured by Malvern Mastersizer S long bed, configuration Alpha, Linse 300R. The instrument was calibrated with a polymer standard to a specification of $0.993 \mu\text{m} \pm 0.021 \mu\text{m}$. The sample is diluted in water (2 g sample to 10 ml water with 1% SDS). SDS was added to avoid particles aggregation, as aggregation will give a false result.

5 RESULTS

Analysis results:

[0456]

	Sample 1	Sample 2	Sample 3	Sample 4	Sample 5	Sample 6	Sample 7	Sample 8
Cholesterol	Normal level	Completely esterified	Completely esterified	Completely esterified	Normal level	Partly esterified	Partly esterified	Partly esterified
Phospholipids	Normal level	Not present	Not present	Not present	Normal level	Not present	Not present	Not present

10

Particle size analysis:

[0457]

	Sample 1	Sample 2	Sample 3	Sample 4	Sample 5	Sample 6	Sample 7	Sample 8
Mean particle diameter μm	0.57	0.58	0.58	0.53	0.55	0.54	0.53	0.49

[0458] All samples have a mean particle size under $1 \mu\text{m}$.

15

[0459] Samples are weighed and then subjected to ultracentrifugation at 2800G for 20 minutes and at 20°C . After centrifugation the supernatant is removed and the dry pellet is weighed and sediment is calculated as percentage of original sample size. As noted above viscosity is measured in centipoises and sedimentation in %.

	Sample 1	Sample 2	Sample 3	Sample 4	Sample 5	Sample 6	Sample 7	Sample 8
Viscosity	5	6	6	22	15	15	17	28
Sediment	2,1	0,8	1,2	0,7	1,4	0,6	0,5	0,5

20

[0460] Results show that use of KLM3 can improve the emulsion stability in UHT milk, and remove the cholesterol.

Example 3 Effect of KLM-3 enzyme in pasteurized or UHT treated milk

25

Materials and Methods**[0461]**

Glycerophospholipid cholesterol acyltransferase KLM3 (K460)

5 Recodan RS 100: Stabilizer system

Cream: Commercial source

Skim milk: Commercial source.

EXPERIMENTAL

10

[0462] In order to further establish whether the use of KLM3 in milk has an effect on improving the emulsion stability the following trial run was made, comparing results in ordinary UHT milk and pasteurised milk, produced on basis of recombined fresh milk. In this experiment the enzyme reaction was conducted at 5°C.

Test of KLM3 in pasteurised (sample 11 and 12) and UHT milk (sample 13 and 14)

15

[0463]

Composition in %	11	12	13	14
RECODAN RS 100	0,15	0,15	0,13	0,13
Cream 38 % fat	8,61	8,61	8,66	8,66
Skimmed milk	91,24	91,24	91,21	91,21
KLM3, 100 U/ml	-	+	-	+
Temperature °C	90	90	142	142
Holding time in seconds	30	30	3	3

[0464] The said samples were processed in the Dairy Pilot Plant as follows:

20

Sample 11, 12 , 13 and 14:

UHT milk - Pilot (PHE)

1. -Mix skim milk and cream
2. - Add KLM 3 enzyme and stir well.
3. - Leave in cold store overnight (20 hr.)

4. - Heat milk to 60°C and add Recodan

Sample 13 and 14:

5. - Preheat to 90°C (holding cell at 30 seconds)

6. - Indirect heating 142°C for 3 seconds

5 7. - Downstream homogenisation 200 bar, 75°C

8. - Cool to 15°C

9. - Aseptic Filling

SAMPLE 11 and 12:

10. - Homogenise up stream at 70°C and 200 bar

10 11. - Pasteurise at 90°C for 30 sec

12. - Cool to 5°C and fill

15 **[0465]** The ingredients used for the trials were commercially purchased whole milk and/or standard raw materials used for majority of trials in the Dairy Pilot Plant.

[0466] The dosage level of enzymes was the same as in the other examples herein showing with KLM3 enzymation of milk at 5°C.

20 **[0467]** In order to evaluate results from the trial, all samples were analysed as follows:

- Turbiscan over 5 days
- Stress test of the UHT samples (long term stability)
- Surface Tension.
- Cholesterol and phosphatidylethanolamine
- 25 • Sensoric analysis by Triangle Test

Turbiscan:

30 **[0468]** Turbiscan MA 2000 was used to measure the stability of emulsions by measuring the backscatter of a laser beam from the product.

The milk samples were filled aseptically into a sterile test tube, the test tubes were kept at ambient temperature. The samples were measured at regular intervals over a period of 5-7 days.

35 Samples were measured from top 5 mm and bottom 5 mm of the test tube, where increase in back scattering from the top layer indicates creaming and increase in the bottom indicates sedimentation of particles in the sample.

STRESS Test of Neutral UHT Milk Products**[0469]**

1. 1. After aseptic filling (typically at ambient temp.) Sample 13 and 14 were placed overnight in cold store at 5°C
2. 2. Samples were then transferred to an incubator at 35°C for 24 hours
3. 3. Samples were transferred to Cold Store at 5°C for 24 hours
4. 4. Samples were transferred to ambient temperature of 20-25°C for 24 hours
5. 5. Samples were transferred to Cold Store at 5°C for 24 hours

[0470] After said temperature treatment, the samples were left at ambient temperature for 2-3 days and is then evaluated visually for Creaming, flocculation, Sedimentation and possible phase separations.

[0471] The correlation of this test with actual long-life stability of products has through 2 years observations proved to be having a very high correlation.

Surface tension:

[0472] The surface tension of the milk samples was measured with a Wilhelmy plate using a Tensiometer K10 from Krüss

Gas Chromatography:

[0473] Gas Chromatography was used to measure the content of cholesterol and cholesterol-ester in the milk samples.

The following CG setup was used:

Perkin Elmer Autosystem 9000 Capillary Gas Chromatograph equipped with WCOT fused silica column 12.5 m x 0.25 mm ID x 0.1 µ film thickness 5% phenyl-methyl-silicone (CP Sil 8 CB from Chrompack).

Carrier gas: Helium.

Injector. PSSI cold split injection (initial temp 50°C heated to 385°C), volume 1.0µl Detector FID: 395°C

Oven program:	1	2	3
Oven temperature, °C.	90	280	350
Isothermal, time, min.	1	0	10
Temperature rate, °C/min.	15	4	

Preparation of milk samples for GC analysis:

[0474] The milk lipids are extracted according to Mojonnier AOAC 989.05 using ethanol, NH₃, MTBE (methyl-tert-butyl ether) and p-ether. The lipid fraction is redissolved in heptane/pyridine (2:1) containing heptadecan as internal standard and cholesterol is measured by GC.

[0475] Preparing samples for cholesterol-ester measurements Squalane is added as an additional internal

standard. The lipid fraction is redissolved in hexane and cholesterol-esters are concentrated using a NH₂ Bond Elut column and hexane elution. Samples are redissolved in heptane/pyridine (2:1) and cholesterol-esters are measured by CG.

HPTLC:

5

[0476] HPTLC is used to measure the content of phosphatidylethanolamine (PE) in pasteurised milk samples and UHT milk samples.

Applicator: CAMAG applicator AST4.

HPTLC plate: 20 x 10 cm (Merck no. 1.05641)

10

The plate is activated before use by drying in an oven at 160°C for 20-30 minutes. Application: 6.0µl of extracted lipids dissolved in CHCl₃:Methanol (2:1) are applied to the HPTLC plate using AST4 applicator.

0.1, 0.3, 0.5, 0.8, 1.5µl of a standard solution containing standard components with known concentration are also applied to the HPTLC plate

15

Running-buffer 6: Methylacetate:CHCl₃:1-propanol:MeOH:0.25 % KCl (25:25:25:10:9) Elution length: 7 cm

Developing fluid: 6% Cupriacetate in 16% H₃PO₄

20

[0477] After elution the plate is dried in an oven at 160°C for 10 minutes, cooled and immersed in the developing fluid (10 sec) and then dried additional for 6 minutes at 160°C. The plate is evaluated visually and scanned (Camag TLC scanner).

Triangle Test.

ISO 4120:2004 Sensory analysis - Methodology - Triangle test

25

[0478] ISO 4120:2004 describes a procedure for determining whether a perceptible sensory difference or similarity exists between samples of two products. The triangle test is a three-alternative test in which one sample is different from the other two.

30

[0479] The test is counterbalanced for the identity of the odd sample (both ABB and BAA used) and its position in tasting (ABB, BAB, BBA, AAB, ABA, BAA). Chance performance is one third, and performance in a group above that level provides evidence for a perceivable difference. The method is a forced-choice procedure. The method applies whether a difference can exist in a single sensory attribute or in several attributes.

35

RESULTS

TURBISCAN Measurements

[0480] Results from Turbiscan measurements of pasteurized or UHT milk are shown in the Table below and also in Figure 74 and Figure 75.

- 5 Table: Turboscan measurement of Pasterurized milk 12983-1-11(control), 12983-1-12(enzyme treated) and UHT milk 12983-1-13(control), 12983-1-14(enzyme treated)

Average top 5mm Time (min)	Relative 12983-1-11	12983-1-12	12983-1-13	12983-1-14
0	0,00	0,00	0,00	0,00
1	-0,04	-0,51	-0,11	0,08
1225	1,31	2,55	-0,53	-0,68
2683	2,11	2,81	-1,09	-0,02
6951	4,30	2,89	-0,58	0,04
Average bottom 5mm Time (min)	12983-1-11	12983-1-12	12983-1-13	12983-1-14
0	0,00	0,00	0,00	0,00
1	-0,25	0,09	-0,06	-0,12
1225	-1,80	-1,91	-0,10	0,11
2683	-3,03	-2,21	-0,50	0,12
6951	-4,22	-2,71	-0,65	0,17

- 10 [0481] The TURBISCAN measurements show decreased creaming and decreased sedimentation in the pasteurised samples, the storage time was too short to determine the effect in UHT milk. Storage stability of the UHT milk was therefore determined by the Stress test.

Stress Test of enzymatically treated milk in trial DK 12938

[0482]

Sample	Evaluation after stress test, placed 3 weeks at 30°C
13 (no enzymatic treatment)	Slight creaming 0-1 mm
14 (enzymatic treatment)	Sample stable

- 15 [0483] After 3 weeks at 30°C a significant difference was observed between the control and the enzyme treated sample.

Surface tension

- 20 [0484] The surface tension of the milk samples were measured at 20 °C using a Kruss Tensiometer.

[0485] The results are illustrated in Figure 76.

[0486] The results from surface measurement indicates a significant effect of enzymatic treatment of milk with KLM3.

Gas Chromatography of free cholesterol and cholesterol-ester.

5

[0487] Results of Gas Chromatography measurements of milk cholesterol and cholesterol-ester are shown in Figure 77.

10

[0488] In general GC results from enzymatic treatment of both pasteurised and UHT milk with KLM3 acyltransferase confirms the ability of this enzyme to convert cholesterol into cholesterol-ester. KLM3 treatment of milk samples reduces free cholesterol by 85-90 % in UHT as well as pasteurized milk. In addition KLM3 treatment increased cholesterol-ester level in pasteurized and UHT milk by a factor ~6 and ~10, respectively. A clear effect is thus observed from KLM3 treatment of pasteurized and UHT milk with respect to reduction of free cholesterol.

15

[0489] Pasteurised and UHT milk controls both resembled the commercial UHT milk from ARLA with respect to free cholesterol and cholesterol-ester levels.

HPTLC of milk phosphatidylethanolamine:

20

[0490] Results of milk lipids extracted from pasteurised and UHT milk and measured by HPTLC are shown in Figure 78.

HPTLC Measurements.

[0491] Enzymatic treatment of both pasteurised and UHT milk with KLM3 show a marked reduction in milk phosphatidylethanolamine (PE) content as presented in the table below.

25 Table: Milk phosphatidylethanolamine quantified from HPTLC plate scan. SpectraLipid, Soy Lecithin Mix Standard (No. SLM43) was used in the quantification.

Pasteurised milk		UHT milk	
12983-1-11	12983-1-12	12983-1-13	12983-1-14
18.7 ppm	1.5 ppm	23.3 ppm	3.4 ppm

30

[0492] The reduction in milk PE content as a response of KLM3 enzymatic treatment and thus the formation of partially hydrolyzed PE (Lyso-PE) correspond to a better emulsion stability and less tendency to creaming over time. In addition, the reduced milk PE corresponds to the formation of cholesterol-esters and a reduction of free cholesterol as given in Figure 77, and further a better emulsion stability.

Triangle test

35

[0493] Organoleptic differences between control and enzyme treated pasteurised or UHT milk were evaluated by a triangle test. The results from the tests is outlined in the table below:

Table: Triangle tests of UHT milk and Pasteurised (PAST) milk.

Test no	Results of tests (Alpha risks)	Without Answer	Answers Taken	Answers Right	Signif
1	UHT without enzyme/UHT with enzyme	0	8	1	0,961
3	UHT without enzyme/UHT with enzyme	0	8	4	0,259
5	UHT without enzyme/UHT with enzyme	0	8	5	0,088
Average					
1-3-5	UHT without enzyme/UHT with enzyme	0	24	10	0,2538
Test no	Results of tests (Alpha risks)	Without Answer	Answers Taken	Answers Right	Signif
2	PAST without enzyme/PAST with enzyme	0	8	3	0,532
4	PAST without enzyme/PAST with enzyme	0	8	2	0,805
6	PAST without enzyme/PAST with enzyme	0	8	5	0,088
Average					
2-4-6	PAST without enzyme/PAST with enzyme	0	24	10	0,2538

[0494] The triangle test shows that treatment with the enzyme (KLM3) does not adversely affect the taste of UHT milk or pasteurized milk compared with milk without enzyme addition.

EXAMPLE 4 - Preparation of chocolate milk

5

Materials and Methods

[0495] Glycerophospholipid cholesterol acyltransferase KLM3 (K932) (SEQ ID No. 68): 1128 LATU/g

10 [0496] Soy Lecithin Mix Standard (ST16) from Spectra Lipid, Germany.

Recipe

[0497]

Ingredient Name	Sample no 1 DK14636-2-3	Sample no 2 DK14636-2-4
Skimmed milk	89,496	89,496

Ingredient Name	Sample no 1 DK14636-2-3	Sample no 2 DK14636-2-4
Cream 38 % fat	2,804	2,804
Sucrose	6,000	6,000
Cocoa powder D-11A (light alk.)	1,500	1,500
GRINDSTED® Carrageenan CL 220	0,020	0,020
CREMODAN® SUPER Mono-diglyceride	0,180	0,180
KLM3	+ 0,01 LATU/ml	
Total %	100	100

Process

- 5 **[0498]** Add KLM3 (100 U/ml) to the pasteurised skimmed milk for sample DK14636-2-3, at a dosage of 0.100 ml KLM3 per litre milk
 Agitate for two minutes
 Place in cold store at 5°C for 24 hours
 Also place the milk for sample no DK14636-2-4 in the cold store at 5°C for 24 hours.
- 10 **[0499]** After 24 hours storage at 5°C, heat the milk to 70°C and add all other ingredients
 Heat to 90°C for 30 seconds
 UHT treatment (plate heat exchanger) 139-142°C / 2-4 sec.
 Homogenise at 150 bar/50 bar and 75°C
 Cool to 10-15°C
- 15 **[0500]** Transfer to cold store
 Store at below 5°C.

Preparation of Cocoa milk samples for GC and TLC analysis:

- 20 **[0500]** 2 gram Cocoa milk was scaled in a 12 ml test tube with screw lid. 10 Hexan:Isopropanol 3:2 was added.
- 25 **[0501]** The sample was mixed on a Whirley and extracted on a rotamix 30 rpm for 30 minutes.
- 30 **[0502]** The test tube was centrifugated at 1720 ref for 10 minutes. The upper phase accounting 8.5 ml was isolated.
- 35 **[0503]** 5 ml solvent phase was transferred to a 10 ml Dramglass an evaporated to dryness at 50°C under a steam of nitrogen. The sample was re-dissolved in 0,400 ml Chloroform: Methanol 2:1 and used for TLC analysis.
- 40 **[0504]** Another 2 ml of the solvent phase was isolated, evaporated at 50 °C under a steam of Nitrogen and used for GLC analysis

Gas Chromatography:

[0505] Gas Chromatography is used to measure the content of cholesterol and cholesterol-ester in the lipid from Cocoa milk samples.

[0506] The following CG setup is used:

- 5 Perkin Elmer Autosystem 9000 Capillary Gas Chromatograph equipped with WCOT fused silica column 12.5 m x 0.25 mm ID x 0.1 µ film thickness 5% phenyl-methyl-silicone (CP Sil 8 CB from Chrompack).
Carrier gas: Helium.
Injector. PSSI cold split injection (initial temp 50°C heated to 385°C), volume 1.0µl Detector FID: 395°C

Oven program	1	2	3
Oven temperature, °C.	90	280	350
Isothermal, time, min.	1	0	10
Temperature rate, °C/min.	15	4	

10 HPTLC:

[0507] HPTLC is used to measure the content of phosphatidylethanolamine (PE) and Phosphatidylcholine(PC) in the isolated lipid from Cocoa milk samples.

Applicator: CAMAG applicator AST4.

- 15 HPTLC plate: 20 x 10 cm (Merck no. 1.05641)

The plate is activated before use by drying in an oven at 160°C for 10 minutes. Application: 6.0µl of extracted lipids dissolved in CHCl₃:Methanol (2:1) are applied to the HPTLC plate using AST4 applicator.

- 20 0.1, 0.3, 0.5, 0.8, 1.5µl of a standard solution containing standard components of phospholipids with known concentration are also applied to the HPTLC plate

Running-buffer 6: Methylacetate:CHCl₃:1-propanol:MeOH:0.25 % KCl (25:25:25:10:9) Elution length: 7 cm

Developing fluid: 6% Cupriacetate in 16% H₃PO₄

- 25 **[0508]** After elution the plate is dried in an oven at 160°C for 10 minutes, cooled and immersed in the developing fluid (10 sec) and then dried additional for 6 minutes at 160°C. The plate is evaluated visually and scanned (Camag TLC scanner). Phospholipid components are quantified based on calibration curves from the standard phospholipid composition.

Turbiscan:

- 30 **[0509]** Turbiscan MA 2000 is used to measure the stability of emulsions by measuring the backscatter of a laser beam (Lumifugation) from the product.

RESULTS

[0510] The results from GLC and TLC analysis of lipid extracted from Cocoamilk treated with KLM3' and a control sample without enzyme treatment is seen in Table 1.

Table 1: GLC and TLC analysis of lipid from Cocoa milk

GLC-analysis	Cocoa milk Enzyme treated ppm	Cocoa milk Control Ppm
Free fatty acids	300	292
Cholesterol	33	60
Cholesterol ester	48	6
TLC-analysis		
Phosphatidylethanolamine	10,5	27,3
Phosphatidylcholine	2,8	24,9

5

[0511] The results in Table 1 indicate that almost half of the cholesterol in the Cocoa milk has been esterified by the enzyme treatment. And the amount of phospholipids in the enzyme treated sample was reduced. The results indicate that KLM3' is more active on phosphatidylcholine than on phosphatidylethanolamine in the Cocoa milk.

10

Lumifugation of Chocolate milk with and without KLM 3 (DK14636-2)

[0512] Experimental: Lumifugation has been carried out with 300 rpm (12xg), centrifugation glass no. 2 and the results are shown in Figure 79 (DK 14636-2-3) and Figure 80 (DK14636-2-4).

15 Clarification (% Integral Transmission):

[0513]

Sample no.	% Change in Transmission /hour x 10 ³
Sample 1 DK 14636-2-3	64
Sample 2 DK14636-2-4	72

20 **[0514]** The results are shown in Figure 81.

[0515] As the change in the transmission is a measure of the rate in the clearance, sample 2 is the most unstable.

25 **[0516]** In order to investigate the rate of clearance front tracking has been performed.

[0517] Front tracking, i.e. monitoring the movement of the front of clearance, at 15% transmission (see Figure 82)

Sample no	µm/sec at 12xg	mm/month at 1xg
Sample 1 DK 14636-2-3	0,0067	1,45

Sample no	$\mu\text{m/sec}$ at 12xg	mm/month at 1xg
Sample 2 DK 14636-2-4	0,0242	5,23

[0518] Front tracking at 50% transmission (see Figure 83) together with the front tracking at 15% (see Figure 82) shows the difference in the clearance of the two samples, as sample 1 has approx. 1 mm clearance (50%T) supernatant, while sample 2 has a 2 mm less transparent supernatant. This is the result of a broader particle size distribution in sample 2.

Conclusion:

[0519] The enzyme treated sample is the most stable sample and further it has the most narrow particle size distribution

EXAMPLE 5 - Comparison of KLM3' (K932) with different phospholipases

Materials and Methods

Lipid acyltransferase - KLM3' (K932)

[0520] A fungal lipolytic enzyme obtainable from *Fusarium heterosporum* CBS 782.83 (hereinafter referred to a "KLM1" from Danisco A/S) as taught in WO2005/087818. Phospholipase A1 from *Fusarium oxysporum* (LIOPAN F™) from Novozymes Pphospholipase A2 from *Porcine pancreas* (LIPOMOD 699 L™) from Biocatalysts, UK

Standard pasteurised Whole Milk (3.5% fat) from ARLA in Denmark

[0521] Enzymated milk was investigated in comparison to reference milk in terms of stability against creaming visual evaluation of creaming, sedimentation and phase separation in samples stored over 60 days.

[0522] Furthermore the amount of free fatty acids in the milk was analyzed to evaluate level of rancidity in final product, and amount of cholesterol and/or phospholipids was analyzed to get an indication of enzymatic reaction level.

EXPERIMENTAL

Preparation of Milk

[0523]

Table: Recipe

Ingredients in %						
Ingredient Name	1	2	3	4	5	6
Whole milk 3,5 % fat	100,000	100,000	100,000	100,000	100,000	100,000
KLM1				10 LATU/ ml		
KLM3'		0.01 LATU/ ml				0,25 LATU /ml
LIOPAN F			5 LATU/ ml			
Lipomod 699 L					0,25 e-PLU/ml	
Total %	100	100	100	100	100	100

Process

[0524]

- 5 1. 1. Cold milk was mixed with enzyme portion and mixture was left in cold store overnight
2. 2. Preheating to 90°C for 30 sec
3. 3. UHT treatment at 142°C for 3 sec
4. 4. Homogenise at 75°C and 200 bar
5. 5. Cool to 20°C and fill aseptically in 6 bottles

10

Table: Real time shelf-life test

	Sample 1	Sample 2	Sample 3	Sample 4	Sample 5	Sample 6
Cream Layer	4 mm	1 mm	3 mm	2 mm	3mm	2 mm
Sediment layer	0 mm	0 mm	12 mm	1 mm	2 mm	<1 mm
Organoleptic evaluation	Typical UHT flavour, slightly cooked	As sample 1, however, slightly less cooked	Grainy texture with very strong rancidity	As sample 1	As sample 1	As sample 1

- 15 [0525] Samples prepared by UHT processing as described earlier were stored at ambient temperatures (18-25°C) for a period of 60 days, where after the samples were evaluated for creaming layer as well as eventual phase separation or sedimentation in the bottom of the bottles.

[0526] Samples were furthermore tested by a trained panel of 6 persons, with a tasting session made as a randomised triangle test with sample 1 (plain UHT milk) used as the reference sample in all test sessions.

- 20 [0527] Both for real time observation of stability as well as organoleptic evaluation, it can be seen that sample 3 (enzymated with LIOPAN F™) gives significantly deviating results, with lower stability and strong lipolytic flavour in samples.

- 25 [0528] KLM3' (samples 2 and 6) reduced the cream layer without forming a sediment layer and showed a marked improvement compared with the control 1.

[0529] The phospholipase treated samples 3, 4 and 5 may also reduced the cream layer compared with the control (although not to the same degree as KLM3'), but this was at the expense of forming a sediment layer.

- 5 [0530] With regard to organoleptic properties, sample 2 (KLM3') had a slightly less cooked taste compared with the control 1. Hence sample 2 has an improved taste compared with the control 1. Lipopan F™ (sample 3) produced milk with bad organoleptic properties, probably due to the high level of free fatty acids produced.

HPTLC and GLC analysis

- 10 [0531] Enzyme treated UHT milk according to the recipes shown in the table was extracted with organic solvents and the isolated lipids were analyzed for phospholipids by HPTLC and for cholesterol, cholesterol ester and free fatty acids (FFA) by Gaschromatography (GLC).

Table: HPTLC analysis of main phospholipids in milk PC= phosphatidylcholine PE= phosphatidylethanolamine.

Sample	Dosage	PC ppm	PE ppm	Sum PC+PE Ppm	Degree of hydrolysis %
Control		26,6	61,4	88,0	0
KLM3*	0,01 TIPU/ml	9,0	10,9	19,9	77
Lipopan F	5 TIPU/ml	3,9	7,8	11,8	87
KLM1	10 TIPU/ml	14,6	14,6	29,2	67
Lipomod 699L	0,25 e-PLU/ml	5,1	2,0	7,2	92
KLM3'	TIPU/ml	5,0	2,0	7,0	92

Table: GLC analysis of cholesterol, cholesterol ester and free fatty acids (FFA) Cholesterol

Sample	Dosage	FFA total %	Cholesterol %	ester %
Control	0	0,022	0,015	0,0012
	0,01			
KLM3*	TIPU/g	0,029	0,009	0,0106
Lipopan F	5 TIPU/g	0,620	0,016	0,0014
KLM1	10 TIPU/g	0,159	0,016	0,0015
Lipomod 699L	0,25 e-PLU	0,042	0,014	0,0010
KLM3'	TIPU/g	0,065	0,001	0,0215

15

- [0532] The results form HPTLC analysis (see Table above) indicate that all enzymes tested were able to hydrolyse a main part of the phospholipids in the milk accounting from 77% to 92%, but only the lipid acyltransferase KLM3' were able to make a transfer reaction of fatty acid to cholesterol during formation of cholesterol ester.
- 20

- [0533] Although all enzymes produced a high degree of phospholipid hydrolysis the amount of free fatty acids produced were significantly different. Based of the amount of phospholipid hydrolysis and free fatty acid produced it is possible to calculate on a molar basis the amount of free fatty acid relative to the amount of phospholipids produced (see the table below). These results clearly demonstrate that the microbial phospholipases A1 produces much more free fatty acid that KLM3, because these phospholipases are not specific but also hydrolysis triglycerides (milk fat). Pancreas phospholipase (Lipomod 699 L) is known to be very specific for the phospholipids, but still produces more free fatty acids than the low dosage of KLM3'. At
- 25

the high dosage of KLM3' more fatty acid are produced than pancreas phospholipase, but this is explained by activity on lyso-phospholipids. Lipopan F produced the highest amount of free fatty acid because of the hydrolytic activity on triglycerides, which contributed to the negative evaluation in the organoleptic test.

Table: Formation of free fatty acid (FFA) relative to the amount of hydrolysed phospholipids

Sample	Dosage	FFA change mmol/kg	PL change mmol/kg	FFA/PL mol. ratio
Control	0	0	0	-
	0,01			
KLM3*	TIPU/g	0,279	0,093	3
Lipopan F	5 TIPU/g	21,7	0,103	210
KLM1	10 TIPU/g	4,98	0,080	62
Lipomod 699L	0,25 e-PLU	0,742	0,110	7
KLM3'	TIPU/g	1,58	0,110	14

5

[0534] In conclusion: KLM3' showed an enhanced stability (with a reduced cream layer without formation of a sediment layer) compared with both the control (without enzyme) and the comparative phospholipase enzymes. Without wishing to be bound by theory the reason for the enhanced stability may be due to a reduced particle size distribution of the fat globules in milk treated with KLM3'.

10

[0535] A further important effect is that KLM3' produces much less free fatty acid compared with the same concentration of phospholipase. During extended storage at ambient temperatures free fatty acid can easily result in more oxidation of the milk and thus later cause organoleptic problems. Thus high free fatty acid content may cause significant problems in UHT milk which is typically stored at ambient temperatures for more than a month.

15

PATENTKRAV

1. Fremgangsmåde til fremstilling af UHT-mælk, hvor fremgangsmåden omfatter blanding af en lipid acyltransferase og mælk eller en fraktion deraf ved en temperatur og i en inkubationsperiode, der er effektiv til at sikre, at der er mindst 5 % transferaseaktivitet målt ved molmængden af cholesterolester dannet ved acyloverførsel fra phospholipider eller triacylglycerider i mælk til kolesterol, i forhold til mængden af oprindeligt tilgængeligt kolesterol, beregnet ved anvendelse af den følgende ligning:

Transferaseaktivitet =

$$\frac{(\text{Mol/l cholesterolester (t)} - \text{Mol/l cholesterolester (0)}) \times 100}{\text{Mol/l kolesterol (0)}}$$

Mol/l kolesterol (0)

hvor:

cholesterolester (t) = mængden af cholesterolester på tidspunktet t

cholesterolester (0) = mængden af cholesterolester på tidspunktet 0

cholesterol (0) = mængden af kolesterol i mælk på tidspunktet 0,

og behandling af den enzymbehandlede mælk ved ultrahøj varmebehandling for fremstilling af UHT-mælk.

2. Anvendelse af en lipid acyltransferase i fremstillingen af UHT-mælk for mindst én af forbedring af stabiliteten, i særdeleshed langvarig stabilitet, den mærkbare sensoriske forskel eller duften og/eller smagen af UHT-mælken.
3. Anvendelse af en lipid acyltransferase i fremstillingen af UHT-mælk til reducere af cholesterolindholdet i UHT-mælken.

4. Anvendelse af en lipid acyltransferase i fremstillingen af UHT-mælk til eliminering eller reducere af flødeafsætning i UHT-mælken.

5. Fremgangsmåde eller anvendelse ifølge et hvilket som helst af kravene 1-4, hvor den lipide acyltransferase tilsættes til mælken eller en fraktion deraf og inkuberes deri ved en temperatur på mindre end ca. 20 °C, fortrinsvis mindre end ca. 10 °C.

- 10 6. Fremgangsmåde eller anvendelse ifølge et hvilket som helst af kravene 1-5, hvor den lipide acyltransferase tilsættes til mælken eller en fraktion deraf og inkuberes deri ved en temperatur på mellem ca. 1 °C og ca. 10 °C, fortrinsvis mellem ca. 3 °C og ca. 7 °C, mere fortrinsvis ca. 5 °C.

- 15 7. Fremgangsmåde eller anvendelse ifølge et hvilket som helst af kravene 1-6, hvor den lipide acyltransferase omfatter et GDSx-motiv, hvor x er et eller flere af L, A, V, I, F, Y, H, Q, T, N, M eller S og/eller et GANDY-motiv.

8. Fremgangsmåde eller anvendelse ifølge et hvilket som helst af kravene 1-7, hvor det lipide acyltransferaseenzym omfatter aminosyresekvensmotivet GDSX, hvor X er én eller flere af de følgende aminosyrerester L, A, V, I, F, Y, H, Q, T, N, M eller S.

- 20 9. Fremgangsmåde eller anvendelse ifølge et hvilket som helst af kravene 1-8, hvor den lipide acyltransferase kan være opnåelig, fortrinsvis opnået, fra en organisme fra én eller flere af de følgende arter: *Aeromonas*, *Streptomyces*, *Saccharomyces*, *Lactococcus*, *Mycobacterium*, *Streptococcus*, *Lactobacillus*, *Desulfotobacterium*, *Bacillus*, *Campylobacter*, *Vibrionaceae*, *Xylella*, *Sulfolobus*, *Aspergillus*, *Schizosaccharomyces*, *Listeria*, *Neisseria*, *Mesorhizobium*, *Ralstonia*, *Xanthomonas* og
- 25 *Candida*.

10. Fremgangsmåde eller anvendelse ifølge krav 9, hvor den lipide acyltransferase er opnåelig, fortrinsvis opnået, fra en organisme fra slægten *Aeromonas*.

11. Fremgangsmåde eller anvendelse ifølge et hvilket som helst af kravene 1-10, hvor den lipide acyltransferase er et polypeptid opnået ved ekspression af en hvilket som helst af nukleotidsekvenserne ifølge SEQ ID NO: 36, SEQ ID NO: 39, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62 eller SEQ ID NO: 63 eller en nukleotidsekvens, der er 75 % eller mere identisk dermed.
12. Fremgangsmåde eller anvendelse ifølge et hvilket som helst af kravene 1-11, hvor den lipide acyltransferase er et polypeptid opnået ved ekspression af:
- nukleotidsekvensen ifølge SEQ ID NO: 49 eller en nukleotidsekvens, der er 75 % eller mere identisk dermed;
 - en nukleinsyre, der koder for polypeptidet, hvor polypeptidet er mindst 70 % identisk med polypeptidsekvensen ifølge SEQ ID NO: 16 eller med polypeptidsekvensen ifølge SEQ ID NO: 68; eller
 - en nukleinsyre, der hybridiseres under medium stringensforhold til en nukleinprobe, der omfatter nukleotidsekvensen ifølge SEQ ID NO: 49.
13. Fremgangsmåde eller anvendelse ifølge et hvilket som helst af kravene 1-12, hvor den lipide acyltransferase er et polypeptid, der omfatter en hvilken som helst af aminosyresekvenserne ifølge SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 68 eller en aminosyresekvens, der er 75 % eller mere identisk dermed.
14. Fremgangsmåde eller anvendelse ifølge et hvilket som helst af kravene 1-13, hvor den lipide acyltransferase er et polypeptid, der omfatter aminosyresekvensen ifølge SEQ ID NO: 68 eller en aminosyresekvens, der er 75 % eller mere identisk dermed.

15. Fremgangsmåde eller anvendelse ifølge et hvilket som helst af kravene 12-14, hvor polypeptidet opnås ved ekspression i *Bacillus licheniformis*.

Drawing

FIGURE 1

SEQ ID No. 16

```

1  ADTRPAFSRI VMFGDSLSDT GKMYSKMRGY LPSSPPYYEG RFSNGPVWLE QLTQKQFGLT
61  IANEAEGGAT AVAYNKISWD PKYQVINNLD YEVTOFLOKD SFKPDDLVL VVGANDYLAY
121 GWNTEQDAKR VRDAISDAAN RMVLNGAKQI LLFNLPLDQG NPSARSQKV V EAVSHVSAYH
181 NKLLNLARQ LAPTMVKLF EIDKQFAEML RDPQNFGLSD VENPCYDGGY VWKPFATRSV
241 STDRLSAFS PQERLAIACN PLLAQAVASP MARRSASPLN CEGKMFWDQV HPTTVVHAAL
301 SERAATFIET QYEFLAHG

```

FIGURE 2

(SEQ ID No. 1)

```

1  MKKWFVCLLG LVALTVQAAD SRPAFSRIVM FGDSLSDTGK MYSKMRGYLP
51  SSPYYEGRF SNGPVWLEQL TKQFPGLTIA NEAEGGATAV AYNKISWNP
101 YQVINNLDYE VTQFLQKDSF KPDDLVLWV GANDYLAYGW NTEQDAKRVR
151 DAISDAANRM VLNGAKQILL FNLPDLGQNP SARSQKVVEA VSHVSAYHNQ
201 LLLNLARQLA PTGMVKLFEI DKQFAEMLRD PQNFGLSDVE NPCYDGGYVW
251 KPFATRSVST DRQLSAFSPO ERLAIAGNPL LAQAVASPM RRSASPLNCE
301 GKMFWDQVHP TTVVHAALSE RAATFIANQY EFLAH*

```

5

FIGURE 3

(SEQ ID No. 2)

```

1  ivafGD$1Td geayygdsdg ggwgagladr Ltallrlrar prgvdvfnrg isGrtsdGr1
61  ivDalvallF laqslglpnL pPYLsgdflr GANFAsagAt Ilptsgpfli QvqFkdfksq
121 vlelrqalgl lqellrllpv ldakspdlvt imiGtN$lit saffgpkste sdrnvsvpef
181 kdnlrqlikr Lrsnngarii vlitlvilnl gplGC1Flkl alalassknv dasgclerln
241 eavadfneal relaiskled qlrkdgldpv kgadvpyvDl ysifqlddgi qnpsayvyGF
301 ettkaCCGyG gryNynrvCG naglcnvtak aCnpssylls flfwDgfHps ekGykavAea
361 1

```

FIGURE 4

(SEQ ID No. 3)

```

1  mkkwfvcllg lvaltvqaad srpafsrivm fgdslsdgk myskmrgylyl sspyyegrf
61  sngpvwleql tnefpgltia neaeggptav aynkiswnpk yqvinnldye vtqflqkdsf
121 kpddlvlwv gandylaygw nteqdakrvr daisdaanrm vlngakeill fnlpdlgqnp
181 sarsqkvvea ashvsayhnq lllnlargla ptgmvkifei dkqfaemlrd pqnfglsdqr
241 nacyggsyvw kpfasrsast dsqlsafnpq erlaiagnpl laqavaspma arsastlnce
301 gkmfwdqvhv ttvvhhaalse paatfiesqy eflah

```

FIGURE 5

SEQ ID No. 4

```

1 mkkwfvcllg lialtvqaad trpafsrivm fgdslsdtgk myskmurgylp ssppyyegrf
61 sngpwwleql tkqipgltia neaeggatav aynkiswnpk yqvynaldye vtqflqkdsf
121 kpddlvilwv gandylaygw ntegdakrvr daisdaanrm vingakqill fnipdlggnp
181 sarsqkvvea vshvsayhmk lllnlarqla ptgmvkifei dkqfaemlrd pgnfglsdve
241 npcydgggyvw kpfatrsvst drqlsafspq erlaiagnpl laqavaspmr rrsasplnce
301 gxmfwdqvhp ttvvaalse raatfietqy eflahg

```

FIGURE 6

SEQ ID No. 5

```

1 mpkpalrrvm tatvaavgtl algltdatah aapaqatptl dyvalgdsys agsgvlpvdp
61 anlliclrsta nyphviadtt garltdvtcg aaqtadfta qypgvapqld algtgtdlvt
121 ltiggnndst finaitacgt agvlsqgkgs pckdrhgtsf ddeieantyp alkeallgvr
181 arapharvaa lgypwitpat adpscfklkp laagdvpplr aiqahindav rraaeetgat
241 yvdfsgvsdg hdaceapgtr wiepllfghs lvpvhpnaig ermaehtmd vlgld

```

FIGURE 7

SEQ ID No. 6

```

1 mpkpalrrvm tatvaavgtl algltdatah aapaqatptl dyvalgdsys agsgvlpvdp
61 anlliclrsta nyphviadtt garltdvtcg aaqtadfta qypgvapqld algtgtdlvt
121 ltiggnndst finaitacgt agvlsqgkgs pckdrhgtsf ddeieantyp alkeallgvr
181 arapharvaa lgypwitpat adpscfklkp laagdvpplr aiqahindav rraaeetgat
241 yvdfsgvsdg hdaceapgtr wiepllfghs lvpvhpnaig ermaehtmd vlgld

```

FIGURE 8

SEQ ID No. 7

```

1 mdyekfllfg dsitefafnt xpiedgkdqy algaalvney trkmdilqrg fkgysrwal
61 kilpeilkhe snivmatifl gandacsagp qsvplpefid nirqmvsimk syhirpiig
121 pglvdrekwe kekseeialg yftrtnenfai ysdalaklan eekvpfvaln kafqgegga
181 wqqlitdglh fsgkgykifh dellkviety ypqyhpknmq ykikdwrdvl ddgsnims

```

FIGURE 9

(SEQ ID No. 8)

10	20	30	40	50	60
MNLRQWMGAA	TAALALGLAA	CGGGGTDQSG	NPNVAKVQRM	VVFGDSLSDI	GTYPVAQAV
70	80	90	100	110	120
GGGKFTTNGP	PIWAETVAAQ	LGVTLPVAVM	GYATSVQNCF	KAGCFDYAQQ	GSRVTPNGI
130	140	150	160	170	180
GHNGGAGALT	YPVQQQLANF	YAASNNTFNG	NNDVVFVLAG	SNDIFFWTTA	AATSGSGVTP
190	200	210	220	230	240
AIATAQVQQA	ATDLVGYVKD	MIARGATQVY	VFNLPDSSLT	PDGVASGTTG	QALLHALVGT
250	260	270	280	290	300
FNTTLQSGLA	GTSARIIDFN	AQLTAAIQNG	ASFGFANTSA	RACDATKINA	LVPSAGGSSL
310	320	330	340		
FCSANTLVAS	GADQSYLFAD	GVHPTTAGER	LIASNVLARL	LADNVAH	

FIGURE 10 (SEQ ID No. 9)

```

1 migsyvavgd sftegvqdpd pdgafvbwad rlavlladrr pegdfitynl avrgrildqi
61 vaegvprvvg lapdlvsfaa ggndiirpgt dpdevaerfe lavaaltaaa gtlvlttgfd
121 trgvvpvlkhl rgklatyngh vraiadrygc pvidlwsirs vqdrrawdada rhlhspeght
181 rvalraggal glrvpadpdq pwpplpprgt ldvrrddvhw areylvpwig rrlrgessgd
241 hvtakgtlsp daiktriaav a

```

FIGURE 11

(SEQ ID No. 10)

```

1 mqtntpaysl vavgsfteg msdlipdgsy rgwadllatr maarspgfry anlavrgkli
61 gqivdeqvdv aaamgadvit lvgglndtlr pkcdmarvrd lltqaverla phceqlvlmr
121 spgrqgpvlr rfrpmealf aviddlagrh gavvvdlyga qsladpmmwd vdrhlhtaeg
181 hrrvaeavwq slghepedpe whapipatpp pgwvtrrtad vrfarghlip wigrrltgrs
241 sgdgllpakrp dlipyedpar

```

FIGURE 12

(SEQ ID No. 11)

```

1 mtrgrdggag apptkhrall aaivtlivai saaiyagasa ddgsrdhalq aggrlprgda
61 apastgawvg awatapaaae pgtettglag rsvrvvhts vggtagariti snlyggspit
121 vthasialaa gpdtaaaiaa tmrrltfggs arviipaggg vmsdalarlai pyganvlvtt
181 yspipsgpvt yhpqarqtsy ladgdrtadv tavayttptp ywryltaldv lsheadgtvv
241 afgdsitdga rsqsdanhrw tdvlaarlhe aagdgdrdtp ysvvnegisg nrltsrpggr
301 padnpsglr fqrdivlertn vkavvvvlgv ndvlinspela drdaailtglr tlvdraharg
361 lrvvgatitp fggygytea retmrgevne eirsgrvfdt vvdfdkalrd pydprmrmsd
421 ydsghihpg dkgyarmgav idlaalkgaa pvka

```

FIGURE 13 (SEQ ID No. 12)

```

1 mtsmsrarva rriaagaayg gggiglagaa avglvvaevq larrrvvgvt ptrvpnaqgl
61 yggtlptagd pplrlmngd staaggvhr agtptgalla sglavaaerp vrlgsvaqpg
121 acsddldrvq alvlaepdrv pdicvmvga ndvthmpat rsvrhlssav rrlrtagaev
181 vvgtpcdlgt iervrgplr larrasrqla aaqtigaveq ggtrvslgdl lgpefaqnpr
241 elfgpdnyhp saegyataam avlpsvcaal glwpadeehp dalrregflp varaaaaaas
301 eaqtevaam ptgprgppwal lkrrrrrrvs eaepsspsgv

```

FIGURE 14 (SEQ ID No. 13)

```

1 mgrgtldqrtr ygrrrarval aaltaavlgv gvagcdsvgg dspapsqspk krtrtapawd
61 tspasvaavg dsitrgfdac avlsdcpevs watgssakvd slavrllgka daaehswnya
121 vtgarmadlt aqvtraaqre pelvavmaga ndacrsttsa mtpvadfrag feeamatlrk
181 klpkagvyvs sipdlkrlws qgrtnplgkq vwkgiglcpsm lgdadslds atrlrntvrd
241 rvadynevlr evcakdrccr sddgavhefr fgtdqlshwd wfhpssvdgqa rlaeiayrav
301 taknp

```

FIGURE 15 (SEQ ID No. 14)

```

1 mrlsrraata sallltpala lfgasaavsa priqatdyva lgdsyssgvg agsydsssgs
61 ckrtksypa lwaashtgtr inftacsgr tgdlvialqtl pvnsqtdlvs itiggndagi
121 adtmittcnlq gesaclaria karayiqqtl paqldqvyda idsrapaaqv wlgyprrfyk
181 lggscavqls eksraaina addinavtak raadhgfafg dvnttfaghe lcsgapwlhs
241 vtlpvensyh ptangqskgy lpvlinsat

```

FIGURE 16 (SEQ ID No. 15)

```

1 MKKWFVCLLG LIALTVQAAD TRPAFSRIVM FGDSLSDTGK MYSKMRGYLP
51 SSPYYEGRF SNGPVWLEQL TKQFPGLTIA NEAEGGATAV AYNKISWNP
101 YQVINNLDE VTQFLQKDSF KPDDLVLWV GANDYLAYGW NTEQDAKRVR
151 DAISDAANRM VINGAKQILL FNLPDLGQNP SARSKVVEA VSHVSAYHNK
201 LLLNLARQLA PTGMVKLFBI DKQFAEMLRD PQNFGLSDVE NPCYDGGYVW
251 KPFATRSVST DRQLSAFSPQ ERLAIAGNPL LAQAVASEMA RRSASPLNCE
301 GKMFWDQVHP TTVVHAALSE RAATFIETQY EFLAHG*

```

FIGURE 17 (SEQ ID No. 19)

```

1 migsyvavgd sftegvgdpg pdgafvgwad rlavlladrr pegdftytnl avrgrlldqi
61 vaeqvprvvg lapdlvsfaa ggndiirpqt dpdevaerfe lavaaltaaa gtlvlttgfd
121 trgvplkhl rgkiatyngh vxaiadrygc pvlldwslrs vqdrrawdad rhlspgght
181 rvalraggal glrvpadpdq pwpplpprgt ldvirdvhw areylvpwig rrlrgessgd
241 hvtagktlsp daiktriaav a

```

FIGURE 18 (SEQ ID No. 25)

```

1 MEKFKKNFLV GLSAALMSIS LFSATASAAS ADSRPAFSRI VMFGDSLSDT
51 GKMYSKMRGY LPSSPPYYEG RFSNGPVWLE QLTQKQFGLT IANEAEGGAT
101 AVAYNKISWN PKYQVINNLDE YEVTOFLQKD SFKPDDLVLIL WVGANDYLAY
151 GWNTEQDAKR VRDAISDAAN RMVINGAKQI LLFNLPDLGQ NPSARSKQVV
201 EAVSHVSAYH NQLLLNLARQ LAPTMVKLF EIDKQFAEML RDPQNFGLSD
251 VENPCYDGGY VWKPFATRSV STDRQLSAFS PQERLAIAGN PLLAQAVASP
301 MARRSASPLN CEGKMFWDQV HPTTVVHAAL SERAATFIAN QYEFLAH**

```

FIGURE 19

(SEQ ID NO. 26)

```

MRLTRLSAASVIVFALLLLALGISPAQAAGPAYVALGDSYSSGNGAGSYIDSSGDCHRN
NAYPARWAAANAPSSFTFAACSGAVTTDVINNQLGALNASTGLVSITIGGNDAGFADAMTT
CVTSSDSTCLNRLATATNYINTTLARLDVYSQIKARAPNARVVVIGYPRMYLASNPWYC
LGLSNTKRAAINTTADTLNSVISSRATAHGFRFGDVRPTFNNHELFFGNDWLHSLTLPVWE
SYHPTSTGHQSGYLPVLNANSST

```

Figure 20

SEQ ID No. 27

ZP 00058717

```

1 mlphpagerg evgaffallv gtpqdrirlrl echetrplrg rcgcgerrvp pltlpgdgvl
61 cttssrdaae tvwrkhlqpr pdggfrrphlg vgcllagqgs pgvlwcgrrg crfevcirdt
121 pglstrnqgd ssppfragws lppkcgelsq sarktpavpr yslirtdxpd gprgrfvgsq
181 praatrirlf lgipalvlvt altlavlavpt gretlwrnwc eatqdcwclgv pvdsrgqpae
241 dgeflllspv qaatwgnyya lgdsyssgdg ardyypgtav kggcwrnsana ypelvaeayd
301 faghlsflac sqgrgyamid aidevgsqld wnsphstslvt igiggnldgf stvlktcmvr
361 vpllldskact dgsdairkrm akfettfeel isevrtrapd arilvvgypv ifpeeptgay
421 yltasnrw lnatiqefnq qlaeavavhd eeiaasggvg svafvdyha ldgheigsde
481 pwvngvqlrd latgvtvdrs tfhpnaaghr avgervieqi etgpgrrplya tfavvagatv
541 dtlagevg

```

FIGURE 21

(SEQ ID No. 28)

```

1 mgsqpraatr rrlflgipal vlvtaltlvt avptgretlw rmwceatqdw clgvvpdsrg
61 qpaedgefill lspvqaatwg nyvalgdsys sqdgardyyv gtavkggcwr sanaypelva
121 eaydfaghls flacsqgrgy amldaidevg sqldwnspht slvtigiggn dlqfstvlkt
181 cmvrvpplds kactdqedai rkrmakfett feelisevrt rapdarilvv gyprifpeep
241 tgayytltas nqrwlnetiq efnqqlaeav avhdeelaas ggvgsvfvd vyhaldghei
301 gsdepwvngv qlrdlatgtv vdrstfhpna aghravgerv ieqltgpgr plyatfavva
361 gatvdltlage vg

```

FIGURE 22

(SEQ ID No. 29)

```

1 mrttvlaasa llllagcadg areetagapp gessggiree gaeastsitd vyialgdsya
61 amggrdqplr gepfclrssg nypellhaev tdltcqgavt gdllleprtlg ertlpaqvda
121 ltedttlvtl siggndlgfg evagcireri agenaddcvd llgetigeql dqlppqldrv
181 heairdragd aqvvtvgylp lvsagdcpep qdvseadrw aveltgqine tvreaaerhd
241 aifvlpddad ehtscappqg rwadiqqgqt dayplhptsa gheamaaavr dalglepvqp

```

FIGURE 23

(SEQ ID No. 30)

ZP 00094165

```

1 mgqvklfarr capvllalag lepaatvare aplaegaryv algssfaagp gvgpnagpss
61 ercgrgtlly phllaeakl dlvdatcsga tthhvlgpwn evppqidsvn gdtrlvtlti
121 ggndvsfvgn ifaaacekma spdprcgkwr eiteewgad eermrsivrq iharaplary
181 vvdyitvlp psqtcaamai spdrlaqsrs aakrlarita rvareeqasl lkfshisrrh
241 hpcsakpwsn gisapaddgi pvhpnrlgha eaaaalvklv klmk //

```

FIGURE 24

SEQ ID No. 31

NP_625998.

```

1 mrrfrlvglf ssvlaagaa ltgaataqaa qpaaadgyva lgdsyssgvg agsyissgd
61 ckrstkahpy lwaaahspst fdftacsgar tgdvlsqqlg plssgtglvs isiggndagf
121 admtttcvlq sessclsria taeayvdstl pgkldgvysa isdkapnahv vvigypriyk
181 lgttciglse tkrtainkas dhlntvlaqr aaahgftfgd vrttftghel csgspwlhsv
241 nwlmgiesyh ptaagqsggy lplvngaa
//

```

FIGURE 25

SEQ ID No. 32

NP_827753.

```

1 mrrsritayv tslllavgca ltgaataqas paaaatgyva lgdsyssgvg agsyissgd
61 ckrsskaypy lwqaahspss fsfmacsgar tgdvlsqqlg tlnsstglvs ltiggndagf
121 sdvattcvlq sdsaclsrin takayvdstl pgqldsvyta istkapsahv avlgyprfyk
181 lggscilagls etkrsainda adylnsaiak raadhgftfg dvkstftghe icssstwihs
241 ldilnigqsy hptaagqsggy ylpvmnsva
//

```

FIGURE 26

SEQ ID No. 33

```

MRLTRSLSAASVIVFALLLALLGISPAQAAGPAYVALGDSYSSGNGAGSYIDSSGDCHRSN
NAYPARWAAANAPSSFTFAACSGAVTTDIVINNQLGALNASTGLVSIITIGGNDAGFADAMTT
CVTSSDSTCLNRLATATNYINTTLLARLDAVYSQIKARAPNARVVVLGYPRMYLASNEWYC
LGLSNTKRAAINTTADTLNSVSSRATAHGFRFGDVRPTFNNHELFFGNDWLHSLTLPVWE
SYHPTSTGHQSGYLPVLNANSST

```

FIGURE 27

(SEQ ID No. 34)

ADSRPAFSRIVMFGDSLSDTGKMYSKMRGYLPSSPPYYEGRFSNGPVWLEQLTNEFFGLTIANEAEGGPT
 AVAYNKISWNPKYQVINNLDEYVTQFLQKDSFKPDDLVLWVGANDYLAYGWNTAQDAKRVDAISDAAN
 RMVLNGAKEIILLENLPDLGQNPSARSQKVVEASHVSAYHNQLLLNLARQLAPTCMVKLF EIDKQFAEML
 RDPQNFGLSDQRNACYGGSYVWKPFASRSASTDSQLSAENPQERLAIAGNPLLAQAVASPMARSASTLN
 CE
 GKMFWDQVHPTTVVHAALSEPAATFIESQYEF LAH

FIGURE 28

(SEQ ID No. 35)

1	ADT	RPAFSRI	VMFGDSLSDT	GKMYSKMRGY	LPSSPPYYEG	RFSNGPVWLE	QLTKQFPGLT
61	IANEAEGGAT	AVAYNKISWN	PKYQVINNL	DEYVTQFLQKD	SFKPDDLVL	WVGANDYLAY	
121	GWNTAQDAKR	VRDAISDAAN	RMVLNGAKQI	LLFNLPDLGQ	NPSARSQKV	EAVSHVSAYH	
181	NKLLNLARQ	LAPTCMVKLF	EIDKQFAEML	RDPQNFGLSD	VENPCYDGGY	VWKPFATRSV	
241	STDRQLSAFS	PQERLAIAGN	PLLAQAVASP	MARRSASPLN	CEGKMFWDQV	HPTTVVHAAL	
301	SERAATFIET	QYEF LAH					

FIGURE 29

(SEQ ID No. 36)

ACAGGCCGATGCACGGAACCGTACCTTTCCGCGAGTGAAGCGCTCTCCCCCATCGTTCCG
 CGGGACTTCATCCGCGATTTTGGCATGAACACTTCCTTCAACGCGCGTAGCTTGCTACAA
 GTGCGGCAGCAGACCCGCTCGTTGGAGGCTCAGTGAGATTGACCCGATCCCTGTCCGCCG
 CATCCGTATCGTCTTCGCCCTGCTGCTCGCGCTGCTGGGCATCAGCCCGGCCAGGCAG
 CCGGCCCGGCCCTATGTGGCCCTGGGGGATTCTAITCTCTCGGGCAACGGCGCCGGAAGTT
 ACATCGATTGAGCGGTGACTGTACCCGAGCAACAACGCTACCCCGCCGCTGGGCGG
 CGGCCAACGACCGTCTCTTACCTTCGCGGCCCTGCTCGGGAGCGGTGACCACGGATG
 TGATCAACAATCAGTGGGCGCCCTCAACGCGTCCACGGGCTGGTGAGCATCACCATCG
 GCGGCAATGACGCGGGCTTCGCGGACGCGATGACCACCTGCGTCAACAGCTCGGACAGCA
 CCTGCCCTCAACCGGCTGGCCACCGCCACCAACTACATCAACACCACCTGCTCGCCCGGC
 TCGACCGGCTTACAGCCAGATCAAGGCCCGTGCCCCCAACGCCGCGTGGTGGTCTCTCG
 GCTACCCGCGCATGTACCTGGCCTCGAACCCCTGGTACTGCTGGGCTGAGCAACACCA
 AGCGCGCGGCATCAACACCACCGCCGACACCTCAACTCGGTGATCTCTCCCGGGCCA
 CGCCCAACGGATTCCGATTGCGCGATGTCCGCCCCGACCTTCAACAACCAAGAACTGTTCT
 TCGGCAACGACTGGCTGCACTCACTCACCTGCGGCTGTGGGAGTCTGACACCCACCA
 GCACGGGCCATCAGAGCGGCTATCTGCGGCTCTCAACGCCAACAGCTCGACCTGATCAA
 CGCAACGGCGTGCCCCCGCGCGCTCACGCTCGGCGCGGGCGCGCGAGCGCGTTGATCA
 GCCCACAGTGCCGGTGACGGTCCCACCGTCACGTCGAGGGGTGTAAGTCAAGTGGCGCC
 GCTCCAGAAGTGGAAACGTGAGCAGGACCGTGGAGCGCTCCCTGACCTCGTGAAGAACTC
 CCGGGTCAGCGTGATCACCCCTCCCCCGTAGCCGGGGCGAAGCGGCGCGAACTCCTT
 GTAGGACGTCCAGTCGTGCGGCCCGCGGTGCCACCGTCCGCGTAGACCGCTTCCATGGT
 CGCCAGCGCGTCCCCGCGGAACCTCGGTGGGGATGTCCGTGCCCAAGTGGTCCCGGTGGT
 GTCCGAGAGCACCGGGGGCTCGTACCGGATGATGTGCAGATCCAAAGAATT

FIGURE 30

(SEQ ID NO. 37):

MRLTRSLAASVIVFALLLALLGISPAQAAGPAYVALGDSYSSGNGAGSYIDSSGDCHRSN
 NAYPARWAAANAPSSFTFAACSGAVTTDVINNQLGALNASTGLVSIITIGGNDAGFADAMTT
 CVTSSDSTCLNRLATATNYINTLLARLDAVYSQIKARAPNARVVVILGYPRMYLASNPWYC
 LGLSNTKRAAINTTADTLNSVISSRATAHGFRFGDVRPTFNNHELFFGNDWLHSLTLPVWE
 SYHPTSTGHQSGYLPVLNANSST

FIGURE 31

SEQ ID No. 38

```
1  mlphpagerg evgaaffallv gtpqdrllrl echetrplrg rcgcgerrvp pltlpgdgvl
61  cttssstrdae tvwrkhlqpr pdggfrrphlg vgccllagqgs pgvlwcgreg crfevcrrdt
121 pglstrtrngd ssppfragws lppkcgaisg sarktpavpr yslrttdrpd gprgrfvgsq
181 praatrrrlf lgipalvlvt altlavlavpt gretlwmmwc eatqdwclgv pvdsrcqpae
241 dgefilllspv qaatwgnyya lgdsyssgdg ardyypgtav kggcwrsana ypelvaeayd
301 faghlsflac sgqrgyamld aidevgsqld wnsphtslvt igiggndlgf stvlktcmvr
361 vpllidskact dqedairkim akfettfeel isevrtrapd arilvvgypr ifpeeptgay
421 ytltasnqrw inetiqefnq qlaeavavhd eelaasggvg svefvdvyha ldgheigsde
481 pwvngvqlrd latgvtvdrs tfhpnaaghr avgervieqi etgpgprplya tfavvagatv
541 dtlagevg
```

FIGURE 32

(SEQ ID No. 39)

```

1 ggtggtgaa cagaacaccc ggtcgtcgcc gtgggcgtcc aggtgcaggt gcaggttctt
61 caactgctcc agcaggatgc cgcctgtggc gtgcacgatg gccttgggca ggcctgtggt
121 ccccgacgag tacagcacc atagcggatg gtcgaacggc agcggggtga actccagttc
181 cgcgccttcg ccgcgggctt cgaactccgc ccaggacagg gtgtcggcga cagggccgca
241 gcccaggta cggcaggacga cgggtgtgctg caggctgggc atgccgtcgc gcagggcttt
301 gagcagtc a cggcggtcga agtccttacc gccgtagcgg tagccgtcca cggccagcag
361 cactttcggt tcgatctgcg cgaaccggtc gaggacgctg cgcacccga agtcggggga
421 acaggacgac caggctgcac cgtcgcggc gacggcgagg aatgcggccg tcgcctcgcc
481 gatgttcggc aggttagcca cgaaccggtc gccggggccc accccgaggc tgcggagggc
541 cgcagcgatc gcggcgggtg gggtcgcgag ttctcccaq gtccactcg tcaacggccg
601 gagttcggac gcgtgcggga tcgccacggc tgatgggtca cgttcgcgga agatgtgctc
661 ggcgtagttg aggggtgggc cggggaacca gacggcgccg gccatggcgt cggaggcgag
721 cactgtggtg tacggggtg cggcgcgac ccggtagta tccagatcg cggaccagaa
781 tccttcgagg tcggttaccc accagcgcca cagtgcctcg tagtcgggtg cgtccacacc
841 cgggtgctcc cgcaccagc ggtgaaacgc ggtgaggttg gccgttctt tgcgtcctc
901 gtccggactc cacaggatcg gcggctgcgg cttagtgtc atgaaacgcg accccttcgt
961 ggacgggtgc gatgcgggtg gcgtcgggtg cctccctaa cgtcccccg tyacggagt
1021 ttgtgcacca catctagcac gcgggacgcg gaaaccgtat ggagaaaca cctacaaccc
1081 cggcgggacg gtgggtttcg gccacactta ggggtcgggt gcctgcttgc cgggcagggc
1141 agtcccgggg tgctgtggtg cgggcgggag ggctgtcgct tcgaggtgtg ccggcgggac
1201 actccggggc tcagccgtac ccgcaacggg gacagtctc ctccctccg ggcgtgatgg
1261 tccctccccc cgaatgcgg cgagatctcc cagtacgccc ggaacacac cgtgtgccc
1321 aggtactctt tgcttcgaac agacaggccg gacggtccac gggggagggt tgtgggcagc
1381 ggaccacgtg cggcgaccag acgacggttg ttctcggta tcccgctct tgtacttggt
1441 acagcgctca cgtcgtctt ggcgtcccg acggggcgcg agacgctgtg gcgatgtgg
1501 tgtgagggca ccagagactg gtgcctgggg gtcccggtcg actcccgcg acagcctgcg
1561 gaggacggcg agtttctgct gctttctccg gtccaggcag cgaactgggg gaactattac
1621 gcgctcgggg attcgtactc ttccgggggac ggggcccgcg actactatcc cggcaccccg
1681 gtgaaggggc gttgctggcg gtccgctaac gctatcccg agctggtcgc cgaagcctac
1741 gacttcgccc gacacttctc gttcctggcc tgcagcgccc agcgcggcta cgcctatgct
1801 gacgctatcg acgaggtcgg ctgcagctg gactggaact cccctcacac gtcgtgtggt
1861 acgatcggga tcggcgggaa cgatctgggg ttctccacg ttttgaagac ctgcattggt
1921 cgggtgccgc tgctggacag caaggcgtgc accgaccagg aggacgctat ccgcaagcgg
1981 atggcgaaat tcgagaccgac gtttgaagag ctcatcagcg aagtgcgcac ccgcgcggcg
2041 gacgcccggg tccttctcgt gggctacccc cggatttttc cggaggaacc gaccggcgcc
2101 tactacacgc tgaccgcgag caaccagcgg tggctcaacg aaaccattca ggagtccaac
2161 cagcagctcg ccgaggtgt cgcgtccac gacgaggaga ttgcccgctc gggcgggggtg
2221 ggcagcgtg agttcgtgga cgtctaccac gcyttggacg gccacgagat cggctcggac
2281 gagcgtggg tgaacggggt gcagttgcgg gacctcgcca ccgggggtgac tgtggaccgc
2341 agtaccttcc accccaacgc cgttgggac cgggcggctg gtgagcgggt catcgagcag
2401 atcgaaaccg gcccgggccg tccgctctat gccactttcg cggtggtggc gggggcgacc
2461 gtggacactc tcgcgggcga ggtgggtga cccggttac cgtccggccc qcaggctctc
2521 gagcactgcg gcgatctggt ccaactgcca gtgcagttcg tcttcggtga tgaccagcgg
2581 cggggagagc cggatcgttg acccgtgctg gtctttgacg agcacacccc gctgcaggag
2641 ccgttcgcac agttctcttc cggtgccag agtcgggtcg acgtcgatcc cagccacag
2701 gccgatgctg cgggcgcgga ccacgcggtt gccgaccagt tggtcgaggc gggcgcgag
2761 caccggggcg agggcgcgga catggtccag gtaaggcccg tcgcggacga ggtcaccac
2821 ggcagtgcg accgcgcagg cagggcggtt gccgcgaag gtgctgctg gctggcggg
2881 gcggatcacg tcgaagactt ccgcgtcgcc tacgcgcgc gccacgggca ggtgcggcc
2941 gccacgcgt ttgccgaaca ggtagatata ggcgtcgact ccgctgtggt cgcaggcccc

```

FIGURE 33

(SEQ ID No. 40)

```
1  vqsgpraatr  rrflgipal  vltaltlvtl  avptgretlw  mwceatqdw  clgvvpvdsrg
61  qpaedgefll  lspvqaatwg  nyyalgdsys  sgdgardyyp  gtavkggcwr  sanaypelva
121 eaydfaghls  flacsgqrgy  amldaidevg  sqldwnspht  slvtigiggn  dlqfstvlkt
181 cmvrvpllds  kactdgedai  rkrmakfett  feelisevrt  rapdarilvv  gyprifpeep
241 tgayytltas  nqrwlnetiq  efnqqlaeav  avhdeelaas  ggvgsvfvd  vyhaldghei
301 gsdepwvngv  qirdlatgvt  vdrstfhpna  aghravgerv  ieqietgpgr  plyatfavva
361 gatvdtlage  vg
```

FIGURE 34

(SEQ ID No. 41)

```
1  mrttviaasa  llllagcadg  areetagapp  gessggiree  gaeastsitd  vyialgdsya
61  amggrdqplr  gepfclrssq  nypellhaev  tdltcqqgvt  gdilleprtlg  ertlpaqvda
121 itedttlvtl  siggndlgfg  evagcireri  agenaddcvd  llgetigeql  dqlppqldrv
181 heairdragd  aqvvtgylp  lvsagdcpel  gdvseadrw  aveltgqine  tvreaaerhd
241 alfvlpddad  ehtscappqg  rwadiqqgqt  dayplhptsa  gheamaaavr  dalglepvqp
```

FIGURE 35

(SEQ ID No. 42)

```

1  ttctgggggtg  ttatgggggtt  gttatcgggt  cgtctctgggt  ggatccccgc  aggtggggta
61  ttacacggggg  actttttgtgt  ccaacagccg  agaatgagtg  ccctgagcgg  tgggaatgag
121  gtggggcgggg  ctgtgtcgcc  atgagggggc  ggcgggctct  gtggtgcccc  gcgacccccg
181  gccccggtga  gcggtgaatg  aaatccggct  gtaatcagca  tcccggtccc  accccgtcgg
241  ggaggtcagc  gcccgagtg  tctacgcagt  cggatcctct  cggactcggc  catgctgtcg
301  gcagcatcgc  gctcccggtt  cttggcgctc  ctcggctggt  ctgctgtctg  tccctggaag
361  gcgaatgat  caccggggag  tgatacaccc  gtggtctcat  cccggtatgc  cacttcggcg
421  ccattccggca  attcgggcag  ctccgggtgg  aagtaggtgg  catccgatgc  gtcggtgacg
481  ccattagtggt  cgaagatctc  atcctgtctg  aggggtgctc  ggcactctc  cggatcgata
541  tcgggggcgt  ccttgatggc  gtccttgctg  aaaccgaggt  gcagcttggt  ggcttccaat
601  ttccgccacc  ggagcgggac  gaggtcggaa  tgacggccga  agagccccgt  gtggacctca
661  acgaaggtgg  gtagtcccg  gtcattctg  aggaacacgc  cctccaccgc  acccagcttg
721  tgccgggggt  gtcgttaggc  gctggcatcc  agaagggaac  cgatctcata  tttgtcgggt
781  tgctcagaca  tgatcttct  ttgctgtcgg  tgtctgttac  taccacggta  ggcctgaatg
841  caactgttat  ttttctgta  ttttaggaat  tggtccatat  ccacacgggt  ggctgtggtc
901  aaatcgtcat  caagtaatcc  ctgtcacaca  aaatgggtgg  tgggagccct  ggtcgcgggt
961  ccgtggggag  cgcctgccc  cgcaggtatc  tcggcatcgg  cggatctggc  cgttaccocg
1021  cgggtgaataa  aatcattctg  taacctcat  caccgttggt  tttaggtatc  cgcctcttc
1081  gtcctgacct  cgtcccgcc  gcgcgggagc  ccgcgggttg  cggtagacag  gggagacgtg
1141  gacaccatga  ggacaacggt  catcgagca  agcgattac  tccttctcgc  cggatcgccg
1201  gatggggccc  gggaggagac  cgcgggtgca  ccgcgggtg  agtctccgg  gggcatccgg
1261  gaggaggggg  cggaggcgtc  gacaagcatc  accgactct  acatcgccct  cggggattcc
1321  tatgcggcga  tggcgggcg  ggcacagcc  ttacgggggt  agccgttctg  cctgcgctcg
1381  tccggttaatt  acccggaact  cctccacgca  gaggtcaccg  atctcacctg  ccagggggcg
1441  gtgaccgggt  atctgtcga  acccaggacg  ctgggggagc  gcacgctgcc  ggcgcaggtg
1501  gatgcgtga  cggaggacac  caccctggtc  accctctcca  tcgggggcaa  tgacctcgga
1561  ttccggggag  tggcgggatg  catccgggaa  cggatcccg  gggagaacgc  tgatgattgc
1621  gtgagacctg  tgggggaaac  catcggggag  cagctcgatc  agcttcccc  gcagctggag
1681  cgcgtgcacg  aggtatccg  ggaccgcgcc  ggggacgcgc  aggttggtgt  caccggttac
1741  ctgcgcctcg  tgtctgcgg  ggaactgcgc  gaactgggg  atgtctccga  ggcggatcgt
1801  cgttggggcg  ttgagctgac  cgggagatc  aacgagaccg  tgccgagggc  ggcgaacga
1861  cagatgccc  tctttgtct  gcccgacgat  gccgatgagc  acaccagtg  tgcaccccc
1921  cagcagcgt  gggcggtat  ccaggggcaa  cagaccgat  cctatccgt  gcacccgacc
1981  tccgcggccc  atgaggcgat  ggcgcggccc  gtccgggacg  cgtgggccct  ggaaccggtc
2041  cagccgtagc  gccgggcgg  cgttgtcga  cgaccaacc  atgccaggct  gcagtcacat
2101  ccgcacatag  cgcgcgggg  cgttgagta  cgcaccatag  aggatgagcc  cgtgcccac
2161  gatgatgagc  agcacactgc  cgaagggttg  ttccccgagg  gtgcgcagag  ccgagtcag
2221  acctgcggcc  tgctccggat  catgggccc  accggcgatg  acgatcaaca  cccccaggat
2281  cccgaaggcg  ataccacggg  cgacataacc  ggctgttccg  gtgatgatga  tcgcgggtcc
2341  gacctgccct  gaccccgcac  ccgctccag  atctcccg  aaatcccggg  tggccccctt
2401  ccagaggttg  tagacaccc  cccccagtac  caccagcccg  gcgaccacaa  ccagcaccac
2461  accccagggt  tgggatagga  cgtggcggt  gacatcggtg  gcggtctccc  catcgagggt
2521  gctgcgcgcc  cgggcgaagg  tggaggtggt  caccgcagg  gagaagtaga  ccatggccat
2581  gaccgccccc  ttggcccttt  ccttgaggtc  ctgcggccgc  agcagctggc  tcaattgcca
2641  gagtccagg  gccgccagg  cgtgacggc  aaccacagg  aggaactgcc  caccgggagc
2701  ctccgcgat  gtggccagg  cactgaatt  caggccctca  tcaccgaac  cgcggatcc
2761  agtgccgatg  cgcaccgcga  tccaccgat  gaggatgtgc  agtatgccc  ggacaatgaa
2821  accacctctg  gccagggtg  tcagcgcggg  gtggtcctcg  gcctggctcg  cagcccgctt
2881  gatcgtcgt  ttgcgggat  tgggtgcgc  cttatccata  gctcccatg  aaccgccttg
2941  aggggtgggc  ggccactgtc  agggcggtat  gtgatctgaa  ctgtgatgtt  ccatacaacc

```

FIGURE 36

(SEQ ID No. 43)

```

1 mrrfrlvglf ssvilaagaa ltgaataqaa qpaaadgyva lgdsyssgvv agsyisssgd
61 ckrstkahpy lwaahspst fdftacsgar tgdvlsqqlg plssgtqlvs isiggndagf
121 adtmittcvlg sessclsria taeayvdstl pgkldgvysa isdkapnahv vvigyprfyk
181 lgttciglse tkrtainkas dhlnvlaqr aaahgftfgd vrttftghel csqspwlhsv
241 nwlignesyh ptaagqsggy lplvngaa

```

Figure 37

(SEQ ID No. 44)

```

1 cccggcggcc cgtgcaggag cagcagccgg cccgcgatgt cctcgggcgt cgtcttcac
61 aggcggtcca tcgcgtcgcc gaccggcgcc gtgtagttgg cccggacctc gtcccagggtg
121 cccgcggcga tctggcgggt ggtgcggtgc gggccgcgcc gaggggagac gtaccagaag
181 cccatcgta cgttctccgg ctgcggttcg ggctcgtccg cccgtccgtc cgtcgccctcg
241 ccgagcacct tctcggcgag gtccggcgctg gtccgcgtca cctgacgtc ggcgcccgg
301 ctcacgcgcg agatcagcag cgtccagccg tcgcccctcg ccagcgtcgc gtgcggtcg
361 tcgtcgcggg cgtccgcgag cagcgcgcgc cggggcgcca gcagcgtggc gccggaccgt
421 acgcggtcga tgttcgcgcg gtgcgagtac ggctgctcac cctggcgcaa acggccgagg
481 aacagcgcggt cgacgacgtc ggacggggag tcgctgtcgt ccacgttgag ccggtacggc
541 aggggttcgt gcggtttcac ggacatgtcg ccatgatcgg gcacccggcc gccgcgtgca
601 cccgctttcc cgggcacgca cgacaggggc tttctcgccg tcttcgctcc gaacttgaac
661 gagtgtcagc cttttcttgg catggacact tccagtcaac gcgcgtagct gtaaccacgg
721 ttgtggcagc aatcctgcta agggaggttc catgagacgt ttcgacttg tcggcttct
781 gagttcgctc gtcttcgccc cgggcgcgcg cctcaccggg gcagcgaccg cccagcgccg
841 ccaaccggcc gccgcgcgag gctatgtggc cctcggcgac tctactcct cgggggtcgg
901 agcgggcagc tacatcagct cgagcggcga ctgcaagcgc agcacgaagg cccatcccta
961 cctgtggggc gccgcgccact cgccctccac gttcgacttc accgcctgtt cgggcgcggc
1021 tacgggtgat gttctctccg gacagctcgg cccgctcagc tccggcaccg gctcgtctc
1081 gatcagcatc ggcggcaacg acgcccgttt cgcgcacacc atgacgacct gtgtgctcca
1141 gtccgagagc tctgcctgt cgcggatcgc caccgcgag gcgtaagtcg actcgacct
1201 gcccggaag ctcgacggcg tctactcggc aatcagcgac aaggcgccga acgcccacgt
1261 cgtcgtcatc ggtacccgcg gcttctacaa gctcggcacc acctgcacg gctgttccga
1321 gaccaagcgg acggcgatca acaaggcctc cgaccacctc aacaccgtcc tcgcccagcg
1381 cgcgcgcgcc caggtttca ccttcggcga cgtacgcacc accttcaccg gccacgagct
1441 gtgctcgggc agccccgtgc tgcacagcgt caactggctg aacatcgggc agtcgtacca
1501 cccaccgcgc gccggccagt cgggtggcta cctgcgggtc ctcaacggcg ccgcctgacc
1561 tcaggcggaa ggagaagaag aaggagcgga gggagacgag gagtgggagg cccgcggcga
1621 cgggggtccc gtcccgtct cgtctcgtt cccggtcccg caagtcaccg agaacgccac
1681 cgcgtcggac gtggcccgca cgggactccg cactccacg cgcacggcac tctcgaaacg
1741 gccggtgtcg tcgtcgtcg tcaccaccac gccgtcctgg cgcgagcgct cgcgcggcga
1801 cgggaaggac agcgtccgcc accccggatc ggagaccgac cgtcccgcg tcacccaccg
1861 gtacccgacc tccgcgggca cccgcggcgc cgtgaacgtc gccgtgaacg cgggtgcccc
1921 gtcgtgcggc ggcggacagg ccccccagta gtgggtcgcc gagcccacca cggtcacctc
1981 caccgactgc gctgcggggc

```

FIGURE 38

(SEQ ID No. 45)

```

1 mrrsrityay tslllavgca ltgaataqas paaaatgyva lgdsyssgvq agsylsssgd
61 ckrsskaypy lwqaahspss fsfmacsgar tgdvlnqlg tlnsstglvs ltiggndagf
121 sdvmttcvliq sdsaclsrin takayvdstl pqqlidsvyta istkapsahv avlgyprfyk
181 lggsclagis etkrsainda adylnsaiak raadhgftfg dvkstftghe icsstwlhs
241 ldllniqgsy hptaagqsqg ylpvnmnsva

```

FIGURE 39

SEQ ID No. 46

```

1 ccaccgccgg gtcggcgggc agtctctctg cctcggctgc ggagaggttg gccgtgtagc
61 cgttcagcgc ggcgcgaac gtctttctca ccgtgcgcgc gtactcgttg atcaggccct
121 tgccttgcet cgacgcggcc ttgaagccgg tgccttctt gagcgtgacg atgtagctgc
181 ccttgatcgc ggtgggggag ccggcgccga gcaccgtgcc ctggcgccgg gtggcctggg
241 cgggcagtgc ggtgaatccg cccacgaggg cgcggctgc caccgcggtt atcgcgccga
301 tccggatctt cttgtacgc agctgtgcc tacgagggag tctcctctg ggcagcggcg
361 cgctcggtg ggcgcacgg ctgtggggg tgcgcgcgtc atcacgcaca cggccctgga
421 gcgtcgtgtt ccgccctggg ttgagtaaag cctcggccat ctacgggggt ggcacaggg
481 agttgagacc ctgtcatgag tctgacatga gcacgcaatc aacggggccg tgagcaccac
541 ggggcgaccc cggaaagtgc cgagaagtct tggcatggac acttctctgc aacacgcgta
601 gctggtagca cgttacggc agagatcctg ctaaaggagg gttccatgag acgttcccca
661 attacggcat acgtgacctc actcctcctc gccgtcggct ggcacctcac cggggcagcg
721 acggcgtagg cgtcccccgc ccccgccgcc acgggctatg tggccctcgg cgaactcgtac
781 tcgtccggtg tcggcgccgg cagctacctc agctccagcg ggcactgcaa ggcagttcg
841 aaggcctatc cgtacctctg gcaggccggc cattcaccct cgtcgttcag tttcatggt
901 tgcctggggc ctctacggg tgatgtctct gccaatcagc tcggcaccct gaactcgtcc
961 accggccttg tctcctcac cctcggaggc aacgacggcg gcttctccga cgtcatgacg
1021 acctgtgtgc tccagtccga cagcgccctg ctctcccgca tcaacacggc gaaggcgtag
1081 gtcgactcca cctgccccg ccaactcgac agcgtgtaca cggcgatcag caggaaggcc
1141 ccgtcggccc atgtggccgt gctgggctac ccccgcttct acaaaactgg cggctcctgc
1201 ctccggggcc tctcggagac caagcggtcc gccatcaacg acgcggccga ctatctgaac
1261 agcggccatc ccaagcgccg cgcgcaccac ggcttcacct tcggcgacgt caagagcacc
1321 ttcaccggcc atgagatctg ctccagcagc acctggctgc acagtctcga cctgctgaac
1381 atcggccagt cctaccaccc gaccgcggcc ggccagtcgg cggcgtatct gccggctatg
1441 aacagcgttg cctgagctcc cagggcctga atttttaagg cctgaatttt taaggcgaag
1501 gtgaaccgga agcggaggcc ccgtccgtcg ggtctcctg cgacacagtc accgagaacg
1561 gcacggagtt ggacgtcgtg cgcaccgggt cgcgcacctc gacggcgatc tcgttcgaga
1621 tcgttcctgt cgtgtcgtac gtggtgacga acacctgctt ctgctgggtc tttccgccgc
1681 tcgccgggaa ggacagcgtc ttccagcccg gatccgggac ctgcaccttc ttggtacccc
1741 agcggtagct cactcagacc ggcacccggc ccaccgtgaa ggtcgcgtg aacgtggggc
1801 cctggggcgt gggcgccggg caggcaccgg agtagtcggt gtgcacggcg gtgaccgtca
1861 ccttcacgga ctggcgccgc ggggtcgtcg taaccgcgcc gccaccggcg cctcccgga
1921 tggagcccca gctgtggtcg ccccgccgt cggcgttgct gtcctcgggg gtttcgaac

```

FIGURE 40

SEQ ID No. 47

```

1 mgsqpraatr rriflgipal vltaltlvi avptgretlw mwceatqdw clgvvdsrg
61 .qpaedgefll lsvvqaatwg nyyalgdsys sgdgadyyp gtavkkgcwr sanaypelva
121 eaydfaghlis flacsqgrgy amldaidevg sqldwnspht slvtigiggn dlqfstvlkt
181 cmvrvpllds kactdgedai rkrmakfett feelisevrt rapdarilvv gypriifpeep
241 tgayytiltas nqrwlnetiq efnqqlaeav avhdeeiias gvggsvefvd vyhaldghei
301 gsdepwvngv qlrdlatgvt vdrstfhpna aghravgerv ieqietgpqr plyatfavva
361 gatvdtlage vg

```

FIGURE 41

SEQ ID No. 48

```

1      ctgcagacac ccgccccgcc ttctcccgga tcgtcatggt cggcgactcc ctcagcgaca
61      ccggcaagat gtactccaag atgcgcggct acctgccgtc ctcccccgcc tactacgagg
121     gccgcttctc gaacggcccc gtctggctgg agcagctgac gaagcagttc cccggcctga
181     cgatcgccaa cgaggccgag gggggcgaga ccgcagtcgc ctacaacaag atctcctgga
241     acccgaaagta ccaggtcatt aacaacctcg actacgaggt caccagttc ttgcagaagg
301     actcgttcaa gcccgacgac ctggtcatcc tgtgggtggg cgccaacgac tacctggcct
361     acggttgga cccggagcag gacgccaagc ggggtgcgga cgccatctcg gacggggcaa
421     accgcatggt cctgaacgyc gcgaagcaga tcctgctggt caacctgcc gacctgggcc
481     agaaccgctc cggccgctcc cagaaggctc tcgaggccgt ctgcacgtg tccgcctacc
541     acaacaagct gctcctcaac ctgcgccggc agctcgcccc gacgggcatg gtcaagctgt
601     tcgagatcga caagcagttc gcggagatgc tgcgcgaccc ccagaacttc ggcctgagcg
661     acgtggagaa cccgtgctac gacggcggct acgtgtggaa gccgttcgcc acccggtccg
721     tctcgaccga ccggcagctg tcggccttct cggcccagga gcgcctggcg atcgctggca
781     accgctcctt ggcacaggcg gtagcttcgc cgatggcccg ccgctcggcc tcgcccctca
841     actgcgaggg caagatgttc tgggaccagc tccacccac caccgtggtc cagcccgccc
901     tctcgagagc cgcgcgccac ttcactcgaga cccagtagca gttcctcgcc cactagtcta
961     gaggatcc

```

Figure 42

1. L131
2. *S. avermitilis*
3. *T. fusca*
4. Consensus

```

1      1                               50
1  (1) -----MRLTRSLSAASVIVFALLLALLGISPAQAAG-----
2  (1) -----MRRSRITAYVTSLLLAVGCALTGAATAQASPA-----
3  (1) VGSGPRAATRRLFLGIPALVLTALTLLVLAVPTGRETLWRMWCEATQDW
4  (1)      MRRSRFLA ALILLTLA AL GAA ARAAP

1      51                               100
1  (32) -----P-AYVALGDSYSSGNGAGSYID
2  (33) -----AAATGYVALGDSYSSGVGAGSYLS
3  (51) CLGVVPVDSRGQPAEDGEFLLSPVQAATWGNYYALGDSYSSGDGARDYYP
4  (51)      A A YVALGDSYSSG GAGSY

1      101                              150
1  (53) SSGD---CHRSNNAYPARWAAANAF---SSFTFAACSGAVTTDVIN---
2  (57) SSGD---CKRSSKAYPYLWQAAHSP---SSFSFMACSGARTGDVLA---
3  (101) GTAVKGGCWRSANAYPELVAEAYDFA--GHLSEFLACSGQRGYAMLDAIDE
4  (101) SSGD C RSTKAYPALWAAHA: SSFSF ACSGARTYDVLA

1      151                              200
1  (93) --NQLGAINAST--GLVSIITGGNDAGFADAMTTCVTS-----SDSTCL
2  (97) --NQLGTLNSST--GLVSLITGGNDAGFSDVMTTCVLQ-----SDSACL
3  (149) VGSQLDWNSPHT--SLVTITGGNDLGFSTVLKTCMVR-----VPLLDS
4  (151) QL  LNS T  LVSITGGNDAGFAD MTTCVL      SDSACL

1      201                              250
1  (133) NRLATATNYINTLLA-----RLDAVYSQIKARAPNARVVVLGYPRMY
2  (137) SRINTAKAYVDSTLPG-----QLDSVYTAISTKAPSAHVAVLGYPRFY
3  (191) KACTDQEDAIRKMAKF----ETTFEELISEVRTRAPDARILVVGYPRIE
4  (201) RIA AK YI TLPA      RLDSVYSAL TRAP ARVVVLGYPRIY

1      251                              300
1  (176) LASNPWYCLGLSNTKRAINTTADTLNSVISSRATAH-----GF
2  (180) KLGG-SCLAGLSETKRSAINDAADYLNSAIAKRAADH-----GF
3  (237) PEEPTGAYYTLTASNQRWLNETIQEFNQQLAEAVAVHDEEIAASGGVGSV
4  (251) SG      LGLS TKRAINDAAD LNSVIKRAADH      GF

1      301                              350
1  (215) RFGDVRPTFNNHELFEGNDWLHSLTLP-----VWESYH
2  (218) TFGDVKSTFTGHEICSSSTWLHSLDLN-----IGQSYH
3  (287) EFVDVYHALDGHEIGSDEPWVNGVQLRDLATG-----VTVDIRSTFH
4  (301) TFGDV TF GHELCSA PWLHSLTLP      V SYH

1      351                              395
1  (248) PTSTGHQSGYLPVLNANSST-----
2  (252) PTAAGQSGGYLPVMNSVA-----
3  (328) PNAAGHRAVGERVIEQIETGPGRPPLYATFAVVAGATVDTLAGEVG
4  (351) PTA GHAAGYLPVLNSI T

```

FIGURE 43

SEQ ID No 17 which is the amino acid sequence of a lipid acyltransferase from *Candida parapsilosis*;

```
MRYFAIAFLL INTISAFVLA PKKESQDDFY TPPQGYEAQP LGSILKTRNV FNPLTNVFTP VKVQNAWOLL
VRSEDTFGNP NAIVTITIQP FNAKKDKLVS YQTFEDSGKL DCAPSYAIQY GSDISTLTQ GEMYVISALL
DQGYVVVTPD YEGPKSTFTV GLQSGRATLN SLRATLKSGN LTGVSSDAET LLWGYSGGSL ASGWAAAIQK
EYAPELSKNL LGAALGGFVT NITATAEAVD SGPFAGIISN ALAGIGNEYF DFKNYLLKKV SPLLSITYRL
GNTHCLLDGG IAYFGKSFFS
RIIRYFPDGW DLVNQEPKIK ILQDNGLVYQ PKDLTPQIPL FIYHGTLDAL VPIVNSRKTF QQWCDWGLKS
GEYNEDLTNG HITESIVGAP AALTWIINRF NGQPPVDGCQ HNVNASNLEY PGTPQSIKNY FEALHAILG
FDLGPDKRD KVTLGGLLKL ERFAP
```

FIGURE 44

SEQ ID No 18 which is the amino acid sequence of a lipid acyltransferase from *Candida parapsilosis*;

```
MRYFAIAFLL INTISAFVLA PKKPSQDDFY TPPQGYEAQP LGSILKTRNV FNPLTNVFTP VKVQNAWOLL
VRSEDTFGNP NAIVTITIQP FNAKKDKLVS YQTFEDSGKL DCAPSYAIQY GSDISTLTQ GEMYVISALL
DQGYVVVTPD YEGPKSTFTV GLQSGRATLN SLRATLKSGN LTGVSSDAET LLWGYSGGSL ASGWAAAIQK
EYAPELSKNL LGAALGGFVT NITATAEAVD SGPFAGIISN ALAGIGNEYF DFKNYLLKKV SPLLSITYRL
GNTHCLLDGG IAYFGKSFFS RIIRYFPDGW DLVNQEPKIK ILQDNGLVYQ PKDLTPQIPL FIYHGTLDAL
VPIVNSRKTF QQWCDWGLKS GEYNEDLTNG HITESIVGAP AALTWIINRF NGQPPVDGCQ HNVNASNLEY
PGTPQSIKNY FEALHAILG FDLGPDKRD KVTLGGLLKL ERFAPHHHH H
```

FIGURE 45




FIGURE 46





FIGURE 47



[illegible]

106

FIGURE 51

```

10      20      30      40      50
60
.....|.....*.....|.....*.....|.....*.....|.....*.....|
11VN_A      4 LLILGDSLSAG-----YRMSASAAWPAALLNDKWgsk---
----- 34
P10480      28
1VMFGDSLSDTgkmyskmrgylpssppyyeCRFSNGPVPWLEQLTNEFPGLTlaneaeggp 87

70      80      90      100     110
120
.....|.....*.....|.....*.....|.....*.....|.....*.....|
11VN_A      35 -tsvVNASISGDT-----
SQOGLARLPALLKQHQRW 65
P10480      98 tavaYNKISWNPkyg-----
VINNLDYEVTQFLQKDSFKPDDL 125

130     140     150     160     170
180
.....|.....*.....|.....*.....|.....*.....|.....*.....|
11VN_A      66 VLVELGGNDG-----
LRGFQPPQTEQT 87
P10480      126 VILWVGANDY-----LA--
YGNWTEQDAKRVRDA 152

190     200     210     220     230
240
.....|.....*.....|.....*.....|.....*.....|.....*.....|
11VN_A      88 LRQILQDVkaANAEPilnqirlPANYGR-----
----- 115
P10480      153 ISDAANRMV-LNGAK----EILLFNLPdig-----
----qnP 180

250     260     270     280     290
300
.....|.....*.....|.....*.....|.....*.....|.....*.....|
11VN_A      116 -----RYNEAFSAIYPKLake-----
fdVFLLPFFME 142
P10480      181 SARSQKVVEAASHVSAYHNQLLLNLArqlaptg-----
mvklfeiDKQFAENLRD 230

310     320     330     340     350
360
.....|.....*.....|.....*.....|.....*.....|.....*.....|
11VN_A      143 EVYLPQW-----
----- 150
P10480      231
PQNFGLSDQRNacyggsyvwkpfasrsastdsqlsafnpqerlaiaqnpllaqavaspma 290

370     380     390     400
11VN_A      151 -----MQDDGi-----HPNRDAQPFADWM 170
P10480      291 arsastlnceggkMFWDQV-----HPTTVVHAALSEPA 322

```

FIGURE 52

		1	50
P10480	(1)	MKKWFVCLLGLVALTVQAADSRPAFSRIVMFGDSLSDTGKMYSKMRGYLP	
A. sal	(1)	-----ADTRPAFSRIVMFGDSLSDTGKMYSKMRGYLP	
A. hyd	(1)	-----ADSRPAFSRIVMFGDSLSDTGKMYSKMRGYLP	
Consensus	(1)	AD*RPAFSRIVMFGDSLSDTGKMYSKMRGYLP	
		51	100
P10480	(51)	SSPPYYEGRFSGFVWLEQLTNEFPGLTIANEAEGGPTAVAYNKISWNPK	
A. sal	(33)	SSPPYYEGRFSGFVWLEQLTKQFPGLTIANEAEGGATAVAYNKISWNPK	
A. hyd	(33)	SSPPYYEGRFSGFVWLEQLTKQFPGLTIANEAEGGATAVAYNKISWNPK	
Consensus	(51)	SSPPYYEGRFSGFVWLEQLT**FPGLTIANEAEGG*TAVAYNKISWNPK	
		101	150
P10480	(101)	YQVINNLDEYVTQFLQKDSFKPDDLVLWVGANDYLAYGWNTQDAKVR	
A. sal	(83)	YQVINNLDEYVTQFLQKDSFKPDDLVLWVGANDYLAYGWNTQDAKVR	
A. hyd	(83)	YQVINNLDEYVTQFLQKDSFKPDDLVLWVGANDYLAYGWNTQDAKVR	
Consensus	(101)	YQVINNLDEYVTQFLQKDSFKPDDLVLWVGANDYLAYGWNTQDAKVR	
		151	200
P10480	(151)	DAISDAANRMVLNGAKIILLFNLPDLGQNPSARSQKVVEASHVSAYHNQ	
A. sal	(133)	DAISDAANRMVLNGAKIILLFNLPDLGQNPSARSQKVVEASHVSAYHNK	
A. hyd	(133)	DAISDAANRMVLNGAKIILLFNLPDLGQNPSARSQKVVEASHVSAYHNQ	
Consensus	(151)	DAISDAANRMVLNGAK*IILLFNLPDLGQNPSARSQKVVEA*SHVSAYHN*	
		201	250
P10480	(201)	LLNLARQLAFTGMVKLFEIDKQFAEMLRDPQNFGLSDQRNACYGGSYVW	
A. sal	(183)	LLNLARQLAFTGMVKLFEIDKQFAEMLRDPQNFGLSDVENPCYDGGYVW	
A. hyd	(183)	LLNLARQLAFTGMVKLFEIDKQFAEMLRDPQNFGLSDVENPCYDGGYVW	
Consensus	(201)	LLNLARQLAFTGMVKLFEIDKQFAEMLRDPQNFGLSD**N*CY*G*YVW	
		251	300
P10480	(251)	KPFASRSASTDSQLSAFNPQERLAIAGNPLLAQAVASPMARSASTLNCE	
A. sal	(233)	KPFATRSVSTDRLSAFSPQERLAIAGNPLLAQAVASPMARRASPLNCE	
A. hyd	(233)	KPFATRSVSTDRLSAFSPQERLAIAGNPLLAQAVASPMARRASPLNCE	
Consensus	(251)	KPIA*RS*STD*QLSAF*PQERLAIAGNPLLAQAVASPMARS*AS*LNCE	
		301	336
P10480	(301)	GRMFWDQVHPTTVVHAALSEPAATFIESOYEFLAH-	
A. sal	(283)	GRMFWDQVHPTTVVHAALSERAAATFETQYEFLAHG	
A. hyd	(283)	GRMFWDQVHPTTVVHAALSERAAATFIANQYEFLAH-	
Consensus	(301)	GRMFWDQVHPTTVVHAALSE*AATFI**QYEFLAH*	

FIGURE 53




FIGURE 54




FIGURE 55

-35

```

1  GCTTTTCTTT TGGAAAGAAA TATAGGGAAA ATGCTACTTG TTAATAATTC GGAATATTTA
   CGAAAAGAAA ACCTTCTTTT ATATCCCTTT TACCATGAAC AATTTTAAAG CCTTATAAAT
   -10
61 TACAATATCA TATGTTTCAC ATTGAAAGGG GAGGAGAATC ATGAAACAAC AAAAACGGCT
   ATGTTATAGT ATACAAAGTG TAACCTTCCC CTCCTCTTAG TACTTTGTTG TTTTGGCCGA
   · Y A R L L T L L F A L I F L L P H S A A ·
121 TTACGCCCGA TTGCTGACGC TGTATTTGCG GCTCATCTTC TTGCTGCCCTC ATTCTGCAGC
   AATGCGGGCT AACGACTGCG ACAATAAACG CGAGTAGAAG AACGACGGAG TAAGACGTCG
   · S A A D T R P A F S R I V M F G D S L S ·
181 TTCAGCAGCA GATACAAGAC CGGCGTTTAG CCGGATCGTC ATCTTTGGAG ATAGCCTGAG
   AAGTCGTCGT CTATGTTCTG GCCGCAAAATC GGCCTAGCAG TACAAACCTC TATCGGACTC
   · D T G K M Y S K M R G Y L P S S P P Y Y ·
241 CGATACGGGC AAAATGTATA GCAAAATGAG AGGCTATCTT CCGTCAAGCC CGCCGTATTA
   GCTATGCCCG TTTTACATAT CTTTCTACTC TCCGATAGAA GGCAGTTCGG CGCGCATAAT
   · E G R F S N G P V W L E Q L T K Q F P G ·
301 TGAAGGCCGC TTTAGCAATG GACCGGTCCT GCTGGAACAA CTGACGAAAC AATTTCCGGG
   ACTTCCGGCG AAATCGTTAC CTGGCCAGAC CGACCTTGTT GACTGCTTGG TTAAGGCCCC
   · L T I A N E A E G G A T A V A Y N K I S ·
361 ACTGACGATC GCTAATGAAG CAGAAGGAGG AGCAACACCG CTCGCCATATA ACAAATCAG
   TGACTGCTAG CGATTACTTC GTCTTCTCTC TCGTTGTCGC CAGCGGATAT TGTTTTAGTC
   · W D P K Y Q V I N N L D Y E V T Q F L Q ·
421 CTGGGACCCG AAATATCAGC TCATCAACAA CCTGGACTAT GAAGTCACAC AGTTTCTTCA
   GACCTCGGGC TTTATAGTCC AGTAGTTGTT GGACCTGATA CTTCACTGTG TCAAGAAGT
   · K D S F K P D D L V I L W V G A N D Y L ·
481 GAAAGACAGC TTTAAACCGG ATGATCTGGT CATCCTTTGG GTCCGGCCCA ATGATTATCT
   CTTTCTGTCC AAATTTGGCC TACTAGACCA GTAGGAACCC CAGCCGCGGT TACTAATAGA
   · A Y G W N T E Q D A K R V R D A I S D A ·
541 GCGGTATGGC TGGAAACAGC AACAAGATGC CAAAAGAGTC AGAGRTGCCA TCAGCGATGC
   CCGCATACCG ACCTTGTGTC TTGTTCTACG GTTTTCTCAG TCTCTACGGT AGTCGCTACG
   · A N R M V L N G A K Q I L L F N L P D L ·
601 CGCTAATAGA ATGGTCCTGA ACGGCGCCAA ACAATCCTG CTGTTTAAAC TGCCGGATCT
   GCGATTATCT TACCAGGACT TGCCGCGGTT TGTTTAGGAC GACAAATGGC ACGGCCTAGA
   · G Q N P S A R S Q K V V E A V S H V S A ·
661 GGGACAAATC CCGAGCGCCA GAAGCCAAAA AGTCSTCGAA GCAGTCAGCC ATGTCAGCGC
   CCCTGTTTTA GGCTCGCGGT CTTCGCTTTT TCAGCAGCTT CGTCAGTCGG TACAGTCGGC
   · Y H N K L L L N I A R Q L A P T G M V K ·
721 CTATGATAAC AAACCTGCTC TGAACCTGGC AAGACAATTG GCACCGACGG GAATGGTTAA
   GATAGTATTG TTPGACGACG ACTTGGACCG TTCTGTTAAC CGTGGCTGCC CTTACCAATT
   · L F E I D K O F A E M L R D P Q N F G L ·
781 ATTGTTTGAA ATTGACAAAC AGTTTGCCGA AATGCTGAGA GATCCGCAAA ATTTTGGCCT
   TAACAAACTT TAACCTGTTG TCAACCGGCT TTACGACTCT CTAGGCGTTT TAAACCCGGA
   · S D V E N P C Y D G G Y V W K P F A T R ·
841 GAGCGATGTC GAAAACCCGT GCTATGATGG CGGATATGTC TGGAAACCGT TTGCCACAG
   CTCGCTACAG CTTTGGGCA CGATACTACC GCCTATACAG ACCTTTGGCA AACGGTGTTC
   · S V S T D R Q L S A F S P Q E R L A I A ·
901 AAGCGTCAGC ACGGATAGAC AACTETCAGC GTTTAGCCCG CAAGAAAGAC TGGCAATCGC
   TTCGCACTCG TGCCATATCTG TTGACAGTCG CAAATCGGGC GTTCTTTCTG ACCGTTAGCG
   · G N P L L A Q A V A S P M A R R S A S P ·
961 CGGAAATCCG CTTTGGCAC AAGCAGTTGC TTCACCGATG GCAAGAAGAT CAGCAAGCCC
   GCCTTTAGGC GAAAACCGTG TTCGTCAACG AAGTGGCTAC CGTTCTTTCTA GTCGTTCCGG
   · L N C E G K M F W D Q V H P T T V V H A ·
1021 GCTGAATTGC GAAGGCCAAA TGTTTTGGGA TCAGTCCCAT CCGACAACAG TTGTCCATGC
   CGACTTAACG CTTCCGTTTT ACAAACCCCT AGTCCAGGTA GGCTGTTGTC AACAGGTACG
   · A L S E R A A T F I E T Q Y E F L A H G ·
1081 TGCCCTTTCA GAAAGACGGG CGACGTTTAT CGAAACACAG TATGAATTTT TGGCCCATGG
   ACGGGGAAGT CTTTCTCGCC GCTGCAATAA GCTTTGTGTC ATACTTAAAG ACCGGGTACC
   · stop ·
1141 CTGAGTTAAC AGAGGACCGA TTTCTGAAG GAAATCCGTT TTTTATTTT AAGCTTGGAG
   GACTCAATTG TCTCCTGCCT AAAGGACTTC CTTTAGGCAA AAAAAATAAA TTGGAACCTC
1201 ACAAGGTAAA GGATAAAACC TCGAG
   TGTTCATTT CCTATTTTGG AGCTC

```

FIGURE 56




FIGURE 57 (SEQ ID No 49)

```

1  ATGAACAAC AAAACGGCT TTACGCCGA TTGCTGACGC TGTATTTCG
   TACTTTGTTG TTTTGGCCGA AATGCCGGCT AACGACTGCG ACAATAAACG

51  GCTCATCTTC TTGCTGCCCTC ATTCTGCAGC TTCAGCAGCA GATACAAGAC
   CGAGTAGAAG AACGACGGAG TAAGACGTCG AAGTCGTCGT CTATGTTCTG

101 CGGCGTTTAG CCGGATCGTC ATGTTTGGAG ATAGCCTGAG CGATACGGGC
   GCCGCAATC GGCCTAGCAG TACAAACCTC TATCGGACTC GCTATGCCCG

151 AAAATGTATA GCAAAATGAG AGGCTATCTT CCGTCAAGCC CGCCGTATTA
   TTTTACATAT CGTTTACTC TCCGATAGAA GGCAGTTCGG CGGCATAAT

201 TGAAGGCCGC TTTAGCAATG GACCGGTCTG GCTGGAACAA CTGACGAAAC
   ACTTCGGGCG AATTCGTTAC CTGSCCAGAC CGACCTGTTT GACTGCTTTG

251 AATTTCCGGG ACTGACGATC GCTAATGAAG CAGAAGGAGG AGCAACAGCG
   TTAAAGGCCG TGACTGCTAG CGATTACTTC GTCTTCTCC TCCTTGTCCG

301 GTCCCTATA ACAAATCAG CTGGGACCCG AATATCAGG TCATCAACAA
   CAGCGGATAT TGTTTAGTC GACCTCGGGC TTTATAGTCC AGTAGTTGTT

351 CCTGGACTAT GAAGTCACAC AGTTTCTTCA GAAAGACAGC TTTAARCCGG
   GGACCTGATA CTTCAGTGTG TCAAAGAAGT CTTTCTGTG AAAATTGGCC

401 ATGATCTGGT CATCCTTTGG GTCCGCCCCA ATGATTATCT GCGTATGGC
   TACTAGACCA GTAGGAAACC CAGCCCGCGT TACTAATAGA CCGCATACCG

451 TGGAACACAG AACAGATGC CAAAGAGTC AGAGATGCCA TCAGCGATGC
   ACCTTGTGTC TTGTTCTACG GTTTCTCAG TCTCTACGGT AGTCGTACG

501 CGCTAATAGA ATGCTCTGA ACGCGCCCA ACAAATCCTG CTGTTTAACC
   GCGATTATCT TACCAGGACT TGCCGCGGTT TGTTAGGAC GACAAATTGG

551 TGCCGGATCT GGGACAAAAT CCGAGCGCCA GAAGCCAAA AGTCGTGAA
   ACGGCTAGA CCTGTTTTA GGCTCGCGGT CTTGSGTTT TCAGCAGCTT

601 GCACTCAGCC ATGTCAGCGC CTATCATAAC AAATGCTGC TGAACCTGGC
   CGTCAGTCGG TACAGTCGGG GATAGTATTG TTTGACGAGC ACTTGGACCG

651 AAGACAATTG GCACCGACGG GAATGGTTAA ATTGTTTGA ATTGACAAAC
   TTCTGTTAAC CGTGGCTGCC CTTACCAATT TAACAAACTT TAACTGTTTG

701 AGTTTGCCGA AATGCTGAGA GATCCGCAA ATTTTGGCCT GAGCGATGTC
   TCAAACGGCT TTACGACTCT CTAGGCGTTT TAAACCCGA CTCGCTACAG

751 GAAACCCGT GCTATGATGG CCGATATGTC TGGAAACCGT TTGCCACAAG
   CTTTGGGCA CGATACTACC GCCTATACAG ACCTTGGCA AACGGTGTTC

801 AAGCGTCAGC ACGGATAGAC AACTGTCAGC GTTTAGCCCG CAAGAAAGAC
   TTGCGAGTCG TGCCTATCTG TTGACAGTCG CAATCGGGC GTTCTTTCTG

851 TGGCAATCGC CGGAAATCCG CTTTGGCAC AAGCAGTTGC TTCACCGATG
   ACCGTTAGCG GCCTTAGGC GAAACCGTG TTCGTCAACG AAGTGGCTAC

901 GCAAGAAGAT CAGCAAGCCC GCTGAATTGC GAAGGCAAAA TGTTTGGGA
   CGTTCTTCTA GTGTTTCGGG CGACTTAACG CTTCCGTTT ACAAACCTT

951 TCAGGTCCAT CCGACAACAG TTGTCCATGC TGCCCTTTCA GAAAGAGCGG
   AGTCCAGGTA GGCTGTTGTC AACAGGTACG ACGGGAAGT CTTTCTCGCC

1001 CGACGTTTAT CGAAACACAG TATGAATTTC TGGCCCATGG CTGA
   GCTGCAATA GCTTTGTGTC ATACTTAAG ACCGGGTACC GACT

```

FIGURE 58 (SEQ ID No. 50)

```

1  ATGAAAAAAT GGTTCGTGTC TTTATTGGGA TTGGTCGCGC TGACAGTTCA GGCAGCCGAC
61  AGCCGTCGCC CCTTCTCCCG GATCGTGATG TTTGGCGACA GCCTCTCCGA TACCGGCAAG
121  ATGTACAGCA AGATGCGCGG TTACCTCCCC TCCAGCCCCC CCTACTATGA GGGCCGCTTC
181  TCCAACGGGG CCGTCTGGCT GGAGCAGCTG ACCAAGCAGT TCCCGGGCCT GACCATAGCC
241  AACGAGGCGG AAGGCGGACC GACCGCGGTG GCTTACAACA AGATCTCCTG GAATCCCAAG
301  TATCAGGTCA TCAACAACCT GGACTACGAG GTCACCCAGT TCCTGCAAAA AGACAGCTTC
361  AAGCCGGACG ATCTGGTGAT CCTCTGGGTC GCGGCCAAGC ACTATCTGGC CTATGGCTGG
421  AACACAGAGC AGGATGCCAA CGGGGTGCGC GACGCCATCA GCGATGCGGC CAACCGCATG
481  GTGCTGAACG GCGCCAAGGA GATACTGCTG TTCAACCTGC CGGATCTGGG CCAGAACCCC
541  TCGGCCCGCA GCCAGAAGGT GGTGAGGGCG GCCAGCCATG TCTCCGCCTA CCACAACCAG
601  CTGCTGCTGA ACCTGGCAGC CCAGCTGGCT CCCACCGGCA TGGTGAAGCT GTTCGAGATC
661  GACAAGCAGT TTGCCGAGAT GCTGCGTGAT CCGCAGAACT TCGGCCTGAG CGACAGAGCG
721  AACGCCGTGT ACGGTGGCAG CTATGTATGG AAGCCGTTTG CCTCCCGCAG CGCCAGCACC
781  GACAGCCAGC TCTCCGCTT CAACCCGAGC GAGCGCTCG CCATCGCCGG CAACCCGCTG
841  CTGGCCCGAG CCGTUGGCAG CCCCATGGCT GCGCGCAGCG CCAGCACCCT CAACTGTGAG
901  GGCAGATGT TCTGGGATCA GGTCCACCCC ACCACTGTCT TGCACGCGC CCTGAGCGAG
961  CCGCCGCCCA CCTTCATCGA GAGCCAGTAC GAGTTCCTCG CCCAC

```

FIGURE 59 (SEQ ID No. 51)

```

1  ATGAAAAAAT GGTTCGTTTG TTTATTGGGG TTGATCGCGC TGACAGTTCA GGCAGCCGAC
61  ACTCGCCCCG CCTTCTCCCG GATCGTGATG TTCGGCGACA GCCTCTCCGA TACCGGCAAA
121  ATGTACAGCA AGATGCGCGG TTACCTCCCC TCCAGCCCCC CCTACTATGA GGGCCGTTTC
181  TCCAACGGAC CCGTCTGGCT GGAGCAGCTG ACCAAGCAGT TCCCGGGTCT GACCATCGCC
241  AACGAAGCGG AAGGCGGTGC CACTGCCGTG GCTTACAACA AGATCTCCTG GAATCCCAAG
301  TATCAGGTCT AACAACAACCT GGACTACGAG GTCACCCAGT TCCTGCAAAA AGACAGCTTC
361  AAGCCGGACG ATCTGGTGAT CCTCTGGGTC GGTGCCAATG ACTATCTGGC ATATGGCTGG
421  AATACGGAGC AGGATGCCAA GCGAGTTTCG GATGCCATCA GCGATGCGGC CAACCGCATG
481  GTACTGAACG GTGCCAAGCA GATACTGCTG TTCAACCTGC CGGATCTGGG CCAGAACCCG
541  TCAGCCCGCA GTCAGAAGGT GGTGAGGGCG GTCAGCCATG TCTCCGCCTA TCACAACAA
601  CTGCTGCTGA ACCTGGCAGC CCAGCTGGCC CCCACCGGCA TGGTGAAGCT GTTCGAGATC
661  GACAAGCAAT TTGCCGAGAT GCTGCGTGAT CCGCAGAACT TCGGCCTGAG CGACGTCGAG
721  AACCCCTGCT ACGACGCGCG CTATGTGTGG AAGCCGTTTG CCACCCGAGC CGTCAGCACC
781  GACCGCCAGC TCTCCGCTT CAGTCCGAGC GAACGCTCG CCATCGCCGG CAACCCGCTG
841  CTGGCACAGG CCGTUGGCAG TCCTATGGCC GCGCGCAGCG CCAGCACCCT CAACTGTGAG
901  GGCAGATGT TCTGGGATCA GGTACACCCG ACCACTGTCT TGCACGAGC CCTGAGCGAG
961  CCGCCGCCCA CCTTCATCGA GAGCCAGTAC GAGTTCCTCG CCCACGGATG A

```

FIGURE 60 (SEQ ID No. 52)

```

1  ATGCCGAAGC CTGCCCTTCG CCGTGTCTAG ACCGCGACAG TCGCCGCGCT CGGCACGCTC
61  GCCCTCGGCC TCACCGACGC CACCGCCAC GCGCGGCGCG CCCAGGCCAC TCCGACCCCTG
121  GACTACGTCT CCCTCGGCGA CAGCTACAGC GCGGCTCCG GCGTCTGCTC CBTGACCCCG
181  GCCAACCTGC TGTGTCTGCG CTCGACGGCC AACTACCCCG ACCTCATCGC GGCACACGAG
241  GCGGCCCGCC TCACGACGCT CACTGCGGCG GCGCGCGAGA CCGCCGACTT CACGCGGGCC
301  CAGTACCCGG GCGTGCACCC CCAGTTGGAC GCGCTCGGCA CCGGCACGGA CCTGGTACCG
361  CTCACCATCG GCGGCAACGA CAACAGCACC TTCAATCAAG CCATCACGCG CTGCGGACCG
421  GCGGCTGTCC TCAGCGGCGG CAAGGGCAGC CCGTGCAAGG ACAGGCACGG CACCTCCTTC
481  GACGACGAGA TCGAGGCCAA CAGTACCCCG GCGCTCAAGG AGGCGCTGCT CCGGCTCGCG
541  GCCAGGGGTC CCCACGCCAG GGTGGCGGCT CTCGGCTACC CGTGGATCAC CCGGCGACCC
601  GCGGACCCGT CCGTCTTCTT GAAGCTCCCG CTCGCGCGCG GTGACGTGCC CTACCTCGCG
661  GCGATCGAGT CACACCTCAA CGACGCGGTC CCGCGGGGCG CCGAGGAGAC CGGAGCCACC
721  TACGTGGACT TCTCCGGGCT GTCCGACGCG CACGACGCGT CCGAGGCCCG CCGGACCCCG
781  TGGATCGAAC CGCTGCTCTT CCGGCACAGC CTCGTTCCCG TCCACCCCAA CGCCCTGGGC
841  GAGCGGGCGA TGGCCGAGCA CAGATGGAGC GTCCTCGGCC TGGACTGA

```

FIGURE 61 (SEQ ID No. 53)

```

1  TCAGTCCAGG CCGAGGACGT CCATCGTGTG CTCGGCCATG CGCCGCTCGC CCAGGGCGTT
61  GGGGTGGACG GGAACGAGGC TGTGCCCCGA GAGCAGCGGT TCGATCCAGC GGGTCCCGGG
121  GGCTTCGCAG GCTCGTGGC CGTGGGACAC CCGGAGAGAG TCCACGTAGG TGGTCCGGT
181  CTCCTCGGCG GCGCGCGGGA CCGCGTCGTT GAGGTGTGCC TGGATGGCCC GCAGGTAGGG
241  CACGTACCCG CCGGCGAGGG GGAGCTTCAG GAAGCAGGAC GGGTCGGCGG TGGCGGGGT
301  GATCCACGGG TAGCGGAGAG CCGCCACCTT GCGTGGGGA GCCCTGCGCG GGACGCCGAG
361  CAGCGCTCC TTAGCGCGGG GTTACGTGTT GGCTCGATC TCGTCTCGA AGGAGGTGCC
421  GTGCTGTGCC TTGACGGGGC TGCCCTTGCC GCGGCTGAGG ACACCCGCGC TGCGCCAGGC
481  CGTGATGGCG TTGATGAAGG TGCTGTGTG GTTGGCGCGG ATGGTGAGCG TGACCAAGGT
541  CGTGGCGGTG CCGAGCGGCT CCAACTGGGG TGCGACGCCG GGGTACTGGG CCGCGGTGAA
601  GTCGCGGTC TCGCGGCGCG CCGAGGTGAC GTCCGTGAGG CCGGCGCGCG TCGTGTCCGC
661  GATGACGTGG GGTAGTTGG CCGTCGAGCG CAGACAGAGC AGGTGGCGG GGTGACGGG
721  CAGGACGCCG GAGCGGCGCG TGTAGCTGTC GCCGAGGGCG ACGTAGTCCA GGGTCGGAGT
781  GGCCTGGCGC GCGCGGCGCT GGGCGGTGGC GTCGCTGAGG CCGAGGGCGA GCGTGGCCAC
841  GCGCGCGACT GTCCCGCTCA TGACACGGCG AAGGCGAGGC TTCGGCAT

```

FIGURE 62 (SEQ ID No. 54)

```

1  ATGGATTACG AGAAGTTTCT GTTATTGGG GATTCCATTA CTGAATTTCG TTTAATACT
61  AGGCCCATTTG AAGATGGCAA AGATCAGTAT GCTCTTGGAG CCGCATTAGT CAACGAATAT
121  ACGGAGAAAA TGGATATJCT TCAAAGAGGG TTCAAAGGGT ACACCTCTAG ATGGGCGTTG
181  AAAATACTTC CTGAGATTTT AAAGCATGAA TCCATATTG TCAATGCCAC AATATTTTG
241  GGTGCCAACC ATGCATGCTC AGCAGGTCCC CAAAGTGTC CCCTCCCGGA ATTTATCGAT
301  AATATTCTGT AAATGGTATC TTTGATGAAG TCTTACCATA TCCGTCTTAT TATAATAGGA
361  CCGGGGCTAG TAGATAGAGA GAAGTGGGAA AAAGAAAAT CTGAAGAAAT AGCTCTCGGA
421  TACTTCCGTA CCAACGAGAA CTTTGCCATT TATTCCGATG CCTAGCAAA ACTAGCCAAT
481  GAGGAAAAAG TTCCCTTCGT GCGTTTGAAT AAGGCGTTTC AACAGGAAGG TGGTGATGCT
541  TGGCAACAAC TGCTAACAGA TGGACTGCAC TTTTCCGGAA AAGGGTACAA AATTTTCAT
601  GACCAATAT TGAAGGTCAI TGAGACATTC TACCCCAAT ATCATCCCA AAACATGCAG
661  TACAACTGA AAGATTGGAG AGATGTGCTA GATGATGGAT CTAACATAAT GTCTTGA

```

FIGURE 63 (SEQ ID No. 55)

```

atgaacctgc gtcaatggat gggcgccgcc acggtgccc ttgcttggg cttggccgcg 60
tgcgggggcg gtgggaccga ccagagcggc aatcccaatg tcgccaaggt gcagcgcatg 120
gtggtgttcg gcgacagcct gagcgatate ggcacctaca ccccgctcgc gcaggcggtg 180
ggcgggcgga agttcaccac caaccgggac ccgatctggg ccgagaccgt ggcgcgcgaa 240
ctgggctgta cgtcacgccc ggcggtgatg ggctacgcca cctccgtgca gaattgcccc 300
aaggccggct gcttcgacta tgcgcagggc ggctcgcgcg tgaccgatcc gaacggcate 360
ggccacaacg gcggcgcggg ggcgctgacc taccgggttc agcagcagct cgccaacttc 420
taegcgccca gcaacaacac attcaacggc aataacgatg tcgtcttcgt gctggccggc 480
agcaacgaca ttttctctg gaccatgcy gcggccacca gcggtccggy cgtgacgccc 540
gccattgcca cggcccaggt gcagcaggcc gcgacggacc tggtcggcta tgtcaaggac 600
atgatcgcca aggggtgcgac gcaggtctac gtgttcaacc tgcgcgacag cagcctgacg 660
ccggacggcg tggcaagcgg cagcaccggc caggcgctgc tgacgcgct ggtgggcacg 720
ttcaacacga cgtcgcaag cgggctggcc ggcacctcgg cgcgcacat cgacttcaac 780
gcacaaactga ccgcggcgat ccagaatgcy gctctgttcg gcttcgcca caccagcgcc 840
cgggacctgc acgcccacaa gatcaatgcc ctggtgccga gcggcgcgga cagctcgctg 900
ttctgctcgg ccaacacgct ggtggttcc ggtgcggacc agagctacct gttcgccgac 960
ggcgtgcacc cgaccacggc cggccatcgc ctgatcgcca gcaacgtgct ggcgcgcctg 1020
ctggcgata acgtcgca ctga 1044

```

FIGURE 64 (SEQ ID No. 56)

```

1  gtgatacgggt  cgtacgtggc  ggtggggggac  agcttcaccg  agggcgctcg  cgaccccggc
61  cccgacgggg  cgttcgtcgg  ctggggccgac  cggctcgccg  tactgctcgc  ggaccggcgc
121  cccgagggcg  acttcacgta  caggaacctc  gccgtgcgcg  gcaggctcct  cgaccagatc
181  gtggcggaac  aggtcccgcg  ggtcgtcgga  ctgcgcgccg  acctgctctc  gttcgcggcg
241  ggccggcaacg  acatcatccg  gcccggcacc  gatcccgacg  aggtcgccga  gcggttcgag
301  ctggcggtgg  ccgcgtgac  ccgcgcggcc  ggaaccgtcc  tggtagaccac  cgggttcgac
361  acccgggggg  tgcctgtcct  caagcacctg  cgcggcaaga  tcgccacgta  caacgggcac
421  gtccgcgcca  tcgccgaccg  ctacggctgc  ccggtgctcg  acctgtggtc  gctgcggagc
481  gtccaggacc  gcaggcgctg  ggacggccgc  cggctgcacc  tgtcgccgga  ggggcacacc
541  cgggtggcgc  tgcgcgcggg  gcaggccctg  ggcttgcgcg  tcccgccga  cctgaccag
601  cctgcgcgc  cctgcgcgc  gcgcggcgc  ctgcacgtcc  ggccgcacga  cgtgcactgg
661  gcgcgcgagt  acctggtgct  gtggatcggg  cgcggctgc  ggggcgagtc  gtcgggcgac
721  cactgacgg  ccaaggggac  gctgtcgccg  gacgccatca  agacgcggat  cggcgcggtg
781  gcctga

```

FIGURE 65 (SEQ ID No. 57)

```

1  atgcagacga  accccgcgta  caccagtctc  gtgcgcgtcg  gcgactcctt  caccgagggc
61  atgtcggacc  tgcctgcgga  cggctcctac  cgtggctggg  ccgacctcct  cggcaccggg
121  atggcgggcc  gctcccccgg  ctcccggtac  gccaacctgg  cggtagcgcg  gaagctgac
181  ggacagatcg  tcgacgagca  ggtggacgtg  gccgcgcgca  tgggagccga  cgtgatcag
241  ctggctggcg  ggtcacaaga  caccgtgcgg  cccaagtgcg  acatggcccg  ggtgcgggac
301  ctgctgaccc  aggcctggga  ccggctcgcc  ccgcactgcg  agcagctggt  gctgatgcgc
361  agtcccggtc  gccagggtcc  ggtgctggag  cgttccggc  ccgcacatga  ggcctgttc
421  gccgtgatcg  acgacctggc  cggcgggcac  ggcgccgtgg  tcgtcgacct  gtacggggcc
481  cagtcgctgg  ccgacctcgc  gatgtgggac  gtggaccggc  tgcacctgac  cggcgagggc
541  caccgcgggg  tcgcggaggg  ggtgtggcag  tcgctcgccc  acgagccgga  ggaccccgag
601  tggcacgcgc  cgatcccggc  gacgcccgcc  ccgggggtgg  tgacgcgcag  gaccgcggac
661  gtccggttcg  cccggcagca  cctgctgcgc  tggataggcc  gcaggctgac  cgggcgctcg
721  tcgggggacg  gcctgcgggc  caagcgcccg  gacctgctgc  cctacgagga  ccccgcacgg
781  tga

```

FIGURE 66 (SEQ ID No. 58)

```

1  atgacccggg  gtcgtgacgg  gggtagcggg  gcgccccca  ccaagcaccc  tgccctgctc
61  gcggcgatcg  tcaccctgat  agtgccgatc  tccgcggcca  tatacgccgg  agcgtcccg
121  gacgacggca  gcagggacca  cgcgctgcag  gccggaggcc  gtctcccacg  aggagacgcc
181  gcccccgcgt  ccaccgggtg  ctgggtgggc  gcctggggca  ccgcaccggc  cgcggccgag
241  ccgggcaccg  agacgaccgg  cctggcgggc  cgctccgtgc  gcaacgtcgt  gcacacctcg
301  gtcggcgcca  ccggcgcgcg  gatcaccttc  tcgaacctgt  acgggcagtc  gccgtgacc
361  gtcacacacg  cctcgatcgc  cctggccgcc  gggcccgaca  ccggcccgcc  gatcccgac
421  accatgcgcc  ggctcacctt  cggcggcagc  gccgggtgta  tcaccccgcc  gggcgccag
481  gtgatgagcg  acaccgcccg  cctcgccatc  ccctacgggg  cgaacgtcct  ggtcacaccg
541  tactccccc  tcccgctccg  gccggtgacc  taccatccgc  aggcccgga  gaccagctac
601  ctggccgacg  gcgaccgcac  ggcggacgtc  accgcgctcg  cgtacaccac  ccccaagccc
661  tactggcgct  acctgacggc  cctcgacgtg  ctgagccacg  aggcggacgg  caggtcgtg
721  gcgttcggcg  actccatcac  cgacggcgcc  cgctcgacga  gcgacgccaa  ccaccgctgg
781  accgacgtcc  tcgcgcgacg  cctgcacgag  gcggcgggcg  acggccggga  cagccccgc
841  tacagcgtcg  tcaacgaggg  catcagcggc  aaccggtccc  tgaccagcag  gccggggcgg
901  ccggccgaca  acccgagcgg  actgagccgg  ttccagcggg  acgtgctgga  acgcaccaac
961  gtcaaggccg  tcgtcgtcgt  cctcgcgctc  aacgacgtcc  tgaacagccc  ggaactcgcc
1021  gaccgcgacg  ccatactgac  cggcctgcgc  accctcgtcg  accggcgcca  ccccgggga
1081  tactgggtcg  tcggcgccac  gatcacgcgg  ttcggcggtc  acggcggcta  caccgagggc
1141  cgcgagacga  tgcggcagga  ggtcaacgag  gagatccgct  ccggccgggt  cttcgacacg
1201  gtctgcgact  tcgacaaggg  cctgcgcgac  ccgtacgacc  cgcgccggat  gcgctccgac
1261  tacgacagcg  gcgaccacct  gcaccccgcc  gacaagggtt  acgcgcgcat  gggcgcggtc
1321  atcgacctgg  ccgcgtgaa  gggcgcgcg  ccggtcaagg  cgtag

```

FIGURE 67 (SEQ ID No. 59)

```

1 atgacgagca tgtcagggc gagggtggc cggcgatcg cggccggcg ggcgtacggc
61 ggcggcgcca tcggcctggc gggagcggc gcggtcggc tggctgggc cagagtgca
121 ctggccagac gcagggtggg ggtgggcac cggaccggg tgcggaacg caggggactg
181 tacggcgcca cctgcccac ggcggcgac cggcgctgc ggctgatgat gctggcgac
241 tccacggcgg cggggcagg cgtgacccg gcccggcaga cggcgggcg gctgctggc
301 tccgggctcg cggcggtggc gggcgggcg gtcgggctgg ggtcggtcgc ccagccgggg
361 gcgctgctcg acgacctgga cggcagggtg gcgctggtc tgcggagcc ggaccgggtg
421 cccgacatct gcgtgatcat ggtcggcgcc aacgacgtca cccaccgat gccggcgacc
481 cgctcggtcg ggcacctgtc ctggcggtg cggcggtgc gcacggcgg tgcggagggtg
541 gtggtcggca cctgtccgga cctgggcacg atcgagcggg tgcggcagcc gctgcgctgg
601 ctggcccgcc gggcctcagc gcagctcgcg cgggcacaga ccacggcgcc cgtcgagcag
661 ggcggggcca cgggtcgtc gggcgacctg ctgggtccgg agtgcgcga gaaccgcgg
721 gagctcttcg gcccgacaa ctaccacccc tccggcagg ggtacgccac ggcggcgatg
781 gcggtactgc cctcgtgtg gcgcgcgtc ggcctgtggc cggccgagca ggagcacccg
841 gacgcgctcg gccgcaggg cttcctgccc gtggcgcgcg cggcgcgga ggcggcgctc
901 gaggcggtga cggaggtcgc cgcgcgatg cctacggggc ctcgggggcc ctggcgctg
961 ctgaagcgcc ggagacggc tcgggtgtcg gaggcggaac cgtccagccc gtcggcgct
1021 tga

```

FIGURE 68 (SEQ ID No. 60)

```

1 atgggtcgag ggacggacca ggcgacggc tacggcgctc gccggcgcg tgtcggctc
61 gccgccccta cgcgcgcgt cctggcgctg ggcgtggcg gctgcgactc cgtggcgccg
121 gactcaccgg ctctctccgg cagcccgctg aagcgagcga ggacggcgcc cgcctgggac
181 accagcccg cgtccgtcgc cgcgtgggc gactccatca cgcgcggctt cgacgcctgt
241 gcggtgctgt cggactgccc ggaggtgtcg tggcgagcg gcagcagcgc gaaggtcgac
301 tcgctggccc tacggctgct ggggaaggcg gacgcggccg agcacagctg gaactacgcg
361 gtcaccgggg cccggatggc ggacctgacc gctcaggtga cgcggcgccg gcagcgcgag
421 ccggagctgg tggcggtgat ggcggggcg aacgacgcgt gccggtccac gacctcgccg
481 atgacgcccg tggcgactt ccggcgcgag ttcgaggaag cgatggccac cctgcgcaag
541 aagctcccca aggcgcaggt gtacgtgtcg agcatcccg acctcaagcg gctctggtcc
601 caggcgccca ccaaccgct gggcaagcag gtgtggaagc tcggcctgtg cccgtcgatg
661 ctggggcgag cgaactccct ggactcggcg gcgaccctgc ggcgcaacac ggtgcgcgac
721 cgggtggcgg actacaacga ggtgctcggc gaggctctcg cgaaggaccg gcggtgcgcg
781 agcgacgacg gcgcggtgca cgagttccgg ttcggcacgg accagttgag ccactgggac
841 tggttccacc cgagtggtga cggccaggcc cggctggcg agatcgcta ccgcgcggc
901 acccggaaga atccctga

```

FIGURE 69 (SEQ ID No. 61)

```

1 ttcacacaaa cgatgtcaca acaccggcca tcgggtcat ccctgatcgt gggaaatggg
61 gacaagcctt ccggtgacga aagggtcctg ctacatcaga aatgacagaa atcctgctca
121 gggaggttcc atgagactgt cccgacgcgc ggccacggcg tccgcgctcc tctcaccccc
181 ggcgctcgcg ctcttcggcg cgagcgccgc cgtgtccgcg ccgcgaatcc aggcaccaga
241 ctacgtggcc ctggcgact cctactcctc ggggttcggc gcggcgagct acgacagcag
301 cagtggtctc tgtaagcgca gcaccaagtc ctaccggccc ctgtggcgcc cctcgacac
361 cggtagcgcg ttaacttca ccgcctgttc gggcgcccg acaggagagc tgtggccaa
421 gcagctgacc ccggtcaact ccggcaccca cctggtcagc attaccatcg gcggcaacga
481 cgcgggcttc gccgacacca tgaccacctg caacctccag ggcgagagcg cgtgcctggc
541 gcggatcgcc aaggcgcgcg cctacatcca gcagacgctg cccgccagc tggaccaggt
601 ctacgacgcc atcgacagcc gggcccccg agcccaggtc gtcgtctctg gctacccgcg
661 cttctacaag ctgggcggca gctgcgccgt cgtgtctctg gagaagtccc gcgcggccat
721 caacgccgcc gccgacgaca tcaacgccgt caccgccaag cgcgcgcggc accacggctt
781 cgccttcggg gacgtcaaca cgaccttcgc cgggcacgag ctgtgtctcg gcgccccctg
841 gctgcacagc gtcaccttc ccgtggagaa ctctaccac cccacggcca acggacagtc
901 caagggttac ctgcccgtcc tgaactccgc caactgatct cgcggctact ccgccctga
961 cgaagtcccg ccccgggcg gggcttcgcc gtaggctgcg gtaccggct cgcgcgtcg
1021 gccggtggcc ccgcgtacg tgccgcggcc ccggacgcg gtcgggtc

```

FIGURE 70 (SEQ ID No. 62)

```

1  ATGAAAAAAT GGTITGTGTG TTTATTGGGA ITGSTCGCGC TGACAGTTCA
   TACTTTTTTA CCAACACAC AAATAACCCCT AACCAAGCGG ACTGTCAAGT

51  GGCAGCCGAC AGTCGCCCGG CCTTTTCCCG GATCGTGATG TTCGGCGACA
   CCGTCGGCTG TCAGCGGGGC GGAAGAGGGC CTAGCACTAC AAGCCGCTGT

101 GCCTCTCCGA TACCGGCAAA ATGTACAGCA AGATGCGCGG TTACCTCCCC
   CGGAGAGGCT ATGGCCGTTT TACATGTCGT TCTACGCGCC AATGGAGGGG

151 TCCAGCCCGC CCTACTATGA GGGCCGTTTC TCCAACGGAC CCGTCTGGCT
   AGCTCGCGCG GGATGATACT CCGGSCAAAG AGCTTGCCCTG GGCAGACCGA

201 GGAGCAGCTG ACCAAACAGT TCCCGGGTCT GACCATCGCC AACGAAGCGG
   CCTCGTCGAC TGGTTTGTC AAGGCCCAGA CTGGTAGCGG TTGCTTCGCC

251 AAGGCGGTGC CACTGCCGTG GCTTACAACA AGATCTCCCT GAATCCCAAG
   TTCCGCCACG CTGACGGCAC CGAATGTTGT TCTAGAGGAC CTTAGGGTTC

301 TATCAGGTCA TCAACAACCT GGACTACGAG GTCACCCACT TCTTGAGAA
   ATAGTCCAGT AGTTGTTGGA CCTGATGCTC CAGTGGGTCA AGAACGTCTT

351 AGACAGCTTC AAGCCGGACG ATCTGGTGAT CCTCTGGGTC GGTGCCAATG
   TCTGTGGAAG TTCGGCCTGC TAGACCACTA GGAGACCCAG CCACGGTTAC

401 ACTATCTCGC CTATGGCTGG AACACGGAGC AGGATGCCAA GCGGGTTCGC
   TGATAGACCG GATACCGACC TTGTGCCCTG TCCTACGGTT CCCCCAAGCG

451 GATGCCATCA GCGATGCCGC CAACCGCATG GTACTGAACG GTGCCAAGCA
   CTACGGTAGT CGCTACGCCG GTTGGCGTAC CAGTACTTGC CACGGTTCGT

501 GATACTGCTG TTCAACCTGC CGGATCTGGG CCAGAACCCG TCAGCTCGCA
   CTATGACGAC AAGTTGGACG GCCTAGACCC GGTCTTGGGC AGTCGAGCGT

551 GTCAGAGGCT GGTGAGGGCG GTCAGCCATG TCTCCGCCCTA TCACAACCAG
   CAGTCTTCCA CCAAGCTCCG CAGTCGGTAC AGAGGCGGAT AGTGTGGGTC

601 CTGCTGTGTA ACCTGGCAGG CCAGCTGGGC CCCACCGGCA TGGTAAGCT
   GACGACGACT TGGACCGTGC GGTGACCCG GGTGCGCCGT ACCATTTGCA

651 GTTCGAGATC GACAAGCAAT TTCCCGAGAT GCTGCGTGAT CCGCAGAACT
   CAAGCTCTAG CTGTTGCTTA AACGGCTCTA CGACGCACTA GCGGTCTTGA

701 TCGGCCCTGAG CGACGTCGAG AACCCCTGCT ACGACGGCGG CTATGTGTGG
   AGCGGGATC GCTGCAGCTC TTGGGGACGA TGCTGCCGCC GATACACACU

751 AAGCCGTTTG CCACCCGCGG CGTCAGCACC GACCGCCAGC TCTCCGCTT
   TTCGGCAAC GGTGGGCGTC GCAGTCGTGG CTGGCGCTCG AGAGCGGAA

801 CAGTCCGCGG GAACGCTCG CCATCGCCGG CAACCCGCTG CTGGCACAGG
   GTCAGGCTC CTTGCGGAGC GGTAGCGGCC GTTGGGCGAC GACCGTGTCC

851 CCGTTGCCAG TCCTATGGCC CGCCGCGAGC CCAGCCCCCT CAACTGTGAG
   GGCACCGCTC AGGATACCGG GCGGCGTCCG GGTGCGGGA GTTGACACTC

901 GGCAAGATGT TCTGGGATCA GGTACACCG ACCACTGTCT TGCACGACG
   CCGTTCTACA AGACCCTAGT CCAATGTGGC TGGTGACAGC ACGTGGCTCG

951 CCTGAGCGAG CGCGCCGCCA CCTTCATCGC GAACCACTAC GASTTCTCG
   GGACTCGCTC GCGCGGCGGT GGAAGTAGCG CTTGGTCATG CTCAAGGAGC

1001 CCCAC TGA
      GGGTG ACT

```

FIGURE 71 (SEQ ID No. 63)

```

1  ATGAAAAAAT GGTITGTTTG TTTATTGGGG TTGATCGCGC TGACAGTTCA
   TACTTTTTTA CCAACAACAA AAATAACCCC AACTAGCGCG ACTGTCAAGT

51  GGCAGCCGAC ACTCGCCCCG CTTTCTCCCG GATCGTGATG TTCGGCGACA
   CCGTCGGCTG TGAGCGGGGC GGAAGAGGGC CTAGCACTAC AAGCCGCTGT

101 GCCTCTCCGA TACCGGCAAA ATGTACAGCA AGATGCGCGG TTACCTCCCC
   CGGAGAGGCT ATGGCCGTTT TACATGTCGT TCTACGCGCC AATGGAGGGG

151 TCCAGCCCGC CCTACTATGA GGGCCGTTTC TCCAACGGAC CCGTCTGGCT
   AGGTGCGGCG GGATGATACT CCGGGCAAAG AGGTTGCTGT GGCAGACCGA

201 GGAGCAGCTG ACCAAGCAGT TCCCGGGTCT GACCATCGCC AACGAAGCGG
   CCTCGTCGAC TGTTTCGTCA AGGGCCGAGA CTGGTAGCGG TTGCTTCGCC

251 AAGGCGGTGC CACTGCCGTG GCTTACAACA AGATCTCCTG GAATCCCAAG
   TTCCGCCACG GTGACGGCAC CGAATGTTGT TCTAGAGGAC CTTAGGGTTC

301 TATCAGTCA TCAACAACCT GGACTACGAG GTCACCCAGT TCTTGCAAG
   ATAGTCCAGT AGTTGTTGGA CCTGATGCTC CAGTGGGTCA AGAACGTCTT

351 AGACAGCTTC AAGCCGGACG ATCTGGTGAT CCTCTGGGTC GGTGCCAATG
   TCTGTGGAAG TTCGGCCTGC TAGACCACTA GGAGACCCAG CCACGGTTAC

401 ACTATCTGGC ATATGGCTGG AATACGGAGC AGGATGCCAA GCGAGTTCCG
   TGATAGACCG TATACCGACC TTATGCCTCG TCCTACGGTT CGCTCAAGCG

451 GATGCCATCA GCGATGCGGC CAACCGCATG GTACTGAACG GTGCCAAGCA
   CTACGGTAGT CGCTACGCCG GTTGGCGTAC CATGACTTGC CACGGTTCGT

501 GATACTGCTG TTCAACCTGC CGGATCTGGG CCAGAACCCG TCAGCCCGCA
   CTATGACGAC AAGTTGGACG GCCTAGACCC GGTCTTGGGC AGTCGGGCGT

551 GTCAGAAGGT GGTGAGGGCG GTCAGCCATG TCTCCGCTTA TCACAACAAG
   CAGTCTTCCA CCAGCTCCGC CAGTCGGTAC AGAGGCGGAT AGTGTGTTTC

601 CTGCTGCTGA ACCTGGCACG CCAGCTGGCC CCCACCGGCA TGGTAAAGCT
   GACGACGACT TGGACCGTGC GGTGACCCG GGTGGCCGT ACCATTTCGA

651 GTTCGAGATC GACAAGCAAT TTGCCGAGAT GCTGCGTGAT CCGCAGAACT
   CAAGCTCTAG CTGTTCTGTA AACGGCTCTA CGACGCACTA GCGCTCTTGA

701 TCGGCCTGAG CGACGTCGAG AACCCCTGCT ACGACGGGCG CTATGTGTGG
   AGCCGGACTC GCTGCAGCTC TTGGGGACGA TGCTGCCGCC GATACACACC

751 AAGCCGTTTG CCACCCGCGG CGTCAGCACC GACCGCCAGC TCTCCGCCTT
   TTCGGCAAC GGTGGGCGTC GCAGTCGTGG CTGGCGGTGC AGAGGCGGAA

801 CAGTCCGCAG GAACGCCTCG CCATCGCCGG CAACCCGCTG CTGGCACAGG
   GTCAGCGCTC CTTGCGGAGC GGTAGCGGCC GTTGGGCGAC GACCGTGTCC

851 CCGTTGCCAG TCCTATGGCC CGCCGCAGCG CCAGCCCCCT CAACTGTGAG
   GGCAACGCTC AGGATACCGG GCGGCGTCCG GGTGCGGGGA GTTGACACTC

901 GGCAAGATGT TCTGGGATCA GGTACACCCG ACCACTGTGC TGCACGAGC
   CCGTTCTACA AGACCCTAGT CCATGTGGGC TGGTGACAGC ACGTGCCTCG

951 CCTGAGCGAG CGCGCCGCCA CCTTCATCGA GACCCAGTAC GAGTTCCTCG
   GGACTCGCTC GCGCGGCGGT GGAAGTAGCT CTGGGTCAAG CTCAGGAGC

1001 CCCACGGATG A
      GGGTGCCCTAC T

```

FIGURE 72 (SEQ ID No. 24)

```

1  ATGTTTAAGT TTA AAAAGAA TTTCTTAGTT GGATTATCGG CAGCTTTAAT
   TACAAATTC AATTTTCTT AAAGAATCAA CCTAATAGCC GTCGAAATTA

51  GAGTATTAGC TTGTTTTCGG CAACCGCCTC TGCAGCTAGC GCCGACAGCC
   CTCATAATCG AACAAAAGCC GTTGGCGGAG ACGTCGATCG CGGCTGTCGG

101  GTCCCGCCTT TTCCCGGATC GTGATGTTCC GCGACAGCCT CTCCGATACC
   CAGGGCGGAA AAGGGCCTAG CACTACAAGC CGCTGTCGGA GAGGCTATGG

151  GGCAAAATGT ACAGCAAGAT GCGCGGTTAC CTCCCTCCA GCCCGCCCTA
   CCGTTTACA TGTCGTTCTA CGCGCCAATG GAGGGGAGGT CGGCGGGGAT

201  CTATGAGGGC CGTTTCTCCA ACGGACCCGT CTGGCTGGAG CAGCTGACCA
   GATACTCCCG GCAAGAGAGT TGCTGSGCA GACCGACCTC GTCGACTGGT

251  AACAGTTCCC GGGTCTGACC ATCGCCACG AAGCGGAAGG CGGTGCCACT
   TTGTCAAGGG CCCAGACTGG TAGCGGTTGC TTCGCCITCC GCCACGGTGA

301  GCGGTGGGCTT ACAACAAGAT CTCCTGGAAT CCCAAGTATC AGGTATCAA
   CGGCACCGAA TGTTCTTCTA GAGGACCTTA GGGTTCATAG TCCAGTAGTT

351  CAACCTGGAC TACGAGGTCA CCCAGTCTT GCAGAAAGAC AGCTTCAAGC
   GTTGGACCTG ATGCTCCAGT GGTCAAGAA CGTCTTCTG TCGAAGTTCC

401  CGSACGACTT GGTGATCCTC TGGGTGCGTG CCAATGACTA TCTGGCCTAT
   GCCTGCTAGA CCACTAGGAG ACCCAGCCAC GGTACTGAT AGACCGGATA

451  GGCTGGAACA CGGAGCAGGA TGCCAAGCGG GTTCGCGATG CCATCAGCGA
   CCGACCTTGT GCCTCGTCTT ACGGTTCCGC CAAGCGCTAC GSTAGTCGCT

501  TCGCGCCAAC CGCATGGTAC TGAACGGTGC CAAGCAGATA CTGCTGTTCA
   ACGCCGGTTG GCGTACCATG ACTTGCCACG GTTCGTCTAT GACGACAAGT

551  ACCTGCGGGA TCTGGGCCAG AACCCGTGAG CTCGCACTCA GAAGGTGGTC
   TGGACGGCCT AGACCCGGTC TTGGGCAGTC GAGCGTCAGT CTTCACCCAG

601  GAGGCGGTCA GCCATGTCTC CGCCTATCAC AACCACTGTC TGCTGAACCT
   CTCCGCCAGT CCGTACAGAG GCGGATAGTG TTGTCGACG ACGACTTGGA

651  GGCACGCCAG CTGGCCCCCA CCGGCATGGT AAAGCTGTTT GAGATCGACA
   CCGTGCCTG GACCGGGGGT GGGCGTACCA TTTCGACAAG CTCTAGCTGT

701  AGCAATTTCG CGAGATGCTG CGTGATCCGC AGAACTTCGG CCTGAGCGAC
   TCGTTAAACG GCTCTACGAC GCACTAGGCG TCTTGAAGCC GGACTCGCTG

751  GTCGAGAAC CCGCTACGA CGGCGGCTAT GTGTGGAAGC CGTTTGCCAC
   CAGCTCTTGG GGACGATGCT GCGGCCGATA CACACCTTCG GCAACCGGTG

801  CCGCAGCGTC AGCACCAGCC GCCAGCTCTC CGCCTTCACT CCGCAGGAAC
   GGCCTCGCAG TCGTGGCTGG CGGTGAGAG GCGGAAGTCA GGCCTCCTTG

851  GCCTCGCCAT CGCCGGCAAC CCGCTGCTGG CACAGGCCGT TGCCAGTCCT
   CGGAGCGGTA GCGGCCGTTG GGGCAGCAGC GTGTCCGGCA ACGGTGAGGA

901  ATGGCCCCGC GCAGCGCCAG CCCCCTCAAC TGTGAGGGCA AGATGTTCTG
   TACCGGGCGG CCGCGCGGTC GGGGGAGTTG AACTCCCGT TCTACAAGAC

951  GGATCAGGTA CACCCGACCA CTGTCGTGCA CGCAGCCCTG AGCGAGCGCG
   CTTAGTCCAT GTGGGCTGGT GACAGCACGT GCCTCGGGAC TCGCTCGCGC

1001  CCGCCACCTT CATCGCGAAC CAGTACGAGT TCCTCGCCCA CTGATGA
   GCGGGTGGAA GTAGCGCTTG GTCATGCTCA AGGAGCGGGT GACTACT

```

FIGURE 73

SEQ ID No. 68

1 ADTRPAFSRI VMFGDSLSDT GKMYSKMRGY LPSSPPYYEG RFSNGPVWLE QLTKQFFGLT
 61 IANEAEAGGAT AVAYNKISWD PKYQVINNLD YEVTOFLQKD SFKPDDLVL VVGANDYLAY
 121 GWNTEQDAKR VRDAISDAAN RMVLNGAKQI LLFNLPDLGQ NPSARSQKV EAVSHVSAYH
 181 NKLLNLARQ LAPTGMVKLP EIDKQFAEML RDPQNFGLSD VENPCYDGGY VWKPF
 236 RSASPLNCEG KMFWDQVHPT TVVHAALSER AATFIETQYE FLAAG

FIGURE 74




FIGURE 75




FIGURE 76




FIGURE 77




FIGURE 78




FIGURE 79




FIGURE 80




FIGURE 81




FIGURE 82




FIGURE 83

